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II. Abstract 
Induced pluripotent stem cells (iPSC) have revolutionized biomedical research due to 
their versatility. They have potential for regenerative medicine, drug testing, disease 
modeling and developmental biology. The development of cell-based regenerative 
therapeutics and the subsequent treatment of human degenerative diseases require 
testing in predictive animal models like non-human primates (NHP). Therefore NHP-
iPSC in conjunction with NHP are highly important to conduct preclinical studies. I 
have generated and established in the context of this collaborative effort, to our 
knowledge for the first time, transgene- and feeder-free iPSCs from three NHP species, 
namely the rhesus macaque (Macaca mulatta), the olive baboon (Papio anubis) and 
the common marmoset (Callithrix jacchus), as well as human iPSC. For the generation 
of the different NHP-iPSC lines, we explored different reprogramming approaches and 
culture conditions. Eventually, we succeeded in establishing a universal 
reprogramming protocol for primate fibroblasts. Furthermore, we successfully adapted 
a differentiation protocol for human iPSC into functional cardiomyocytes (iPSC-CM) 
to NHP-iPSC. 
The generated NHP-iPSC, besides their potential to test stem cell-based regeneration 
therapies, can also be used for disease modeling. The generation of genetically 
modified NHP animal models for human diseases may contribute to drug testing and 
enhances pathophysiological studies during disease onset and progression in a 
controlled experimental setup. However, in order to safely introduce predefined 
mutations into the (embryonic) genome of monkeys, the efficiency and accuracy of a 
genome editing approach needs to be pre-screened, ideally using iPSC of the 
respective NHP species. Due to the similarities between iPSC and pluripotent cells 
from the early embryo, it is possible and suggested to study the efficiency, efficacy 
and accuracy of the editing approach using iPSC. Furthermore, the capability of the 
iPSC to differentiate into different somatic cell types may allow the prediction of 
aspects of the in vivo phenotype of genetically modified NHP. In summary, I have 
generated and established in the context of these collaborative studies a set of NHP-
iPSC-lines that (1) can be used for preclinical testing of cell replacement therapies and 
(2) forms the basis of an in vitro platform that allows the validation of genome editing 
approaches, e.g by CRISPR/Cas, for the generation of genetically modified NHP. With 
this approach, we established an in vitro testing and preselection platform for genetic 
modifications before their application in vivo in NHP. Besides its scientific value, this 
platform will also contribute to the 3Rs (reduce, replace, refine) in animal 
experimentation, which are of particular importance in the context of NHP research. 
The current dissertation has been written following the pseudo-cumulative structure 
registered in the Official Bulletin I no. 28 dated 22.06.2018,  doctoral degree 
regulations (RerNat-O) GAUSS. This thesis includes four different chapters / 
manuscripts (both published and not published), each independent and completely 
understandable as a single manuscript. As all chapters reflect the evolution of 
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techniques and results during this Ph.D., they are grouped under a general introduction 
and discussion, giving a full overview and analysis of the thesis.
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III. Introduction  
Cardiovascular diseases (CVDs) are one of the major causes of death worldwide. This 
group of pathologies affects human cardiac and vascular systems and usually presents 
a complex etiology 1. CVDs cover a broad range of diseases, like ischemic heart 
disease, acute myocardial infarction, cardiomyopathies, atherosclerosis, or congenital 
heart disease 2. Due to the high incidence of these pathologies in society, it is crucial 
to investigate their cause, and progression to develop efficient treatments 1. For a better 
understanding of these diseases, it is necessary to strengthen basic research and 
epidemiological studies. Complementarily, it is of utmost importance to establish 
bridges between the above mentioned disciplines and clinical applications using 
animal models that share the complexity of human cardiovascular (CV) system. Most 
of experimental CV in vivo research relies on rodent models. Rodents significantly 
contribute to the progress of our understanding of CVDs 3. However, due to major 
differences between rodent and human CV system (heartbeat or innate resistance to 
CVD) they fail to address a variety of research questions. Therefore it is necessary to 
complement rodent studies with large animal models that will allow a better translation 
of the results obtained to the human pathological set 2.  
 
 
 
Figure 1. Phylogenetic comparison of human and NHP and anatomy of the NHP heart. (A) Phylogenetic 
tree of selected species (Adapted from 4 and 5). (B) Phylogenetic tree of primates (Adapted from 6). 
Evolutionary distance is shown in “millions of years ago” (MYA). (C, C´) Anatomical analysis of an 
adult female marmoset heart. (C) Frontal view. (C´) Posterior view. Scale bar 1cm. 
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The main translational animal models in CV research are pig, dog, sheep, and non-
human primates (NHP) 7 8 9. NHP as our closest relatives, share a primate-specific 
genomic constitution and high similarities in anatomy, physiology, and behavior (Fig. 
1) (Table 1) 10. Therefore, NHP are well-recognized models and have a long history in 
biomedical research. Besides the traditional usage in toxicology, their recognition is 
increasing for other applications. Although, NHP account for only 5% of all research-
related animal models, they are now increasingly used in disease modeling and testing 
of advanced therapy medical products (ATMP) 2 7 11 12  13.  
 
However, in addition to animal models, it is necessary to consider in vitro state of the 
art tools to expand the frontiers of this research field. Stem cells, due to their versatility, 
represent a very interesting approach in this context.  Within the broad range of stem 
cell applications, they play a vital role in CV research. Patient-specific induced 
pluripotent stem cells (iPSC) have been essential to study disease development and 
progression. Furthermore, iPSC present an interesting approach towards regenerative 
therapies for the CV system.  
 
  Old World Monkeys 
New World 
Monkeys 
  Papio hamadryas Macaca mulatta Callithrix jacchus 
Common name Hamadryas baboon Rhesus monkey Marmoset 
Longevity (Max) (y)* 37.5 14 15 16 40 17 16.5-22.8 14 18 
Average life span (y) 30 19 27 17 5-7.07 18 20 
Body temperature (ºC) 38 15 16 37.7 21 37-39 22 
Gestation (d) 171-179 23 165 24 143-144 20 
Male sexual maturity (d) 1762 15 16 1095-1277 25 382 15 
Female sexual maturity  (d)  1514 15 16 912-1095 25 477-547 18 20 
Litter size 1 15 16 1 15 2 (3) 18 20 
Litters per year 0.8 15 16 1 15 2 (3) 18 20 
Weight at birth (g) 814 15 16 464 15 26.5 20 
Adult weight (g) 
20000(f)-
38000(m)26 9700 27 <400 18 
 
Table 1: Phylogenetic proximity of non-human primates and human is reflected in highly similar 
physiological and anatomical features. Represented in the table are selected biological key parameters 
of the three animal models considered in this study: Baboon (Papio anubis is the species used in this 
project, data shown for Papio hamadryas), rhesus macaque (Macaca mulatta), and common marmoset 
(Callithrix jacchus). (d) days, (g) grams, (y) years, (ºC) degrees Celsius, (f) female, and (m) male.  
1 Stem cells 
 
Stem cells are characterized by their capability of self-renew and differentiation into 
at least one cell type 28. Stem cells perform essential functions during development and 
in tissue homeostasis. They can be categorized into three groups according to their 
developmental potency: pluripotent, multipotent, and unipotent stem cells. All adult 
stem cells are either multipotent or unipotent. Multi- and unipotent cells demonstrate 
limited differentiation capacities into one or few cell types from the same embryonic 
lineage. In contrast, pluripotent stem cells (PSC) can differentiate into all cells of the 
organism.  As mentioned, pluripotency can be defined as the regulative capability of a 
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single cell to give rise to cells of all germ layers 29. Embryonic pluripotent cells are 
present in the epiblast,  of the post-implantation pre-gastrulation embryo (blastocyst 
stage) 30.  During embryo development, these cells give rise to all cell types of the 
organism but they are not able to generate the extra-embryonic tissues 28 30.  
 
Embryonic pluripotent cells can be isolated from a developing embryo and, mimicking 
their natural niche, cultured in vitro as embryonic stem cells (ESC). ESC lines have 
been established from human and many different animal models, including mouse, rat, 
macaque, and baboon 31 32 33 34. The possibility of maintaining and expanding these 
cells in vitro plus differentiating them into specific cell types raised new possibilities 
concerning novel treatments and disease modeling. Using PSCs, it is possible to 
generate tissue-specific cells, like cardiomyocytes, and utilize them for human disease 
modeling. Besides the promise of applying ESC in the clinical scenario, there are 
ethical concerns associated with their usage considering the sacrifice of an embryo for 
accessing the cells 35.  
 
In 2006 Takahashi and Yamanaka discovered a method to awake endogenous 
pluripotency in terminally differentiated cells. This was achieved by ectopic 
expression of OCT4, SOX2, KLF4, and cMYC, genes designated as Yamanaka factors. 
The technique was first published using mouse and afterward using human fibroblasts 
36 37. The generated pluripotent stem cells were termed induced pluripotent stem cells 
(iPSC). iPSC share many characteristics with ESC, including gene expression profiles, 
DNA methylation, and covalent histone modifications 38. Furthermore, they 
circumvent the ethical controversy associated with the destruction of embryos. The 
strong similarities between both types of PSC allowed the translation of the in vitro 
culture conditions from ESC to iPSC 38 39.  
 
1.1 Induced pluripotent stem cells (iPSC) and reprogramming 
Reprogramming can be defined as the process of remodeling the epigenetic landscape 
of a cell. The first successful attempts of reprogramming took place much earlier than 
the discovery of iPSCs by Takahashi and Yamanaka. Briggs and J. King first reported 
successful reprogramming in 1950. Here, somatic nuclear transfer from an advance 
blastula into an enucleated northern leopard frog (Rana pipiens) egg, resulted in the 
reprogramming of the oocyte 40 41. The Nobel Prize-awarded Sir John Gurdon used 
tadpole nuclei for successful cloning of the frog Xenopus laevis using the same 
technique 39. These and subsequent studies grounded the basics of reprogramming. 
However, until the discovery of iPSCs, it was still necessary to use embryonic tissue.  
 
iPSCs can differ from each other depending on the cell type from which they were 
derived and the reprogramming approach used  38. It has been shown that almost any 
cell in the human body can be reprogrammed (e.g., skin fibroblast, stomach cells, liver 
cells, or keratinocytes) 42 43 44 45. As mentioned above, the process of reprogramming 
begins with the exogenous expression of the Yamanaka factors. Later approaches used 
further factors, such as NANOG and LIN28, for “reprogramming resistant” cells or 
species.  
 
OCT4 (POU5F1), SOX2, and KLF4 transcription factors work synergistically towards 
pluripotency by inducing dynamic changes in gene expression (Fig. 2) 46 47. These 
three transcription factors co-occupy the promoters of many reprogramming-related 
Introduction 
13 
 
genes, awaking endogenous pluripotency in the somatic cells 48. OCT4 acts alone or 
forms a heterodimer with SOX2. Both SOX2 and OCT4 can differentially bind the 
DNA depending on the configurations of their protein structure. OCT4 is related to the 
maintenance of the self-renewal capabilities in PSC 46 48, while SOX2 facilitates the 
establishment of the trophectoderm lineage 49. Additionally, MYC overexpression 
represses lineage-specifying transcription factors and stimulates cell cycle via 
promotion of DNA synthesis 50 51. Reprogramming without MYC has been 
demonstrated for mouse, however resulting in low efficiencies 51. The initial 
experiments by Takashi and Yamanaka used c-MYC; although, this factor is 
constitutively expressed in cancer cells. Therefore refined reprogramming approaches 
substitute c-MYC for other members of the MYC family, e.g., l-MYC 52.   
 
LIN28 is occasionally included to assist reprogramming in combination with the 
canonical four factors. This RNA-binding protein support pluripotency via regulation 
of the microRNAs let-7 family, which promote differentiation 53 54. Furthermore, the 
transcription factor NANOG is also often used to complement the standard 
reprogramming cocktail. OCT4, NANOG, and SOX2 form an interconnected 
autoregulatory loop binding each other's endogenous promoters and contributing to 
the pluripotency stabilization of the iPSC (Fig. 2) 48.  
 
 
 
Figure 2:  Transcription factor-induced reprogramming of somatic cells into iPSCs. (A) Represented 
regulatory circuit of pluripotency in ESC and iPSCs detailing the transcription factors KLF4, OCT4, 
SOX2, and NANOG. (B) Autoregulatory positive loop between OCT4, SOX2, and NANOG. Green 
circles indicate transcriptional activators and rectangles gene promoters. Binding of regulators (green 
ovals) to promoters (yellow boxes) indicated by a solid arrow and gene expression by dashed arrows. 
Adapted from 48. 
 
There are multiple strategies to induce overexpression of the Yamanaka factors in 
somatic cells. Different reprogramming approaches can be characterized according to 
the delivery method of the factors. To the present, delivery of DNA, RNA, and protein 
have been tested. DNA based delivery is the most utilized amongst reprogramming 
methods, although these methods entail the risk of altering the endogenous genomic 
DNA (gDNA). RNA or protein-based methods are considered to be safer; however, 
the reprogramming efficiencies are lower 55 56. 
 
Within DNA based approaches, two types can be distinguished: integrative and non-
integrative approaches. Integrative methods insert the reprogramming construct into 
the gDNA. This integration can be either reversible or irreversible. Traditionally, iPSC 
have been generated using integrative methods, using, e.g., retro- and lentiviruses. 
These systems demonstrate high efficiencies; however, the genome of the cells is 
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permanently modified. The constitutive expression of the reprogramming factors can 
lead to mutagenesis or failing differentiation. Hence, they make the cells inappropriate 
for transplantation studies. On the contrary, the piggyBac system represents an 
integrative, yet reversible reprogramming approach. It consists of a transposon and a 
transposase, in which expression of the transposase will lead to the excision of the 
transposable cassette from the parental vector. The cassette will then integrate into a 
chromosomal TT/AA site 57. One of the main advantages of this system is that it can 
be excised, leaving no footprint in the genome. The piggyBac system has been used to 
efficiently reprogram human, mouse, marmoset and baboon fibroblasts 57 58 59 60.  
 
Non-integrative DNA-based methods offer the possibility to generate fully footprint-
free iPSC 41. The cells can be generated using non-integrating viruses, like Adenovirus, 
or Sendai Virus. Other non-integrative non-viral based reprogramming methods 
include minicircles or episomal plasmids 57. The episomal plasmid system allows 
transient expression of the reprogramming factors without integration. OriP/EBNA-
based plasmids allow a temporary but prolonged-expression during few passages. This 
allows stable reprogramming and increases efficiency. Episomal vector systems have 
been used to reprogram, e.g., human, macaque, and marmoset cells 42 52 61.  
 
The safest reprogramming approaches are based on RNAs encoding the 
reprogramming factors since RNAs cannot integrate into gDNA. Although these 
approaches have been successfully used, they are either very expensive of have rather 
a low efficiency 62 63.   
 
1.2 Induced pluripotent stem cells characterization 
All molecular changes induced during reprogramming are reflected by a drastic 
epigenetic remodeling, leading to a new phenotype of the cells. Morphology and 
proliferation changes, giving rise to small highly proliferative cells with a high 
nucleus/cytoplasm ratio. Even though morphological changes are a crucial aspect to 
consider, an in-deep characterization of the iPSCs is necessary in order to confirm their 
pluripotent status 42. The scientific community agreed to several assays that allow 
confirmation of pluripotency of the iPSCs 42 64. First, it is important to analyze the 
changes in expression profiles in comparison to differentiated cells. This allows 
confirmation of the reactivation of pluripotency markers. Transcript and protein 
analyses are usually performed for key pluripotency factors like OCT4A, LIN28, and 
NANOG, among others. 
 
After verification of the reactivation of the pluripotency machinery, the differentiation 
capabilities are assessed both in vitro and in vivo. The gold standard assay for potency 
evaluation of rodent iPSC is the chimera assay. Chimeras are generated by injecting 
iPSCs into a host preimplantation embryo, which is then retransferred into a foster 
mother. The potency of the iPSCs is evaluated in the organism developed from the 
chimeric embryo. The contribution of the injected cells in different tissues is 
subsequently assessed 65. This method evaluates potency in a highly accurate way; 
however, due to ethical and practical limitations it is not feasible for human cells or 
cells from other species.  
 
Further assessments of pluripotency include directed differentiation in vitro and 
spontaneous differentiation both in vitro and in vivo. Spontaneous differentiation 
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describes random differentiation elicited by exposing the iPSCs to a general 
differentiation environment. In vivo assessment of pluripotency is demonstrated by the 
teratoma formation assay, in which the test cells are subcutaneously injected into 
immune-deficient mice. Here, the iPSCs proliferate to form a tumor, which is then 
analyzed for histological features of the three germ layers 66. In vitro, cells are 
introduced to a general differentiation media, resulting in random differentiation. 
Analysis of the potency is performed by expression analysis of representative markers 
of the three germ layers. Cells are considered pluripotent if this is found to be true 67. 
An alternative option is directed differentiation, in which the iPSCs are differentiated 
towards a specific cell type, such as neuron- or cardiomyocyte-like cells 42 68. Directed 
differentiation requires established protocols to imitate the natural differentiation 
signals during development to generate a specific cell type. Even though this has been 
achieved for many cells types, for others it remains elusive. Furthermore, the protocols 
are commonly established for human or mouse iPSCs, often cannot be translated 
directly to other species. 
 
The establishment of the mentioned assays has contributed to the generation of a robust 
work-flow for stem cell characterization. However, even though many efforts have 
been made for standardized reprogramming and pluripotency assessment protocols, 
there is still high heterogeneity between iPSCs generated in different laboratories. 
Hence, for the sake of comparability of data from different labs, it is necessary to 
continue increasing the standards for iPSC generation and assessment. Some efforts in 
this direction have already been made by the generation of testing systems like 
Scorecard or PluriTest, which identify specific molecular signatures and functional 
pluripotency 67 69 70. Additionally, the standards for clinical-grade human iPSC 
generation have been defined over the last years. In order to generate high-quality 
iPSCs and to ensure their comparability between human and other species, it is 
necessary to define critical quality attributes that all iPSCs need to fulfill 42. Therefore 
iPSCs from relevant translational models have to follow human iPSC guidelines 64.  
 
1.3 Non-human primate-iPSC (NHP-iPSC) 
NHP models in combination with species-specific iPSC provide the missing link for 
translation of basic regenerative research in rodents to human clinical trials 42. NHP 
present, due to their close phylogenetic relationship, compelling advantages in 
comparison with other animal models concerning autologous and allogeneic stem cell-
based regenerative studies (Fig. 1) 42. NHP in conjunction with NHP-iPSCs provide a 
system that allows addressing specific questions going back and forth from in vitro to 
the in vivo systems. In order to utilize the close phylogenetic proximity of NHP and 
human and to put gained knowledge onto a solid basis, the generation of a broad panel 
of NHP-iPSC is necessary 42.  
 
After the generation of human and mouse iPSC, the first reports of NHP-iPSC 
followed 71 72 73 74. In 2008 the first NHP-iPSCs were generated from the macaque 75. 
Shortly after, in 2010, two independent publications demonstrated reprogramming of 
marmoset fibroblast into iPSCs 76 77. Since then, a broad range of NHP species have 
been successfully reprogrammed including baboon, cynomolgus monkey, chimpanzee 
or drill 74 78 79 80. Although reprogramming protocols have been translated from human 
to NHP, this process has been shown to be slower and less efficient. For example 
reprogramming of NHP is still dependent on mouse embryonic feeder cells (MEF) 42 
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78 81. This limits the preclinical value of the cells since they are mixed with cells from 
other species and the culture conditions are not standardized. 
 
The difficulties in NHP cell reprogramming and iPSC maintenance illustrate yet 
unknown characteristics of the regulation of pluripotency in NHP cells, especially 
considering the high conservation of the main pluripotency related genes across 
species (Table 2) (Fig. 3). One example is the baboon, from which Navarra and 
collaborators reported the generation of iPSCs in 2013 and 2018. In both publications, 
the generated iPSCs needed to be co-cultured with MEFs. These reports underline the 
difficulty of generating iPSC from this species under conditions homologous to human 
culture conditions 78 81. Another example is marmoset reprogramming that has been 
achieved by different reprogramming methods; however, the maintenance of these 
cells in feeder-free culture has not been reported yet 42.  
 
Due to the key role of NHP in translational research, it is necessary to adapt the 
standards for human iPSC generation to NHP-iPSCs. Human protocols for 
reprogramming need to be refined towards the molecular particularities of NHP in 
order to establish them as translational models 42.  
 
 
  Baboon Macaque Marmoset Pig Rat Mouse 
 OCT4 99,39 99,39 98,78  97,56  85,89  90,54  
KLF4 100,00  100,00  100,00  100,00  96,55  96,55  
c-MYC 95,58  98,00  97,95 97,11  95,87  96,00 
LIN28 98,56  99,04  99,04  97,07  99,04  97,61 
NANOG 93,97  97,23  96,88  85,37  76,17  77,34  
SOX2 99,68  100,00 99,37  99,68  98,42  98,42  
ESRRB 99,54  99,54  99,54  98,85 97,92  97,46  
NR5A2 100,00  99,76  98,78 98,51  96,16  96,16  
 
Table 2. Protein sequence similarity of key pluripotency genes between selected species relevant in the 
stem cell research field and human. Protein sequence alignments represented as percentage of similarity.  
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Figure 3. Gene tree showing protein evolution using the UPGMA method, in MEGA 7 software 82 83.  
(A)(B) Analysis of the cardiac relevant proteins dystrophin (DMD), and connexin 43 (GJA1/Cx43). 
Comparison between selected species with relevance in CV research. (C)(D) Analysis of the 
pluripotency relevant proteins, Octamer binding transcription factor 4 (OCT4/POU5F1), and NANOG. 
Comparison between selected animal models relevant in stem cell research. 
2 Application of pluripotent stem cells in cardiovascular 
research 
 
The versatility of PSC makes them an excellent tool in the context of CV research. 
PSC can be used to model clinically relevant pathologies in vitro, as a cell source for 
cell-based regeneration therapies, and drug development and toxicity testing. 
 
2.1 Cell replacement therapies 
Progressive or sudden loss of functional cells in an organ can be overcome by 
regenerative cell-based therapies. These approaches open possibilities to treat diseases 
which to the present are untreatable 42. PSC present an interesting approach towards 
cell replacement therapies due to their high proliferation and the differentiation 
potential. 
 
In the last years, preclinical studies exploring PSC-based therapeutics demonstrated 
the potential of this pharmacological approach 84 85 86. Notwithstanding the progress 
made, some open questions still need to be addressed before clinical translation of 
these therapies. Addressing safety concerns regarding tumorigenicity and 
immunogenicity are of utmost importance 7. Furthermore, it is necessary to consider 
aspects concerning the source of the cells, such as cell type, GMP compliance, or 
maturation state of the differentiated cells. Finally, it is crucial refining procedures 
including graft location, delivery protocols, and minimum effective dose 7 86 87 88.  
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For addressing these concerns, high-quality iPSCs from relevant animal models are 
required. This will allow the exploration of the regenerative potential in a controlled 
research environment. Different preclinical studies using NHP models show promising 
results using stem cells as a cell source to treat spinal cord injuries 89 90,  retinitis 
pigmentosa 91, or myocardial infarction 92 93 among others 8 94.  
 
Myocardial infarction is an ischemic heart disease in which tissue is lost in the heart 
and substituted by non-contractile scar tissue 95. Treatment options reversing the 
damage induced by myocardial infarction do not exist. One potential therapy is to 
replace or support the scarred tissue by stem cell-based replacement therapies. 
Application of pluripotent stem cell-derived cardiomyocytes could be one of such 
therapies 95. Remuscularization of an infarcted heart has been conducted in different 
animal models, showing encouraging results. These studies reported the safety of the 
approach and improvement of the contractile function of the heart after transplantation 
of the cells 7 92 93.  
 
2.2 Drug discovery and toxicity test 
Novel drugs need to be tested before clinical trials to guarantee patient safety. 
Nowadays, the preclinical testing of medication relies on very few animal models, 
namely mouse, rat, pig, and NHP. This preclinical phase is crucial, considering that 
90% of the new treatments fail in this phase and do not progress to the clinics 2. 
Cardiovascular toxicity, in particular, is one of the major causes of drug withdrawal, 
accounting for 33% of drug failure 2. Cardiac toxicity frequently manifests by altered 
contractibility or cardiac rhythm, the formation of reactive oxygen species (ROS), 
apoptosis, and modified cardiac gene expression 2. Even though the animal models 
used for drug toxicity testing are well established, iPSCs present an alternative for 
reproducible and economic drug testing 41. Additionally, iPSCs may contribute 
significantly to the reduction of animals used for these purposes. 
 
Although in vivo drug testing will still be required, patient-specific iPSC represent an 
interesting alternative for preliminary assessment of side effects 2. Furthermore, 
patient-specific iPSCs can also contribute to drug screening efforts. One example is 
the analysis of the contractile function in iPSC-derived CMs exposed to different 
drugs. The feasibility of iPSC-based toxicity testing is reflected in the development of 
the first commercially available platforms in the last years (e.g., Ncardia). 
 
2.3 Disease modeling 
There are two main ways to model genetic human diseases in iPSC: 1- reprogramming 
patient fibroblasts that contain the disease-inducing genotype into iPSCs, or 2- 
inducing a clinically relevant mutation in wildtype (WT) iPSCs using genome editing 
tools 96. Patient-specific iPSCs have the advantage of being a straight forward strategy, 
allowing the fast generation of a selected disease platform. In contrast, inducing 
clinically relevant mutation in WT iPSCs is more laborious. However, this approach 
comes with the advantage of a reduced heterogeneity between replicates and no genetic 
variation affecting the results. Both systems allow in vitro mimicking of an in vivo 
phenotype and the possibility of study it under controlled conditions. 
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In addition to the in vitro model using human iPSCs with defined mutation, it is 
important or even necessary to complement these studies with animal models 
possessing these pathological mutations. Genetically modified NHP will allow 
researchers to investigate diseases in a model closely related to humans. Species-
specific iPSC, like NHP-iPSC, could serve as a preliminary approximation to the 
outcome of these long-term, expensive, and laborious projects. For in vitro disease 
modeling it is necessary to adapt genome editing tools to the particularities of each 
species. Nowadays, there are robust protocols to target human and mouse PSC 
efficiently, but their translatability to PSC from other species is still under 
investigation 97 98. 
 
3 Non-human primates as animal models in cardiovascular 
research 
 
To translate basic research into clinical applications, it is necessary to complement 
rodent studies with preclinical data obtained from large animal models 3 8 9 99 100. The 
main large animal models used in translational cardiovascular research are sheep, pig, 
and NHP 9 101. All mentioned organisms have a higher similarity to human physiology, 
histology, and genetics in comparison to mouse (Fig. 1, 3) (Table 1, 2 and 3). However, 
it has to be kept in mind that each one of them presents advantages and disadvantages. 
Choosing the optimal organism for a study always depends on an in-depth analysis of 
their characteristics in the context of a specific research question 9. 
 
NHP can be divided into three big paraphyletic groups, Old World monkeys (OWM), 
New World monkeys (NWM) and Apes. NWM include five families, namely 
Callitrichidae, Cebidae, Aotidae, Pitheciidae, and Atelidae, belonging to the parvorder 
Platyrrhini. OWM are the closest relatives to Apes and constitute the family 
Cercopithecidae (Fig. 1) 4 5 6. Besides the above-mentioned similarities, OWM 
additionally have a greater similarity in diet and litter size, in comparison to NWM. 
These characteristics historically make OWM the preferred models for biomedical 
research. Nevertheless, NWM are gaining more attention over the last years 8. The 
marmoset monkey, for example, shares the primate-specific genomic constitution with 
OWM while presenting advantages like high reproductive efficiency, low housing cost 
and easier handling 8 97.  
 
NHP, as our closest relatives provide the possibility of studying CVD in animal models 
with high physiological, genetic, and behavioral similarity to humans 102. Furthermore, 
NHP naturally develop diseases homologous human CVDs. Macaques, for example, 
present diverse age-related pathologies, including various heart diseases, like 
myocarditis 103. Additionally, the size of NHP allows utilization of clinical equipment 
with little to no modifications, e.g., MRI 8. Another advantage of the size and longer 
life-span is the possibility of longitudinal studies with several sampling phases. 
Furthermore, NHP colonies usually follow breeding strategies by which the genetic 
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pool is increased. This enriches the populations with genetic variability, which cannot 
be found in mice 8.  
 
Species 
Heart weight  Heart rate Systolic Coronary artery 
(g)  (bpm)  pressure (mmHg)  diameter (mm) 
Human  250-480 8 104 60-100 105 60-120 106 4.5 8  107 
Olive Baboon 55-116 108 60-122 105 109 113-160 109 1.5-2.5 110 
Rhesus macaque 22-30111 */40#  165-229 112 98-126 112 1.40- 2.40 113 ** 
Marmoset 2.28-2.98 114 405-600 115 133.5-159 116  0.51 117 
Pig 400-500 104 65-75 104 106 135–150 106 2,83-3.59 118 
Sheep 240-360 104 60–120 9 90–115 9 106  1,65-2.57 119 
Dog 160-420 104 70-160 106          95–150 104 106 1.71-1.85 120 
Rabbit  9-11 104 
120-300104 
106 90–130 106 0.99-2 117 121 
Mouse 0.14-0.15 8  104 310-840 106   80–160 104 106 0.16 8 117 
     
Table 3. Selected heart characteristics of human and relevant CVD animal models (adults). Two 
references were added in the cases where a discrepancy between two publications was found. (*) Heart 
weight value corresponding to Macaca arctoides. (**) Coronary artery diameter value corresponding 
to Macaca fascicularis. (#) Approximately 40 grams is the heart weight values obtained from our 
macaque colony (German primate center, DPZ, Göttingen). Units used for the different parameters: 
heart weight, grams (g); heart rate, beats per minute (bpm); systolic pressure, millimeters of mercury 
(mmHg); coronary artery diameter, millimeters (mm). 
 
NHP have significantly contributed to the exploration of CVD and the development of 
effective therapies. However, there are still open questions about their genetics, 
metabolism, and physiology. These need to be addressed to increase the impact of 
these animal models in the field and to choose the optimal NHP species to address a 
particular research question. 
 
4 Genome editing 
 
Genome modification has been one of the major research goals in the last two decades. 
Currently, there are three major approaches for genome editing: Zinc finger nucleases 
(ZFNs), Transcription activator-like effector nuclease (TALENs), and Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR). ZFNs consist of zinc-
finger transcription factors, each recognizing three base pairs attached to a restriction 
enzyme (usually FokI). The complexity of the design and construction makes this 
method challenging to use. TALENs are restriction enzymes (also usually FokI) with 
sequence-specific DNA binding domains that can be engineered to target a specific 
DNA sequence. While being highly specific, this system presents some disadvantages, 
for example, its incapability to target inactive chromatin (DNA methylation/histone 
acetylation) 122 123. First described in E. coli and S. epidermidis, the CRISPR/Cas 
system was discovered as an adaptive immune system in bacteria 124. The modified 
CRISPR/Cas consists of two components, 1- a Cas9 nuclease (with two nuclease 
domains) that cuts the DNA, and 2- guide RNAs (gRNAs) with two functions: binding 
to Cas9 and recognition of a specific DNA sequence by base-pairing with the desired 
sequence in the chromosome. 
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ZFNs, TALENs, and CRISPR generate double-strand breaks (DSB) that trigger the 
activation of the endogenous DNA reparation machinery. DNA can be repaired by two 
different means: non-homologous end joining (NHEJ) or homology-directed repair 
(HDR). In NHEJ the cell joins the two DNA ends after a DSB, while adding or deleting 
randomly base pairs (INDEL mutations). In contrast, in HDR the DNA damage is 
repaired precisely using an exogenous (extra-chromosomal) DNA template and no 
random mutations are induced 123.  
 
CRISPR, due to its simplicity and efficiency, is nowadays the preferred genome 
editing tool. The increasing sophistication of the CRISPR/Cas system together with 
refinement of iPSC generation makes it a feasible approach for research into genetic, 
molecular, and cellular mechanisms 123. Besides the double nick activity, CRISPR/Cas 
enhancement makes possible using modified Cas9 for 1- single-strand nick (Cas9 
partially inactive), or 2-blocking transiently expression of a gene (Cas9 inactive, no 
nickase activity) 123.   
 
The improvements of the CRISPR/Cas system tremendously increased its potential in 
biotechnological applications. Improved specificity and efficiency allows genomic 
targeting in any region, playing into the generation of genetically modified animals 
and cell lines. Furthermore, it brings the possibility of mutation corrections in 
genetically based diseases. 
 
 
In conclusion, the combination of the versatility of PSCs, new genome editing tools 
and preclinically relevant (animal) models is revolutionizing our understanding of 
human diseases and helping to develop new treatments. In this study, we develop 
NHP-iPSCs which can be used to explore the potential of NHP for preclinical testing 
of regeneration therapies and for CVD modeling.
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IV. Aims of the thesis 
In this dissertation, I have explored the potential of NHP-PSC to be used 1- in stem 
cell-based regeneration therapies in vivo and, 2- to model CVDs. In the first part of the 
thesis, we aimed to improve the methods for NHP-iPSC generation, culture, and 
differentiation. Refined and highly standardized protocols have been established. In 
the second part, we focussed on overcoming the practical difficulties of applying 
CRISPR/Cas technologies to induce defined INDELs and deletion mutations in clonal 
NHP-iPSCs. Our final aim is to induce patient-specific mutations in NHP in vivo. To 
validate these approaches in vitro, it will be expedient to test the induction and the 
effect of predefined genetic modifications in species-specific iPSCs. Finally, based on 
the in silico analysis of the giant human sarcomeric protein Titin, we explored new 
therapeutic approaches for titinopathies. 
1st Hypothesis: Reprogramming of NHP and human fibroblasts can be achieved using 
a universal protocol, resulting in transgene- and feeder-free iPSC lines. 
-1st General objective: Refine methods for NHP-iPSCs generation. 
a) Specific objective: Apply the previously published reprogramming method 59 
based on the piggyBac transposon delivery of the reprogramming factors, to 
the baboon and rhesus macaque fibroblasts. 
b) Specific objective: Generate human and quasi clinical-grade NHP-iPSCs by a 
universal protocol applicable to all NHP species included in this study.  
 
2nd Hypothesis: Directed differentiation of both human and NHP-iPSC towards 
functional cardiomyocytes can be done using a single protocol. 
-2nd General objective: Test currently available protocols for the generation of human 
iPSC-derived cardiomyocytes for the derivation of cardiomyocytes from NHP-iPSCs.  
Specific objective: Evaluate the applicability and efficiency of human cardiomyocyte 
differentiation protocols in macaque, baboon and marmoset iPSCs. 
 
3rd Hypothesis: Inducing clinically relevant mutations in NHP-iPSCs is a reasonable 
test system for a genetically modified in vivo NHP model of a monogenic CVDs. 
-3rd General objective: Model cardiovascular disease in NHP-iPSCs. 
a) Specific objective: Adapt the protocols for CRISPR based genomic 
modifications to the molecular particularities of NHP-iPSCs.  
b) Specific objective: Induce clinically relevant mutations in NHP-iPSCs to model 
CVD. 
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c) Specific objective: Analyse possible phenotypic alterations in the mutated iPSC 
derived cardiomyocytes.
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transposition of reprogramming factors 
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Abstract. Non-human primates (NHP) are essential for preclinical testing of advanced 
therapy medicinal products (ATMPs), including induced pluripotent stem cell (iPSC)-
based therapies. However, testing and validation of ATMPs is hampered by a variety 
of experimental procedures. Studies published on heart and brain regeneration in NHP 
differ in culture conditions and stem cell source. To the present, the number of iPSC-
lines tested within these studies is low and yet relies on xenogenic support. The 
resulting line-dependant variability poses a risk for future clinical application of the 
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NHP-iPSC. Here, we demonstrate that commercial “human” PSC media are not 
sufficient for undifferentiated NHP-PSC culture. Additionally, rhesus fibroblast 
reprogramming is less efficient compared to human cells. We established a robust and 
universal protocol for transgene- and feeder-free primate iPSC generation and long-
term cultivation. Directed differentiation of the iPSCs into beating cardiomyocytes and 
engineered heart muscle demonstrated their value for preclinical ATMP testing. In 
summary, we provide a standardized protocol for the generation of genetically non-
modified primate iPSCs under chemically defined conditions. 
1 Introduction 
 
The value of non-human primates (NHP) as animal models in translational research is 
increasingly recognized 1. NHP offer advantages compared to other species because 
of their close phylogenetic relationship to humans, reflected in similarities in anatomy, 
a primate-specific genetic constitution and pathology 2-7. This makes NHP predictive 
models for the preclinical testing of new treatments for human diseases. In fact, NHP 
are not only used in classical toxicology studies 8 9 10, but they are also essential in 
basic research 11 12 and for the testing of advanced therapy medicinal products (ATMPs) 
including pluripotent stem cells (PSCs) 13. Since it is possible to generate genomically 
non-modified human induced pluripotent stem cells (iPSCs) 14 15 16 17, these cells are 
moving forward towards clinical application 18 19 20. Consequently, several studies used 
NHP models for preclinical PSC-based transplantation studies in the fields of 
cardiology and neurodegenerative diseases, amongst others 20-26.  
 
Studies on NHP-PSC-based cell replacement therapies differ in the experimental setup 
and species origin of stem cells tested. While Kikuchi et al., 24 and Chong and 
collaborators 21 tested the regeneration potential of human iPSC in monkeys, Shiba et 
al., 20 and Wang et al., 26 focused on allogenic and autologous iPSC transplantation.  
Moreover, numerous different protocols have been published for the generation and 
cultivation of NHP-iPSCs. To our knowledge, they all relied on feeder cells and often 
xenogenic serum for iPSC cultivation 27. Moreover, most iPSC lines were generated 
using integrating retroviral vectors 26 28. Furthermore, limited numbers of PSC lines, 
often only one, were generated and tested disregarding inter-iPSC line variability 20 26. 
One reason for this could be the lower reprogramming efficiencies of NHP compared 
to human cells. For instance, marmoset monkey iPSCs were initially obtained only 
from highly proliferative neonatal cells with five or even six reprogramming factors 
instead of the classical four Yamanaka factors 29 30. Stabilization of a marmoset iPSC 
with the classical four Yamanaka factors from marmoset was successful only after 
~100 days of reprogramming 31. Furthermore, the generation of stable macaque iPSC 
lines is challenging and less efficient in comparison to human or mouse 26. This is 
supported by own observations and personal communications with other laboratories. 
However, for preclinical development of live ATMPs it is critically important, to make 
procedures reproducible. To justify iPSC-based clinical trials the establishment of 
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standardized protocols is of utmost importance.  Generation of these protocols suitable 
for both human and NHP will allow future clinical translation. Besides reproducibility, 
it is instructive to generate and maintain NHP- and human-iPSCs under the same 
conditions in order to test iPSC-based therapies pre-clinically in a meaningful way. 
Finally, highly standardized and reproducible procedures will allow full exploration of 
the differences between allogenic and autologous iPSC-derived ATMPs. 
 
In this study, we developed a robust and reproducible protocol for transgene- and 
feeder-free human and NHP-iPSCs establishment.  We included the rhesus macaque 
(Macaca mulatta) and the olive baboon (Papio anubis), as both NHP species are 
relevant in preclinical research 1. We systematically developed and critically refined 
primate iPSC long-term culture. This protocol allows the undifferentiated “clinical-
grade cultivation” of rhesus, baboon and human PSCs under identical and chemically 
defined conditions. We further found that human cardiac differentiation protocols 32 33 
are ineffective with NHP-iPSCs. Therefore, we developed a novel time- and cost-
optimized protocol for the directed cardiac differentiation of NHP-iPSCs. This 
protocol leads to robust cardiomyocyte differentiation with high efficiencies of rhesus, 
baboon, and human iPSCs. The resulting spontaneously beating cells can be used for 
engineered heart muscle generation, responding to external calcium and β–adrenergic 
stimuli. 
 
2  Results  
 
2.1 Rhesus monkey fibroblast reprogramming is less efficient than 
human fibroblast reprogramming 
 
We aimed to generate integration-free NHP- and human-iPSCs under feeder- and 
serum-free conditions using an easy and cost-effective reprogramming method. 
Therefore, we used established episomal vectors containing OCT4, SOX2, KLF4, L-
MYC, and LIN28 as well as an shRNA against p53 15. For the study we selected two 
NHP species, rhesus macaque and baboon phylogenetically close to human and with 
biomedical relevance (Fig.S1). We consistently noted higher reprogramming 
efficiencies of human compared to NHP. To quantify our observations, we 
reprogrammed fibroblasts from three different adult rhesus macaques and two human 
adults under the same conditions. We counted the alkaline phosphatase (AP) 
expressing primary colonies at day 20, 30 and 40 after nucleofection. Human primary 
colonies appeared earlier and at much higher numbers (Fig.1). Differences were 
particularly evident at day 20 with 10-50 times more human colonies compared to 
macaque (Fig.1B). In the following time points, the deviation became smaller due to 
the delayed appearance of rhesus cell colonies. Additionally, fusion of the expanding 
human cell colonies further resulted in a reduced number of distinguishable colonies. 
In summary, reprogramming of adult rhesus monkey fibroblasts is less efficiently 
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compared to adult human fibroblasts under identical conditions. However, feeder-free 
reprogramming of putative rhesus fibroblasts was successful and reproducible. Using 
this approach, we reprogrammed human, rhesus macaque, and baboon fibroblasts. 
 
  
 
 
Figure 1. Comparison of reprogramming efficiencies between rhesus and human fibroblasts. (A) Skin 
fibroblasts from three different rhesus macaques and two human donors were nucleofected with 
episomal vectors containing human reprogramming genes. Appearing colonies were stained for alkaline 
phosphatase and counted at day 20, 30 and 40 after nucleofection (exemplarily shown for one human 
and one rhesus reprogramming). (B) The colony count confirmed lower reprogramming efficiencies in 
the rhesus cells compared to the human cells (Colonies per well). 
 
2.2 Undifferentiated long-term culture of NHP-PSCs failed under 
“human” feeder-free conditions 
 
Two commercially available media, namely Essential 8 (E8) and StemMACS iPS 
Brew XF, were tested for long term cultivation of feeder-free iPSC. Rhesus ESC were 
cultured in parallel as positive control for the tested human, rhesus and baboon iPSC 
(line 366.4 34 Thomson et al., 1995). While human cells remained undifferentiated in 
both media, NHP cells failed to survive in either. E8 and StemMACS iPS Brew XF 
allowed the long-term undifferentiated culture of human PSCs (Fig.2 for E8 medium; 
data not shown for iPS Brew XF). However, long-term cell culture of newly generated 
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NHP-iPSCs as well as rhesus macaque ESCs failed in both media. The NHP-PSCs 
showed clear signs of differentiation with loss of typical compact colony morphology 
when compared with undifferentiated human iPSCs (Fig.2). Additionally, the 
morphology of individual NHP cells changed over time, exhibiting a lower 
nucleus:cytoplasm ratio and increased cell size when compared with the human iPSCs 
(Fig.2, insets). Altogether, the morphological differences between the human and the 
NHP-PSCs in identical commercial media were evident, although their morphology 
was reported to be similar under conventional feeder-based culture conditions 
(Chapter 1) 28. In conclusion, there are differences between human and NHP-PSCs 
regarding reprogramming efficiencies and their requirements for long-term 
undifferentiated culture under feeder- and serum-free conditions. 
 
2.3 Long-term cultivation of NHP- and human-iPSCs in the newly 
developed UPPS medium 
 
Based on the above findings, we tested media that allowed long-term cultivation of 
iPSCs. Both E8 and iPS Brew were supplemented with variable combinations of small 
molecules and BMP4. iPSC from all three species were maintained for at least 3 
passages in the newly designed conditions (Suppl. Table 5). Finally, a combination of 
StemMACS iPS Brew XF medium supplemented with IWR-1 and Chir99021 was able 
to maintain both NHP and human PSCs in a morphologically undifferentiated state. 
During subsequent protocol optimization, we stepwise decreased the concentrations of 
IWR-1 and Chir99021 in order to determine the minimum concentration of these small 
molecules for the undifferentiated culture of NHP and human PSCs. Ultimately, the 
combination of Stem MACS iPS Brew XF medium supplemented with 1 μM IWR-1 
and 0.5 μM Chir99021 stabilized the iPSC lines, keeping them in an undifferentiated 
state over long culture periods of more than 50 passages (Fig.2). We termed this 
medium universal primate pluripotent stem cell (UPPS) medium. 
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Figure 2. Morphology of human, rhesus and baboon PSCs cultivated feeder-free in Essential 8 (E8) 
medium and Universal Primate Pluripotent Stem Cell (UPPS) medium. Human iPSCs grow as compact 
colonies showing a typical primed PSC morphology when cultivated in both, E8 and UPPS medium. In 
contrast, baboon and rhesus iPSCs differentiate spontaneously when cultivated in E8 medium but form 
undifferentiated compact colonies in UPPS medium. Adaptation of rhesus ESCs (Rh344.6) from feeder 
to feeder-free condition failed in E8 medium. Cultivated in UPPS medium, rhesus ESCs form compact 
undifferentiated colonies. Scale bars = 200 μm. 
 
UPPS medium was tested for long-term maintenance of five rhesus (4 adult, 1 
neonate), one adult baboon and two adult human iPSC lines. The iPSCs were cultured 
feeder-free on Geltrex-coated dishes under chemically defined conditions. All tested 
iPSC lines demonstrate similar morphologies with a high nucleus:cytoplasm ratio and 
distinct nucleoli (Fig.3). They express alkaline phosphatase (Fig.3C,G,K) and show a 
normal karyotype (Fig.3D,H,L). Only one female rhesus macaque line (DPZ_iRh25.4) 
shows a mosaic of X chromosome di-/trisomy, while the original fibroblasts of this 
animal, which were isolated from three independent sites (back skin, ventral skin, skin 
from the leg), were diploid. Immunostainings of the NHP-iPSCs show the expression 
of the pluripotency transcription factors NANOG and SALL4 (which are not encoded 
by the reprogramming plasmids), the cytoplasmic protein LIN28 as well as the surface 
markers SSEA4 and TRA-1-60 (Fig.S2). 
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Figure 3. Generation and characterization of transgene-free NHP-iPSCs. (A), (B) Rhesus iPSCs 
cultivated under feeder-free conditions, (C) express alkaline phosphatase and (D) show a normal 
karyotype. (E), (F) Baboon iPSCs cultivated under feeder-free conditions, (G) express alkaline 
phosphatase and (H) show a normal karyotype. (I), (J) Human iPSCs cultivated under feeder-free 
conditions, (K) express alkaline phosphatase and (L) show a normal karyotype. Scale bar = 100 μm. 
(M) The primer-binding sites (1-4) within the plasmid DNA. Plasmid maps were modified from Okita 
et al. 2011 15. (N) The absence of plasmid DNA was analyzed by PCR on gDNA using primers specific 
for four different regions of the plasmid DNA. Only the rhesus iPSC line DPZ_iRh33.1 shows 
integration of plasmid DNA. Rhesus fibroblasts and water were used as negative, and the three plasmids 
as positive controls. 
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Reverse transcription PCR analyses were performed for exogenous and endogenous 
expression of pluripotency factors (Fig.S3). Exogenous gene expression of OCT4A, 
KLF4, and LIN28 was detectable two days after nucleofection in rhesus fibroblasts 
(Fig.S3). In line DPZ_iRh34.1, no exogenous expression was detectable at passage 11 
or higher. Exogenous OCT4A expression was detectable at passage 11 in 
DPZ_iRh33.1, but became undetectable at later passages (Fig.S3). The endogenous 
expression of the pluripotency factors NANOG, OCT4A, SOX2, and LIN28 was 
observed in both cell lines in all three passages tested, as well as in the rhesus positive 
control ESC line. In rhesus fibroblasts, two days after nucleofection, the endogenous 
expression of NANOG, OCT4, SOX2, and LIN28 was not yet detectable. The loss of 
the reprogramming plasmid DNA from the generated iPSCs between passage 15 and 
20 was confirmed via PCR with four primer pairs (Fig.3M, N). One of the iPSC lines 
(DPZ_iRh33.1) shows PCR signals even at higher passages suggesting the integration 
of a plasmid (Fig.3M). No plasmid DNA was detected in the human and in the other 
NHP-iPSC lines. 
 
Altogether, after long-term culture in UPPS medium, the generated primate iPSC lines 
show the typical morphology of primed primate PSCs, have a normal karyotype, 
express (endogenous) pluripotency markers, and lost (except for line DPZ_iRh33.1) 
the reprogramming episomes. 
 
2.4 NHP-iPSCs cultured in UPPS medium are pluripotent 
 
In order to test whether the NHP-iPSCs are also functionally pluripotent under the 
newly established UPPS medium conditions, we differentiated them in vitro into 
embryoid bodies (Fig.4A,H). Plated bodies derived from rhesus (Fig.4A,D) and 
baboon (Fig.4E,H) iPSCs differentiated spontaneously into smooth muscle actin, α-
fetoprotein and β-III-tubulin expressing cells, suggesting the development of cells 
representing the three germ layers. In vivo differentiation by teratoma formation 
corroborated the in vitro results. Teratomas contained, beside others, muscle, intestinal 
epithelial and neural tissues, representing mesoderm, endoderm, and ectoderm, 
respectively (Fig.4I, J and L). Immunostainings against neuronal-specific β-III-tubulin 
(Fig.4K,N) and SOX9 (primitive endodermal epithelium; Fig.5M) verified ectodermal 
and endodermal tissue, respectively. These data demonstrate that the NHP-iPSCs 
cultured under chemically defined UPPS medium conditions are pluripotent. 
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Figure 4. Differentiation potential of NHP-iPSCs. Embryoid body (EB) formation of (A, B, C and 
D) rhesus and (E, F, G and H) baboon iPSCs in vitro. EBs differentiated spontaneously into different 
cell types, representing the three germ layers. (B) (F) mesoderm (smooth muscle actin), (C) (G) 
endoderm (α-fetoprotein) and (D) (H) ectoderm (βIII-tubulin). Scale bar (A) and (E) = 500 μm, (B)-
(H) = 50 μm. Teratoma formation of (I, J, K) rhesus and (L, M, N) baboon iPSCs after injection into 
immunodeficient mice. Teratomas contain containing derivatives of (I, L) mesoderm (muscle tissue), 
(J) endoderm (intestinal tissue), (M) endoderm (stained with SOX9) and (K), (N) ectoderm (neural 
tissue, stained with β-III-tubulin). Scale bar = 100 μm. 
 
2.5 NHP-iPSC-derived cardiomyocyte and EHM generation 
 
Several directed growth factor-free 2D monolayer cardiac differentiation protocols 
have been established for human PSCs 32 33 35 36 37. We first tried to adopt the small 
molecule-based differentiation protocols lacking growth factors to the rhesus and 
baboon iPSCs. We tested Chir99021 and Wnt agonists IWR-1 or IWP-2 in different 
concentrations and timings in different media (see Suppl, detailed in Unsuccessful 
growth factor-free NHP cardiomyocyte differentiation protocol). However, most of 
these cardiac differentiation experiments failed for most of NHP-iPSC lines; only 
sporadically changing subsets of the NHP-iPSCs responded to the differentiation 
stimuli. In contrast, the human cells efficiently and robustly differentiated into 
cardiomyocytes. An efficient and reproducible cardiac differentiation protocol 
working for all NHP-iPSC lines based only on small molecules, could not be 
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established. This highlights the difference between human and NHP-iPSC 
cardiomyocyte differentiation. Furthermore, these data suggest inter iPSC line 
variability. 
 
We then combined the small molecule protocol with BMP4 and Activin A (Fig.5A). 
With this hybrid method, we successfully and robustly differentiated NHP-iPSCs into 
cardiomyocytes. First beating cardiomyocytes from rhesus, baboon and human cells 
could be observed between day 7-8 of the differentiation protocol. Flow cytometric 
analyses of cTNT positive cells revealed average cardiac differentiation efficiencies 
between 53% and 72% at day 12 of differentiation (rhesus [53%], baboon [70%], 
human [72%]; Fig.S4). 
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Figure 5. Directed cardiac differentiation of human and NHP-iPSCs. (A) Scheme of the cardiac 
differentiation protocol for human, rhesus and baboon cells. (B) The structure and morphology of the 
cardiomyocytes are visualized by immunostainings of cardiac-specific genes: α-actinin, cardiac 
troponin I (cTNI), cardiac troponin T (cTNT), connexin 43 (Cx43), myosin light chain a (MLC2a) and 
titin. Scale bars = 20 μm. (C) The cardiomyocytes respond to isoprenaline (increased beating 
frequencies compared to basal) and propanolol (decreased beating frequencies compared to isoprenaline 
back to basal). Beating frequencies were analyzed by measuring the field potentials with the 
microelectrode array (MEA) system. 
 
For further characterize the cardiomyocyte populations, differentiations were purified 
by metabolic selection using lactate and further cultivated up to two months. The 
morphology, size, structure as well as cardiac-specific gene expression of 2-month-old 
rhesus and baboon iPSC-derived cardiomyocytes were similar and showed the typical 
immature, fetal-like morphology as known for human iPSC-derived cardiomyocytes 
(Fig.5B). Immunostainings of α-actinin, cardiac troponin T, cardiac troponin I and titin 
show an immature net-like striated pattern of sarcomere structures (compared to adult 
cardiomyocytes with a parallel-organized pattern). The NHP cardiomyocytes express 
the gap junction protein connexin 43, supporting electrical cell-to-cell coupling 
(Fig.5B). As an initial functional analysis, field potential measurements of the human 
and NHP-iPSC-derived cardiomyocytes were measured in the 2D microelectrode array 
(MEA) set-up after treatment with the non-selective β1- and β2- adrenoreceptor 
agonist isoprenaline (100 nM). In all three species, isoprenaline caused an increase in 
the beating frequencies of the cardiomyocytes relative to basal (untreated) conditions 
(107.39 ± 121.25, 122.28 ± 68.90, and 16.7 ± 54.38 % change in the beating 
frequencies for human, rhesus macaque, and baboon iPSC-CM, respectively; Fig.5C). 
After 5 minutes of treatment with isoprenaline, propanolol (2 µM) was consecutively 
added to the medium. This β-blocker reversed the chronotropic effect of isoprenaline 
back to basal conditions in all species. 
 
In order to verify the functionality of the iPSC-derived cardiomyocytes in a 
biologically relevant 3D tissue setting, we tested their functionality by engineered 
heart muscle (EHM) 38. Beating EHM were generated from one human (DPZ_Hs_1.2) 
and two Rhesus macaque iPSC lines (DPZ_iRh24.4, DPZ_iRh33.1). Before EHM 
generation, the percentage of cardiomyocytes in the cultures was found to be around 
90% or higher (evaluated by FACS, α-actinin staining) (Fig.6A). The spontaneous 
beating frequency of the human EHM was 50.3 ± 10.1 (mean ± SD) beats per minute 
(bpm), while the respective values for DPZ_iRh24.4 and DPZ_iRh33.1 were 87.5 ± 
8.67 and 102.5 ± 3.5.  Corresponding to the beating frequency, the time to 90% 
contraction and 50% relaxation was longest in the human EHM, while it was shortest 
in the line DPZ_iRh33.1 (Fig.6C, D). Organotropic responses to calcium and 
catecholamine stimulation were evaluated by the addition of increasing concentrations 
of extracellular calcium and acute isoprenaline, respectively. All EHMs showed a 
dose-dependent contraction force response to increasing extracellular calcium levels 
(Fig.6E). While the human EHM showed a very strong response, the rhesus EHMs 
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responses were moderate. To test the responses of the EHMs to beta-adrenergic 
stimulation, isoprenaline was added to the medium, and the % change in the force of 
contraction was measured (Fig.6F). The human EHM showed a 75% change, while 
the DPZ_iRh24.4 EHM exhibited a 90% and the DPZ_iRh33.1 EHM a 40% change. 
In summary, NHP-iPSCs cultured in UPPS medium can form functional 
cardiomyocytes that physiologically respond to external stimuli as the human iPSC-
derived EHM. 
 
In conclusion, we have established a reproducible, fast, and universal cardiac 
differentiation protocol for primate iPSCs under chemically defined conditions. 
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Figure 6. Functional Characterization of primate EHM. (A) The percentage of cardiomyocytes after 
metabolic selection and before EHM generation, for one human (iHs 1.2) and two Rhesus 
(DPZ_iRh24.4, DPZ_iRh33.1) lines. (B) EHM beating frequency (bpm) after four weeks of EHM 
culture. (C) The time to 90% contraction of the EHMs reversely correlates with the beating frequency. 
(D) The time to 50% relaxation correlates with the 90% contraction time. (E) Analysis of the force of 
contraction of EHMs by addition of extracellular calcium in serum-free conditions. The analysis was 
performed for one human (DPZ_iHs1.2), and two Rhesus macaque (DPZ_iRh33.1, and DPZ_iRh24.4) 
lines. Despite differences in the absolute values, all three lines show a response to increased calcium 
concentrations.  (F) Primate EHM inotropic response to acute isoprenaline (1µM, ISO) stimulation 
given as % change in the force of contraction. 
 
3 Materials and methods 
 
3.1 NHP species and ethics statement 
 
Two large NHP species the rhesus macaque (Macaca mulatta) and the olive baboon 
(Papio anubis), were included in the study. Both species show a close phylogenetic 
relationship to humans (Fig.S1), and are favorable NHP species in cardiovascular 
research 20 21 39 40. The range of the body weights of adult rhesus monkeys is 4 to 14 kg 
and of the olive baboon ~10 to 37 kg. The permission and ethical approval to take skin 
biopsies from the macaques were obtained under the license number 42502-04-
16/2370 from the Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit (LAVES). The baboon skin sample was made available to the 
Platform Degenerative Diseases of the German Primate Center (DPZ) during necropsy 
of the animal by veterinarian pathologists, which does not require specific permission. 
The DPZ runs self-sustaining colonies of different primate species including macaques 
and baboons and is registered and authorized by the veterinary governmental 
authorities (Reference number: 122910.3311900, PK Landkreis, Göttingen). 
 
3.2 Isolation and cultivation of NHP and human skin fibroblasts 
 
To cover a broader spectrum of cell donors and to ensure reproducibility, skin 
fibroblasts from five rhesus macaques (one newborn and four adult individuals 
including males and females) and one adult female baboon were isolated from 
outgrowths from small skin samples. Cells were cultivated in fibroblast cultivation 
medium (89 ml DMEM, 10 ml fetal bovine serum (FBS), 1 ml 100x non-essential 
amino acids (NEAA), 0.1 mM 2-mercaptoethanol; all Thermo Fisher) supplemented 
with 10 ng/ml bFGF (PeproTech) and penicillin-streptomycin (Thermo Fisher) on 6 
cm cell culture dishes (CytoOne). Cell outgrowths were split using 0.25% 
trypsin/EDTA (Thermo Fisher) and propagated in fibroblast medium containing bFGF 
but without further antibiotic treatment. Human skin fibroblasts were purchased from 
Lonza (CC-2511, lot 0000545147 [male], lot 0000490824 [female]) and cultivated 
under the same conditions. 
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3.3 Reprogramming NHP and human skin fibroblasts 
 
Skin fibroblasts were nucleofected with the three episomal vectors 15 pCXLE-
hOCT3/4-shp53-F (#27077), pCXLE-hSK (#27078) and pCXLE-hUL (#27080) using 
the 4D-Nucleofector Core Unit and the P2 Primary Cell Solution (Lonza). We 
transfected 2 μg of each plasmid per 6 x 105 cells and plated them onto 6-well plates 
(3 x 105 cells per well; Greiner Bio-One) in fibroblast cultivation medium 
supplemented with 10 ng/ml bFGF, 5 μM Pro-survival compound (Merck) and 
penicillin-streptomycin. The next day, the medium was replaced by fresh fibroblast 
medium containing 10 ng/ml bFGF and 0.5 mM sodium butyrate (Sigma-Aldrich). 
Medium was changed daily. At day 7 after transfection, the cells were spilt onto 
Geltrex (0.16 mg/ml; Thermo Fisher) coated 6-well plates. At day 8, fibroblast 
cultivation medium was replaced by Essential 8 medium (Thermo Fisher) 
supplemented with 0.5 mM sodium butyrate until day 11. From day 12 on, the 
transfected cells were cultivated in Essential 8 medium only. Appearing iPSC colonies 
were picked manually and transferred into 12-well plates (Greiner Bio-One). For 
continuous cultivation and expansion, the medium was replaced by our newly 
developed universal primate pluripotent stem cell (UPPS) medium (see below). 
 
For quantification of the reprogramming efficiency, the skin fibroblasts of three rhesus 
macaques and two humans were transfected and cultured as described above. The 
nucleofected fibroblasts were split into three wells of a 6-well plate at day 7. The 
appearing colonies were stained for alkaline phosphatase and counted at day 20, 30 
and 40 after nucleofection (colonies counted in one well at each time point). Alkaline 
phosphatase activity was detected using an alkaline phosphatase staining kit (Sigma-
Aldrich). 
 
3.4 Cultivation of human and NHP-PSCs 
 
Human- and NHP-PSCs were cultivated in UPPS medium, which is based on 
StemMACS iPS Brew XF (Miltenyi Biotec). This chemically defined human PSC 
cultivation medium was supplemented with 1 μM inhibitor of Wnt response-1 (IWR-
1, Sigma-Aldrich) and 0.5 μM Chir99021 (Merck). The stem cells were cultured on 
Geltrex coated (0.16 mg/ml) culture dishes at 37 °C and 5 % CO2. The cells were split 
every 3-4 days onto new culture dishes using Versene solution (Thermo Fisher). After 
splitting, the UPPS medium was supplemented with 5 μM Pro-survival compound for 
one day. 
 
3.5 In vivo and in vitro differentiation 
 
For in vivo differentiation experiments (teratoma formation assay), human and NHP-
iPSC colonies were treated with collagenase type IV (200 U/ml; Worthington) for 10 
min at 37 °C, washed and dissected into small clusters using a cell scraper (Sarstedt) 
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and by pipetting smoothly up and down. The cell clusters were centrifuged and 
resuspended together with irradiated mouse embryonic fibroblasts in 140 μl UPPS 
medium supplemented with 5 μM Pro-survival compound and 120 μl Geltrex (0.16 
mg/ml). 100 µl of this suspension was then injected subcutaneously into SCID/beige 
(C.B-17/IcrHsd-scid-bg) mice. Earliest teratoma formation was detected one month 
post-injection. The teratomas were fixed with Bouin’s fixative for 24h and embedded 
into paraffin. Histological sections were stained with hematoxylin and eosin (Merck) 
or with antibodies against SOX9 and β-tubulin III (Suppl. Table 1). 
 
NHP-iPSCs were also differentiated in vitro using the embryoid body (EB) formation 
method. Briefly, after treatment with collagenase type IV, cell clusters were cultivated 
in suspension in UPPS medium for 24 h giving them time to form EBs. The next day, 
the medium was replaced by differentiation medium (79 ml IMDM, Thermo Fisher), 
20 ml FBS, 1 ml 100x NEAA, 450 μM 1-thioglycerol (Sigma-Aldrich)). At day 8, the 
EBs were plated onto 0.1 % gelatin-coated coverslips (Menzel) and fixed for 
immunostaining at day 25. 
 
3.6 Cardiac differentiation 
 
Different protocols for cardiac differentiation established for human PSCs were tested 
for our rhesus and baboon iPSCs. The three tested basic approaches (see Suppl, 
detailed in Unsuccessful growth factor-free NHP cardiomyocyte differentiation 
protocol) were based on the small molecule Chir99021 with and without the growth 
factors, BMP4 and Activin A. In contrast to the human, cardiac differentiation growth 
factor-free protocols did not work for NHP. However, the hybrid differentiation 
method, including Chir99021, Activin A and BMP4, was successful. When reaching 
confluency of about 80-90%, the UPPS medium was replaced by mesodermal 
induction medium (RPMI 1640, B27 without insulin, 1 mM sodium pyruvate (Thermo 
Fisher), 200 μM L-ascorbic acid 2-phosphate, 1 μM Chir99021, 9 ng/ml Activin A 
(Miltenyi Biotec, premium grade), 5 ng/ml BMP4 (Miltenyi Biotec, premium grade). 
Medium was changed after 24h. At day 3, medium was replaced by cardiac induction 
medium (RPMI 1640, B27 supplement without insulin, 1 mM sodium pyruvate, 200 
μM L-ascorbic acid 2-phosphate, 5 μM IWR-1). Medium was changed at day 5. At 
day 7, the medium was replaced by cardiomyocyte cultivation medium (RPMI 1640, 
B27 with insulin, 200 μM L-ascorbic acid 2-phosphate). The cultures were monitored 
daily for contractile activity. To increase the yield of pure cardiomyocytes, the cells 
were metabolically selected with lactate. Around 20 days post differentiation, cells 
were plated in Geltrex coated 6-well plates.  Metabolic selection was achieved on 4-5 
days of cultivation in medium containing lactate but no glucose (RPMI 1640 without 
glucose (Thermo Fisher), 4 mM lactate/HEPES solution, 0.2 mg/ml L-ascorbic acid 2-
phosphate, 0.5 mg/ml recombinant human albumin). After cardiomyocyte selection, 
the medium was changed again to cardiomyocyte cultivation medium. 
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3.7 Immunostaining 
 
Cells were cultured on coverslips and fixed with 4% (w/v) paraformaldehyde (Merck) 
in DPBS (Thermo Fisher) for 20 min at room temperature and subsequently washed 
with DPBS. After blocking with 1% bovine serum albumin (BSA; Thermo Fisher), the 
cells were incubated with primary antibodies (Suppl. Table 1) at 4°C overnight. 
Permeabilization for staining intracellular proteins was achieved by treating with 0.1% 
Triton X-100 (Sigma-Aldrich). After washing with DPBS, the secondary antibodies 
were incubated (Suppl. Table 2) for 1 h at 37 °C. Cell nuclei were stained with 1 μg/ml 
DAPI (Sigma-Aldrich). The coverslips were finally mounted with Fluoromount–G 
(eBioscience) and analyzed with a fluorescence microscope (Zeiss). 
Immunohistochemical staining of the teratomas was performed as described recently 
41. 
 
3.8 Flow cytometry 
 
At day 12 after initiation of differentiation, human and NHP iPSC-derived 
cardiomyocytes were treated with 0.25% trypsin/EDTA, flushed through a 40 μM cell 
strainer (Falcon) and single cells were fixed with 4% (w/v) paraformaldehyde for 10 
min. After blocking with 1% BSA at 4°C, the cells were incubated with FITC-labeled 
cTNT antibody (Suppl. Table 1) at 4°C overnight. The next day, cells were washed 
and resuspended in 100 μl flow cytometry buffer (0.5 % BSA, 2 mM EDTA (Roth)). 
Unstained cells from each cell suspension and appropriate isogenic controls were 
included as negative controls in each case. Flow cytometric analyses (10,000 cells per 
sample) were performed with SH800S Cell Sorter using a 130 μm sorting chip (Sony) 
according to the manufacturer´s instructions. 
 
3.9 DNA and RNA isolation and polymerase chain reaction 
 
Genomic DNA from snap-frozen cell pellet samples (between passage 15 and 25) was 
isolated using the DNeasy Blood & Tissue Kit (Qiagen) according to the 
manufacturer´s instructions. To confirm the loss of episomal plasmids in the generated 
iPSCs, we performed a standard polymerase chain reaction (PCR) using plasmid-
specific primer pairs (Suppl. Table 3), which are complementary to four different 
regions present in all three plasmids (Fig.3). One PCR reaction (50 μl) was performed 
using 50-100 ng of genomic DNA, using Taq DNA Polymerase with Standard Taq 
Buffer (New England Biolabs), following the manufacturer´s instructions. 
 
For gene expression analyses, total RNA from snap-frozen cell pellets was isolated 
using NucleoSpin RNA Plus isolation kit (Macherey-Nagel), treated with RNase-free 
DNase (Qiagen) and subsequently transcribed into cDNA with Omniscript RT kit 
(Qiagen) according to the manufacturer´s instructions. The cDNA was then amplified 
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using Taq DNA polymerase with Standard Taq Buffer (New England Biolabs). All 
oligonucleotides (Sigma-Aldrich) are listed in Suppl. Table 3. 
 
3.10 Karyotyping 
 
Karyotyping was done as described previously in Rodriguez-Polo I et al., 2015 42 
(Chapter 1). 
 
3.11 Microelectrode array (MEA) measurements 
 
The iPSC-derived cardiomyocytes were treated with 0.25% trypsin/EDTA and plated 
onto Geltrex coated 6-well MEAs (Multichannel Systems). After 4-7 days of 
recovering, field potentials of the cardiomyocytes were measured using the MEA2100-
2x60-System at 38 °C, which is the physiological body temperature of macaques. After 
basal field potential measurements, the cells were treated with the non-selective β-
adrenoreceptor agonist isoprenaline (100 nM; Sigma-Aldrich) followed, after 5 min 
by propranolol (2 µM). The effect of these drugs on the beating frequency was detected 
by continuously measuring the field potentials of the cardiomyocytes. Data were 
acquired and analyzed using MC_Rack software (Multichannel Systems). 
 
3.12 EHM generation 
 
Engineered heart muscle (EHM) generation was performed according to Tiburcy, M. 
et al. 2017 38. In brief, primate cardiomyocytes after selection were mixed with human 
foreskin fibroblast (HFFs, American Type Culture Collection) (70:30%). Cell solution 
was reconstituted in pH-neutralized medical-grade bovine collagen (0.4 mg per EHM; 
LLC Collagen Solutions) and concentrated serum-free medium (2× RPMI, 8% B27 
without insulin, penicillin [200 U/ml], streptomycin [200 μg/ml]).  Afterwards, EHMs 
were cultured for 3 days in IMDM with 4% B27 without insulin, 1% NEAA, 2 mM 
glutamine, 300 μM ascorbic acid, IGF1 (100 ng/ml; AF-100-11), FGF-2 (10 ng/ml; 
AF-100-18B; PeproTech), VEGF165 (5 ng/ml; AF-100-20; PeproTech), TGF-β1 (5 
ng/ml; AF-100-21C; PeproTech), penicillin (100 U/ml), and streptomycin (100 
μg/ml). After 3 days, the EHM was transferred to flexible holders, and 4 weeks later, 
EHM analysis was performed as described in 38. 
4  Discussion 
 
Pluripotent stem cells, including iPSCs, revolutionize different fields of biomedicine, 
including potential treatments for until the moment incurable diseases. In fact, several 
late preclinical animal studies involving NHP have been already conducted 21 23 40. The 
promising findings in the mention projects reflect in the first clinical trials of PSC-
based ATMPs, e.g., for the treatment of age-related macular degeneration 43 and 
Parkinson’s disease. Expectations are high that in the future PSCs might be used 
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routinely as a therapeutic agent in the clinic. However, these therapies are currently 
experimental, and there are still many open questions. Most of them can be adequately 
addressed only using NHP due to their close phylogenetic relationship to humans, 
which is reflected by generally comparable anatomy, immune systems, and genetic 
and transcriptomic constitution as well as life span 2 4 6. Allogeneic and autologous 
transplantations, using NHP as model organisms, may also provide a deeper 
understanding of the respective immunological responses and the corresponding 
immunosuppression regimens for PSC-derived transplants in humans (for review see 
Wu et al., 44). In the present study, we developed a new cost-efficient and, most 
notably, robustly reproducible reprogramming protocol for the generation of 
integration-free NHP-iPSCs. Moreover, we established a universal cultivation method 
under chemically defined conditions for NHP and human PSCs to ensure optimal 
comparability between cell lines from different primate species and their responses to 
differentiation cues and immunological challenges. This will improve the 
translatability of findings from NHP to the clinics. 
 
We reprogrammed cells from five rhesus macaques, one baboon, and two humans to 
demonstrate the broad applicability of our reprogramming method. To our knowledge, 
most of the relatively few NHP-iPSC lines generated until now (including macaque, 
baboon, gorilla, bonobo and common marmoset) were typically reprogrammed using 
a method involving genomic integration of the reprogramming vectors 27 28 29 30 45-49; 
or genomic integration followed by the excision of the lentiviral vector leaving a 
genetic tag in the host genome 50 51. Human iPSCs with genomic integration of the 
reprogramming vectors are not acceptable for therapeutic applications in patients. 
Regarding the translational value of NHP, we decided to generate genomically non-
modified primate iPSCs using episomal plasmid vectors. The episomal system 
involves p53 suppression and non-transforming L-MYC instead of c-MYC 15. In all of 
the iPSC lines except one (iRh33.1), we could not detect the reprogramming vector 
DNA indicating that the iPSC lines are integration-free. Our results (one out of eight 
iPSC lines with integration) are in line with the original publication of the episomal 
system where two out of seven human cell lines showed vector DNA integration into 
the host genome 15. 
 
An interesting observation was that the NHP cells were less efficient in reprogramming 
compared to the human cells. The reason for this is currently unknown. One possible 
explanation could be that the human reprogramming factors may work less efficient in 
the NHP than in the human cells. However, the reprogramming factors are highly 
conserved between humans and rhesus macaques with identities on the protein level 
of 99% (OCT4, SOX2, KLF4, LIN28) and 96% (L-MYC) (Suppl. Table 4). 
Furthermore, the human p53 shRNA sequence is 100% complementary to the 
respective rhesus sequence. In a previous study, we used marmoset sequences cloned 
into a stably expressing piggyBac transposon to reprogram neonatal marmoset 
fibroblasts and obtained only very few primary colonies 29. Recently, we also 
generated baboon iPSCs using the same piggyBac vector and obtained also only a 
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rather small number of primary colonies (Chapter 1) 42. Finally, it has been shown that 
mouse factors are sufficient to efficiently reprogram human cells and vice versa 21 52. 
Taken together, all this strongly argues against the hypothesis that the human 
reprogramming factors are responsible for the low reprogramming efficiencies of the 
rhesus (and the baboon) cells compared to the human cells. Further investigations are 
necessary for final conclusions. However, our standardized primate (including human) 
reprogramming protocol in combination with single-cell -omics may help to identify 
the differences between human and NHP reprogramming on the molecular level. 
 
Using the same approach as for human cells, we reprogrammed NHP fibroblasts. The 
generated cells were maintained in a chemically defined medium, comparable to 
clinically relevant conditions. To our knowledge, this is the first report showing 
successful NHP-iPSC generation and maintenance without the support of feeder cells 
27 29 30 46 48 51 53 54 55. The generation of human and NHP-iPSCs was successful in our 
study using the well-defined Essential 8 cultivation medium developed for human stem 
cell culture 56. As expected, the generated human iPSCs could be cultivated in this 
medium while keeping their pluripotent state. However, the undifferentiated long-term 
cultivation of the NHP-iPSCs was not possible due to permanent differentiation of the 
culture. To exclude that our NHP-iPSCs were incompletely reprogrammed, we tried 
to cultivate the rhesus ESC line Rh366.4 34 in Essential 8 media. However, the rhesus 
ESC line also differentiated spontaneously when cultivated feeder-free in Essential 8 
medium. The same finding was made using StemMACS iPS Brew XF. This showed 
that the commercial media alone are not sufficient to keep rhesus and baboon PSCs in 
a stable undifferentiated pluripotent state, while the cells could be maintained feeder-
free using the UPPS medium. In addition, we also tested the supplementation of both 
cultivation media with inhibitor of Wnt response-1 (IWR-1), a Wnt signaling inhibitor, 
amongst other factors. It was shown that the addition of IWR-1 could optimize the 
derivation and long-term cultivation of mouse epiblast stem cells (EpiSCs) in 
combination with FGF2 in N2B27 media 57. Mouse EpiSCs are considered as the in 
vitro counterparts of human (primed) ESCs. Wu et al. postulated the supportive effect 
of IWR-1 also on human ESCs, rhesus PSCs and chimpanzee iPSCs 57. The combined 
addition of IWR-1 and bone morphogenetic protein 4 (BMP4) to Essential 8 and 
StemMACS iPS-Brew XF media was tested as a second condition. It was shown that 
BMP4 is secreted by mouse embryonic fibroblasts and was identified as pluripotency- 
and self-renewal promoting factor for mouse ESCs 58. As a third condition, we tested 
IWR-1 combined with the Wnt pathway activator Chir99021. Kim and colleagues 
could show that the dual administration of Chir99201 and Wnt inhibitor XAV939 or 
Chir99201 and IWR-1 allowed long-term maintenance of undifferentiated mouse 
EpiSCs as well as human ESCs. These cells were routinely maintained on mouse 
embryonic fibroblasts in semi-defined cultivation media using Knockout serum 
replacement 59. Of all tested conditions, the combination of Chir99201 and IWR-1 in 
StemMACS iPS Brew XF medium turned out to be the only condition in our study 
facilitating consistent undifferentiated long-term self-renewal (> 50 passages) of 
rhesus, baboon, and human iPSCs. Eventually, we decreased the concentrations from 
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3 µM Chir99201 and 2.5 µM IWR-1, as originally published by Kim and colleagues, 
to 0.5 µM Chir99021 and 1 µM IWR-1. We named our new formulation universal 
primate pluripotent stem cell (UPPS) medium 59. 
 
PSCs play an important role for (comparative) developmental biology as well as for 
regenerative medicine. For these purposes, it is crucial to establish efficient protocols 
for the directed differentiation of NHP-PSCs into specific cell types. Here, we tested 
different protocols for cardiac differentiation, originally established for human PSCs. 
As for the cultivation of human and NHP-PSCs, we aimed for a universal cardiac 
differentiation protocol for better comparability between the primate species. For our 
rhesus and baboon iPSCs, we first tried to adopt an optimized chemically defined and 
growth factor-free cardiac differentiation protocol using a small molecule-based 
induction of differentiation 35. This protocol is based on the modulation of Wnt 
activation and inhibition in a time-dependent manner as originally published by Lian 
and colleagues 32 33. For cardiac induction, Lian et al., used RPMI 1640 supplemented 
with B27 without insulin, which contains the xenogeneic component BSA. In contrast, 
Burridge and colleagues developed for human cells a xeno-free and chemically less 
complex medium using RPMI 1640 supplemented only with L-ascorbic acid 2-
phosphate and rice-derived recombinant human albumin, tested on several human PSC 
lines with differentiation efficiencies up to 95% 35. However, none of our NHP-iPSC 
lines could be efficiently and reproducibly differentiated into cardiomyocytes applying 
both protocols using the Wnt activator Chir99021 and the inhibitors IWP-2 or IWR-1 
alone. Notably, we observed an increased cell death of the NHP cells when using 
RPMI 1640 and Chir99021 only for mesoderm induction compared to RPMI 1640 
supplemented with B27 without insulin and Chir99021. The growth factor-free cardiac 
differentiation protocols that work robustly for human PSCs. In contrast, the 
combination of Wnt signaling activation together with BMP4 and Activin A treatment 
followed by Wnt signaling inhibition was required to achieve efficient cardiac 
differentiation in our NHP-iPSCs.  
 
Finally, we came up with a NHP cardiomyocyte differentiation protocol slightly 
modified compared to the protocol developed previously for human cells 38. First 
beating NHP-iPSC-derived cardiomyocytes could be observed around day 8 of 
differentiation with higher differentiation efficiencies on day 12 in baboon (70%) and 
human (72%) compared to rhesus (53%) cells (without prior selection). The fact that 
Wnt modulation using Chir99021 alone is not sufficient to differentiate the NHP-
iPSCs shows a clear difference between rhesus and baboon PSCs compared to human 
PSCs. There are only very few publications available showing directed cardiac 
differentiation protocols for NHP-PSCs to compare with our findings. Shiba and 
colleagues used the so-called matrix sandwich method, which also involves BMP4 and 
Activin A treatment, to differentiate cynomolgus macaque iPSC into cardiomyocytes 
20 21 23 24. However, their average differentiation efficiencies were relatively low (20% 
cTNT positive cells before metabolic selection), and only one iPSC line was used in 
this study. Also, Zhao and colleagues reported only one rhesus iPSC line 60. 
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Considering iPSC line heterogeneity, the overall value of these data might be limited. 
In order to provide general and robust data, we believe that it is crucial to demonstrate 
the feasibility of procedures with several independent cell lines from different 
individuals. Furthermore, to our knowledge, we report for the first time efficient 
directed cardiac differentiation of baboon iPSCs. 
 
To ensure the functionality of the cardiomyocytes derived from UPPS-cultured iPSCs, 
we performed MEA analysis and generated EHMs 38. Both assays showed that the 
cardiomyocytes respond to the non-selective β1- and β2-adrenoreceptor agonist 
isoprenaline and that this effect can be reverted by propanolol. Also, the force of 
contraction of EHM generated from the primate iPSCs is Ca2+ concentration-
dependent. EHMs are a powerful tool to study cardiomyocyte function and disease in 
vitro and may serve in customized formats as ATMPs for the regeneration of the 
degenerating human heart. To preclinically test this novel therapeutic approach in a 
meaningful way, it is important to do this in a coherent and clinical-equivalent NHP 
setting. In this context, the novel universal protocols allowing xeno-free and 
chemically defined PSC culture and cardiomyocyte differentiation represent an 
important step towards the translation of the experimental iPSC-based regeneration of 
the primate heart into the clinics. 
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8.1 Tables 
 
 Company Cat.-No. Dilution 
AFP Dako A0008 1 to100 
α-actinin Sigma-Aldrich A7811 1 to 1000 
β-tubulin 
III 
Sigma-Aldrich T8660 1 to 1000 
Cx43 Abcam ab11370 1 to 1000 
cTNI Abcam ab47003 1 to 200 
cTNT Miltenyi Biotec 130-106-687 1 to 10 
cTNT Thermo Fisher MS295PABX 1 to 200 
LIN28 R&D Systems AF3757 1 to 300 
MLC2a 
Synaptic 
Systems 
311-011 1 to 200 
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NANOG Cell Signalling 4903 1 to 400 
SALL4 Abcam ab57577 1 to 200 
SMA Sigma-Aldrich A2547 1 to 1000 
SOX9 Merck AB5535 1 to 1000 
SSEA4 Abcam ab16287 1 to 200 
Titin Merck MAB1553 1 to 50 
TRA-1-60 Abcam ab16288 1 to 200 
 
Suppl. Table 1: Primary antibodies used in this study. 
 
 
Name Company 
Cat.-
No. 
Dilution 
Alexa555-goat-α-mouse IgG Thermo Fisher A21424 
1 to  
1000 
Alexa488-goat-α-mouse IgG Thermo Fisher A11029 
1 to 
1000 
Alexa488-goat-α-mouse IgG/IgM Thermo Fisher A10680 
1 to 
1000 
Alexa488-donkey-α-goat IgG Thermo Fisher A11055 
1 to 
1000 
Alexa488-donkey-α-rabbit IgG Thermo Fisher A21206 
1 to 
1000 
 
Suppl. Table 2: Secondary antibodies used in this study.  
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Suppl. Table 3. Oligonucleotides for PCR analyses. F: amplicon length; TM: annealing temperature; 
C: cycles 
  
Name Sequence F [bp] TM [°C] C
for: 5´- GCT ATT GCT TCC CGT ATG GC -3´
rev: 5´- CAA AGG GAG ATC CGA CTC GT -3´
for: 5´- AAG AGG AGG GGT CCC GAG A -3´
rev: 5´- GCC AAT GCA ACT TGG ACG TT -3´
for: 5´- GGT TCA CTA CCC TCG TGG AAT -3´
rev: 5´- CGG GGC AGT GCA TGT AAT -3´
for: 5´- GGT GAC TGT GTG CAG CTT TG -3´
rev: 5´- GGA GCT GAG TGA CGT GAC AA -3´
for: 5´- GAC CTG ACT GAC TAC CTC ATG -3´
rev: 5´- GGT AGT TTC GTG GAT GCC ACA -3´
Name Sequence F [bp] TH [°C] #
for: 5´- TTC ATC GAC GAG GCT AAG CG -3´
rev: 5´- TCA CTG ACA GCC ATG GTG AA -3´
for: 5´- TGA TCC TCG GAC CTG GCT AA -3´
rev: 5´- TCCCCGAAGCTTGAATTCGC -3´
for: 5´- GAG AAG GAG AAG CTG GAG CAA -3´
rev: 5´- ACA TCC TTC TCG AGC CCA A -3´
for: 5´- ACT CAA ACT GGC TGG GGA TG -3´
rev: 5´- TTC AAG CTC CGG AAC CCT TC -3´
for: 5´- GGG TGT TCT GTA TTG GGA GTG -3´
rev: 5´- GCA CCC TAT TCC CAC TTT CTC -3´
for: 5´- CAG AGA TAC CTC AGC CTC CAG -3´
rev: 5´- CTT CAG GTT GCA TGT TCG T -3´
for: 5´- GGT AGG AGC TTT GCA GGA AGT -3´
rev: 5´- CCA ACG ATG TCA ACC TGC ATG -3´
for: 5´- TGG ATG ATG ATA TCG CCG CGC T -3´
rev: 5´-GGG CCT CGG TCA GCA GCA CGG-3´
β-actin 324 61 20
WPRE
OriP1
OriP2
NANOG 562 54 30
SOX2 (endo) 428 61 30
LIN28 (exo) 327 54 30
LIN28 (endo) 371 61 30
OCT4 (exo) 1021 54 30
OCT4 (endo) 841 53 30
β-actin 379/380 61 32
Endogenous (endo) and exogenous (exo) pluripotency marker expression (RT-PCR)
KLF4 (exo) 812 53 30
592 57 32
416 54 32
Plasmid detection in genomic DNA
470 54 32
EBNA-LoxP (2) 555 61 32
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 Protein          
 hKLF
4 
rKLF
4 
hMY
C 
rMY
C 
hSOX
2 
rSOX
2 
hOCT
4 
rOCT
4 
hLIN2
8 
rLIN2
8 
hKLF
4 
100 99,37         
rKLF
4 
99,37 100         
hMYC  100 98,46       
rMYC  98,46 100       
hSOX2    100 100     
rSOX2    99,37 100     
hOCT
4 
      100 99,17   
rOCT
4 
      99,17 100   
hLIN28        100 99,04 
rLIN28        99,04 100 
 
Suppl. Table 4: Protein similarity analysis for both human and rhesus pluripotency genes compared 
via SerialCloner Alignment. All values are given in percent. 
 
 
Unsuccessful growth factor-free NHP cardiomyocyte differentiation protocols 
 
Approach 1: When reaching confluency of about 80-90%, the UPPS medium was 
replaced by mesodermal induction medium (Roswell Park Memorial Institute Medium 
(RPMI 1640, Thermo Fisher), 0.2 mg/ml L-ascorbic acid 2-phosphate (Sigma-
Aldrich), 0.5 mg/ml recombinant human albumin (Sigma-Aldrich), with different 
concentrations of Chir99021 (1, 2.5, 4, and 5 μM)). After 48h, medium was replaced 
by cardiac induction medium (RPMI 1640, 0.2 mg/ml L-ascorbic acid 2-phosphate, 
0.5 mg/ml recombinant human albumin, 5 μM IWP-2 (Millipore) or IWR-1. At day 4 
and 6, medium was changed with RPMI 1640, 0.2 mg/ml L-ascorbic acid 2-phosphate, 
and 0.5 mg/ml recombinant human albumin. From day 8 on, medium was replaced by 
cardiomyocyte cultivation medium (RPMI 1640, B27 with insulin (Thermo Fisher)) 
and changed every 2-3 days. A similar protocol was tested with a slightly modified 
mesodermal induction medium using RPMI 1640 with Chir99021 only. 
Approach 2: A second cardiac differentiation protocol used RPMI 1640 and B27 
without insulin. At a confluency of about 80-90%, the UPPS medium was replaced by 
mesodermal induction medium (RPMI 1640, B27 without insulin (Thermo Fisher), 
with different concentrations of Chir99021 tested (1, 3, 4, 8, 9 and 10 μM)). After 24h, 
medium was changed with RPMI 1640, B27 without insulin. At day 3, medium was 
replaced by cardiac induction medium (RPMI 1640, B27 without insulin (half fresh, 
half left), 5 μM IWP-2 or IWR-1). At day 5, medium was changed with RPMI 1640, 
B27 without insulin. From day 7 on, medium was replaced by cardiomyocyte 
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cultivation medium (RPMI 1640, B27 with insulin) and changed every 2-3 days. A 
similar protocol was tested using IMDM instead of RPMI 1640. 
 
Condition# Cultivation media Additives 
1 Essential 8 medium - 
2 Essential 8 medium 2.5 µM IWR-1 
3 Essential 8 medium 2.5 µM IWR-1 
25 ng/ml BMP4 
4 Essential 8 medium 2.5 µM IWR-1 
3 µM CHIR99021 
5 StemMACS iPS-Brew XF - 
6 StemMACS iPS-Brew XF 2.5 µM IWR-1 
7 StemMACS iPS-Brew XF 2.5 µM IWR-1 
25 ng/ml BMP4 
8 StemMACS iPS-Brew XF 2.5 µM IWR-1 
3 µM CHIR99021 
9 StemMACS iPS-Brew XF 1 µM IWR-1 
0.5 µM CHIR99021 
 
Suppl. Table 5. Tested conditions to optimize a standardized cultivation method for human and NHP-
PSCs. 
 
8.2 Supplementary figures 
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Figure S1. Non-human primates in basic and translational research. (A) Phylogenetic tree of mammals 
used as model organisms in research (after Hedges 2002), (B) phylogenetic tree of selected primates 
(after Rogers & Gibbs 2014 6), (C) rhesus macaques, (D) olive baboons. Photographic images by 
German Primate Center (DPZ). 
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Figure S2. Pluripotency gene expression in NHP iPSCs. Rhesus (upper panel) and baboon (lower panel) 
iPSCs express pluripotency related transcription factors NANOG and SALL4, pluripotency related 
surface markers SSEA4 and TRA-1-60as well as LIN28. Scale bar = 100 μm. 
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Figure S3. Time-dependent exogenous (exo) and endogenous (endo) pluripotency-related gene 
expression in two generated rhesus iPSC lines. The exogenous (plasmid regulated) gene expression of 
OCT4, KLF4 and LIN28 is detectable in rhesus fibroblasts two days after nucleofection. OCT4 (exo) 
expression is still detectable in iPSC line Rh33.1 at passage 11 but disappears in later passages. In cell 
line iRh34.1 exogenous gene expression is not detectable at passage 11 or higher. The pluripotency-
related endogenous gene expression is detectable in both iPSC cell lines at passage 11 and higher as 
well as in the rhesus ESC line Rh366.4, but not in fibroblasts two days after nucleofection. The left 
panel shows results after PCR with prior reverse transcription (+RT) and on the right without reverse 
transcription (-RT). 
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Figure S4. (A-B) Differentiation efficiencies of the human and NHP-iPSCs were defined by cardiac 
troponin T positive cells at day 12 of differentiation by flow cytometry (before metabolic selection). 
(A) Quantitative analysis of differentiation efficiency. (B) Representative gating used for the sorting.  
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VII. Chapter 3: A piggyBac–based platform for genome 
editing and clonal rhesus macaque iPSC line 
derivation 
Author contribution statement 
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IRP wrote the paper with contributions from all coauthors.   
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Figure 2, Suppl. Figure 1, 2 IRP performed iPSC characterization  
Figure 2 Suppl. Figure 3, 4, 
6 
RD performed the teratoma formation assay 
  IRP, SM, RB, and RD analyzed the teratoma histology 
Figure 3, Suppl. Figure 5 FM, AM, TH performed the methylation experiments and analysis 
Figure 4 IRP performed the transposon removal  
Figure 5 and 6 IRP, YT, IG, and DU (All under master lab rotation or master thesis  
  supervised by IRP) performed the single-cell cloning  experiments 
Figure 6 SP construct the vector PTT-PB-pCAG-eCas9-GFP-U6-gRNA-Neo 
Table 1 IRP performed the similarity analysis  
Suppl. Figure 7 IRP generated the isogenic controls 
Experiment design IRP, SM, and RB 
Manuscript writing IRP and RB, with the contribution of all authors 
 
 
 
 
  
Chapter 3: A piggyBac–based platform for genome editing and clonal rhesus 
macaque iPSC line derivation 
75 
 
A piggyBac–based platform for genome editing and clonal 
rhesus macaque iPSC line derivation  
 
Ignacio Rodriguez-Polo1,2, Sophie Mißbach1,2, Stoyan Petkov1,2, Felix Mattern3, Anna 
Maierhofer3, Iga Grządzielewska1,4, Yuliia Tereshchenko1,4, Daniel Urrutia-Cabrera1 
#, Thomas Haaf3, Ralf Dressel2,5, Iris Bartels6, Rüdiger Behr1,2* 
 
 
1 Research Platform Degenerative Diseases, German Primate Center – Leibniz Institute for Primate 
Research, Kellnerweg 4, 37077 Göttingen, Germany 
 
2 German Center for Cardiovascular Research (DZHK), Partner site, Göttingen, Germany 
 
3Institut für Humangenetik, Universität Würzburg, Biozentrum, Am Hubland, 97074 Würzburg 
 
4Max Planck molecular Biology program (M.Sc./Ph.D.), Justus-von-Liebig-Weg 11, 37077 Göttingen, 
Germany 
 
5Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Humboldtalle 
34, 37073 Göttingen, Germany 
 
6Institute of Human Genetics, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 
Göttingen, Germany 
 
#Current address: Cellular reprogramming unit, Center for eye research Australia, 75 Commercial 
Road, Melbourne 3004, Australia 
 
 
 
*Correspondence:   
Rüdiger Behr 
Research Platform Degenerative Diseases 
German Primate Center – Leibniz Institute for Primate Research 
Kellnerweg 4, 37077 Göttingen, Germany  
Fax: 0049-(0)551-3851431 
Email: rbehr@dpz.eu 
 
 
 
 
 
  
Chapter 3: A piggyBac–based platform for genome editing and clonal rhesus 
macaque iPSC line derivation 
76 
 
Abstract. Non-human primates (NHP) are, due to their close phylogenetic relationship 
with humans, excellent animal models to study clinically relevant human mutations. 
However, the toolbox for the genetic modification of NHP is less developed so far than 
that for the genetic manipulation of other species, e.g., mice. Therefore, it is necessary 
to further develop and refine genome editing approaches in NHP. NHP pluripotent 
stem cells (PSC) share key molecular signatures with the early embryo, which is an 
important target for genomic modification. Therefore PSC are a valuable test system 
for the validation of embryonic genome editing approaches. In the present study, we 
made use of the versatility of the piggyBac system for different purposes in NHP 
biotechnology and genome editing. These include 1) Reprogramming of rhesus 
macaque fibroblasts to induced pluripotent stem cells (iPSCs); 2) Removal of the 
transgene resulting in transgene-free iPSCs, that could be cultured under feeder-free 
conditions; 3) Development of an approach to edit the genome of rhesus macaque 
PSCs with high efficiency; 4) Establishment of a novel protocol for the derivation of 
gene-edited monoclonal iPSC lines. These findings facilitate efficient testing of 
genome editing approaches in NHP before in vivo application.  
1 Introduction 
 
Cardiovascular and neurodegenerative diseases are the primary causes of death 
worldwide 1 2. Even though these disorders have a complex etiology they are often of 
genetic origin 3 4. To further understand the development and progression of these 
diseases, highly predictive model systems need to be established. Besides cell and 
organoid models, it is necessary to use animal models that share the complexity of the 
human nervous, immune, and cardiovascular systems 5 6. Non-human primates (NHP) 
as our evolutionary closest relatives are excellent animal models, as reflected by high 
genetic, physiological, developmental, and metabolic resemblance with humans 6 -10.   
 
In comparison with other model organisms, NHP biomedical models are less 
established 10 11, but the demand for NHP models in biomedicine is strongly increasing. 
Due to the difficulties associated with genetic modifications of NHP, most studies 
mimicking human diseases use drug or surgically induced conditions 5 11 12 13. However, 
in the last years, the emergence of new genome editing-tools like CRISPR–Cas9 has 
revolutionized the generation of genetically modified animals 14. The first NHP species 
that were genetically modified, at that time by classical lentiviral transgenesis, were 
the marmoset and the rhesus macaque 9 13 15 16 17 18. However, the genetic modification 
of NHP entails difficulties not found in other model species. Usually, NHP have 
smaller litter size and long gestation periods. In consequence, it is challenging and 
cost-intensive to obtain a high number of embryos 7 13 11. Furthermore, the injection of 
(genetically modified) NHP-PSCs into primate embryos has not been successful so far, 
in contrast to mouse. Many efforts have been made to overcome these difficulties by 
refining and adapting protocols developed for mouse, rat, or bovine to NHP 9. Finally, 
the generation of transgenic NHP is also ethically controversial 10 19. All of these 
obstacles together make the careful evaluation of genome editing tools necessary 
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before their application in vivo 20. In order to search for an appropriate genome editing 
approach, certain aspects must be critically assessed: (1) efficacy and efficiency of the 
system, (2) translatability of the generated data, and (3) safety of the NHP during the 
experiment. To address these issues, species-specific pluripotent stem cells are a 
valuable tool for the in vitro validation of the efficiency and accuracy of the respective 
editing approaches. 
 
NHP-PSC, i.e., embryonic stem cells (ESCs) and iPSCs, share many features with the 
pluripotent cells of the early embryo 21 22. They can be used to study the efficacy of 
genome editing systems and predict, upon directed differentiation into specific cell 
types, potential phenotypic alterations that might be observed later on in the animal. 
Using this workflow, it is possible to evaluate both at the same time, the potential risks 
for the animals as well as the feasibility of the in vivo model.  
 
For DNA based reprogramming and genome editing, it is crucial to deliver relatively 
large constructs with high efficiency. Furthermore, robust long-term expression can be 
relevant for certain purposes, specifically for reprogramming of differentiated cells to 
iPSCs. This requires the exogenous expression of key reprogramming factors to awake 
pluripotency in somatic cells 23 24. In the case of genome editing, it is necessary to 
express nucleases plus guide RNAs 24 25. The piggyBac transposon is a mobile genetic 
element originally identified in a moth (Trichoplusia ni) that efficiently transposes 
between the donor vector and host chromosomes. This system has two major 
advantages, (1)  it has almost no cargo limit, and (2) it is fully reversible, leaving no 
footprint in the genome after excision 24 26. The piggyBac transposon/transposase 
system consists of a transposase that recognizes piggyBac-specific inverted terminal 
repeat sequences (ITRs) located on both sides of the transposon cassette. The 
transposase excises the transposable element to integrate it into TT/AA chromosomal 
sites. Together, these characteristics make the piggyBac an excellent biotechnological 
tool for exploring the genetic modification of NHP 23 26 27 28.  
 
Here we show and characterize two main applications of the piggyBac system, which 
will facilitate the evaluation of genome editing in vitro before in vivo applications. 
First, the previously published piggyBac 6-reprogramming factor construct can 
efficiently generate iPSC from adult rhesus macaque fibroblasts. Moreover, the 
generated iPSCs can be cultured in feeder-free conditions. We demonstrate that the 
exogenous expression of the reprogramming construct gets silenced during 
reprogramming and passaging. To ensure the stability of the reprogrammed state, we 
removed the reprogramming cassette from the iPSC after reprogramming, thereby 
generating transgene-free macaque iPSC. Secondly, we employed the piggyBac vector 
for highly efficient genome editing. Finally, we developed a robust protocol for clonal 
derivation of rhesus macaque pluripotent stem cells (PSC). Combining our tools and 
protocols, we succeeded in the straight forward establishment of clonal rhesus monkey 
iPSC lines harboring clinically relevant mutations in Titin (TTN) gene. 
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2 Results 
2.1 PiggyBac 6-factors in one vector system can reprogram 
adult rhesus macaque skin fibroblast. 
 
Four independent rhesus iPSC lines, named DPZ_iRhpb#1-4, were generated via 
piggyBac transposition using our previously published six factors in one vector 
transposon system (Fig. 1, A) 23. The reprogramming transposon encodes the 
marmoset factors SOX2, OCT4A, KLF4, c-MYC, NANOG, and LIN28. Marmoset and 
rhesus macaque pluripotency factors showed a very high degree of conservation on the 
cDNA and the protein level (Table 1). The iPSC lines were generated from skin 
fibroblast from 2 adult macaques (DPZ_iRhpb#1-3, male) (DPZ_iRhpb#4, female). 
Approximately 20 days after transfection and selection of the fibroblasts, the first 
colonies emerged; new colonies appeared at least until day 60. Between 100 and 150 
colonies were identified per reprogramming experiment. Primary colonies showed the 
typical morphology of human iPSCs in feeder cell culture. During the first passages, 
the best colonies were selected by manual picking according to their morphology. Four 
of the colonies were selected in passage 5 to proceed with further passaging and 
characterization under feeder cell conditions (Fig. 1, A). In passage 10 to 20, the lines 
became stable, showing almost no differentiation. First assessment of the pluripotent 
state of the cells was done by testing alkaline phosphatase activity (AP). All generated 
lines showed alkaline phosphatase activity (Fig. 1, B, C). 
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Figure 1: Rhesus induced pluripotent stem cells generated by piggyBac transposition. (A) Rhesus iPSC 
morphology on feeders (left to right DPZ_iRhpb#1-4), (B) Alkaline phosphatase staining (left to right 
DPZ_iRhpb#1-3), (C) PSC adaptation to feeder-free culture conditions. Left to right bright field 
pictures Rh366.4 ESCs, DPZ_iRhpb#4, and alkaline phosphatase staining of DPZ_iRhpb#4. Scale bars 
100µm. 
Three cell lines, DPZ_iRhpb#2, DPZ_iRhpb#4, and rhesus ESC (Rh_ESC) were 
adapted to feeder-free conditions (DPZ_iRhpb#4 and Rh_ESC, Fig. 1, C) 
(DPZ_iRhpb#2, data not shown) using Stem Max iPS-Brew supplemented with 1 µM 
IWRI and 0,5 µM Chir99021. We recently named this formulation UPPS medium 
(Chapter 2). Colony morphology was very similar before and after adaptation (Fig. 1, 
C also compare with Fig. 1, A). Both iPSC and ESC colonies present a typical compact 
structure, regular borders, and a high nucleus/cytoplasm ratio.  
 
DPZ_iRhpb#1-4 express pluripotency markers OCT4A, LIN28, TRA-1-60, SOX2, 
TRA-1-81, and SALL4 tested by immunostaining (Fig. 2 A, DPZ_iRhpb#1-3) (Suppl. 
Fig. 1, A, DPZ_iRhpb#4). OCT4A, LIN28, SOX2, and SALL4 were detected in the 
nucleus, and LIN28 was present in the cytoplasm. TRA-1-60 and TRA-1-81 were 
present in the membrane. TRA-1-60, TRA-1-81, and SALL4 are pluripotency related 
markers not encoded by the transposon, indicating successful reprogramming. Isotype 
controls were performed as negative control (Suppl. Fig. 1, B).  
 
In order to discriminate between the expression of endogenous and exogenous 
(piggyBac-encoded) pluripotency factors, we performed RT-PCR (Suppl. Fig. 2). 
Primers were designed to specifically amplify the endogenous transcripts of OCT4A, 
SOX2, NANOG, and c-MYC. Primers to evaluate exogenous expression were designed 
to amplify the fused LIN28-NANOG transcript (Chapter 1). None of the four lines 
analyzed showed silencing of the reprogramming construct on the transcript level. 
Nevertheless, all lines showed reactivation of the endogenous pluripotency genes 
OCT4A, SOX2, NANOG, and c-MYC. The intensity of the PCR bands representing the 
endogenous transcripts was similar to the respective bands obtained with Rh_ESC 
(Suppl. Fig. 2). 
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Figure 2: Rhesus iPSC characterization. (A) Characterization by immunofluorescence staining. 
Staining of Rhesus iPSC colonies of lines DPZ_iRhpb#1-3. Detection of the pluripotency markers 
OCT4A, LIN28, TRA-1-60, SOX2, TRA-1-81, and SALL4. TRA-1-81, TRA-1-60, and SALL4 
expression is endogenous, as these factors are not contained in the reprogramming construct. The origin 
of OCT4A, LIN28, and SOX2 expression cannot be determined (Scale bar 20µm). (B) (C) 
Immunohistochemical analysis of DPZ_iRhpb#2 teratoma. (B) Teratoma sections were stained for 
representative markers of the three germ layers: β- Tubulin III staining indicates ectodermal 
Chapter 3: A piggyBac–based platform for genome editing and clonal rhesus 
macaque iPSC line derivation 
81 
 
differentiation. Smooth muscle actin and AFP staining show mesodermal and endodermal 
differentiation, respectively. Complementarily HE staining was performed to identify specific 
cytological structures of representative tissues. Presence of cartilage indicates mesoderm, and gut 
endoderm corroborates endodermal differentiation (Scale bars 100µm). (C) Additionally, 
DPZ_iRhpb#2 teratoma expressed pluripotency markers OCT4A, NANOG, TRA-1-60, and LIN28. 
Small isolated clusters were found positive for the pluripotency markers tested (Left picture, scale bar 
1 mm, right picture, scale bar 100µm). 
2.2 In vivo assessment of pluripotency 
 
In order to functionally demonstrate the pluripotency of DPZ_iRhpb#1-4, teratoma 
formation assay was performed. All four lines formed teratomas (Fig. 2, B, 
DPZ_iRhpb#2) (Suppl. Fig. 3 DPZ_iRhpb#1 and 3) (Suppl. Fig. 4,  A, DPZ_iRhpb#4). 
All tumors present a high degree of histological heterogeneity, i.e., differentiation. 
Cartilage, ossification, smooth muscle cells and gut endothelium, indicating 
mesodermal and endodermal differentiation, respectively, were seen (Fig. 2, B) (Suppl. 
Fig. 3). Subsequently, stainings for representative markers of each germ layer were 
performed. Neural tissues positive for β-Tubulin III, indicating ectodermal 
differentiation, were identified. In addition, alpha-smooth muscle actin (SMA) and 
alpha-fetoprotein (AFP) stained clusters that demonstrate mesodermal and endodermal 
differentiation, respectively (Fig. 2, B) (Suppl. Fig. 3). In summary, the teratoma 
analysis confirms pluripotency of the generated iPSC.  
 
In order to evaluate if the expression of the pluripotency factors was downregulated 
during differentiation, teratomas were stained for pluripotency markers. OCT4A, 
NANOG, TRA-1-60, and LIN28 expression was absent from almost all cells of the 
teratomas and was limited to a few isolated clusters found in all teratomas 
(DPZ_iRhpb#2, Fig. 2, C) (DPZ_iRhpb#1, DPZ_iRhpb#3, data not shown). This 
finding suggests that endogenous (OCT4A, NANOG, TRA-1-60, and LIN28) as well 
as piggyBac (OCT4A, NANOG, and LIN28) pluripotency factor expression is 
generally downregulated during differentiation (Fig. 2, C). Isotype controls were 
performed as negative control (Suppl. Fig, 4, B). 
 
2.3 PiggyBac silencing during reprogramming and 
differentiation 
 
The histological analysis of the teratomas generally suggested silencing of the 
piggyBac transposon used for reprogramming; most of the cells neither expressed 
OCT4A nor Nanog. For both proteins, we have established very specific and sensitive 
IHC detection protocols 29. In order to clarify if the silencing occurs during 
reprogramming or differentiation, we performed comparative methylation analysis of 
the reprogramming construct in iPSCs and teratomas (Fig. 3) (Suppl. Fig. 5). 
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The reprogramming construct contains two separate CAG promoters; one driving the 
reprogramming cassette and one driving the puromycin resistance gene (Fig. 3, A). 
We aimed at getting an overview of the overall methylation of the construct and to 
gain insights into possible differential methylation patterns between both promoters 
(CAG reprogramming vs. CAG puromycin). DNA methylation analysis was 
performed by bisulfite conversion using primers designed to specifically amplify the 
promoter driving the expression of the reprogramming 6-factor cassette (CAG 
reprogramming). Another primer pair was designed to amplify the puromycin 
resistance promoter (CAG puromycin). Additionally, primers amplifying both 
promoters non-selectively were used (CAG) (Fig. 3, A). The three amplicons were 
sequenced with two different oligonucleotides, i.e. S2 (Fig. 3) and S1 (Suppl. Fig. 5). 
Fibroblasts and rhesus ESCs were included as negative controls. 
 
 
 
Figure 3: Methylation analysis of the reprogramming construct using sequencing primer S2. (A) 
PiggyBac reprogramming construct used in this study (13592bp) containing the marmoset (Callithrix 
jacchus) pluripotency factors, SOX2 (S), OCT4 (O), KLF4 (K), c-MYC (M), LIN28 (L), and NANOG 
(N) 23. Stop codons were substituted by 2A peptide sequences (F2A, T2A, and E2A). Expression of the 
reprogramming transcript is driven by a CAG promoter. An independent CAG promoter controls the 
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expression of the puromycin resistance gene (P). Below the vector: Schematic representation of the 
amplicons used for pyrosequencing. Three different primer combinations were used, one to amplify 
both CAG promoters (CAG) simultaneously, one to amplify specifically the CAG promoter driving 
reprogramming cassette expression (CAG reprogramming), and one specific for the promoter associated 
with the puromycin resistance gene (CAG puromycin). (B) (C) (D) Methylation analysis of three 
teratomas (Teratoma 1-3, DPZ_iRhpb#1-3), and three iPSC lines (DPZ_iRhpb#1-3). Two samples were 
included as negative control: Fibroblasts and Rh_ESCs. Internal technical controls are also shown 
(Mean 0% and Mean 100%) (Mean±SD). (B) CAG reprogramming methylation analysis. (C) CAG 
Puromycin methylation analysis. (D) Non-discriminative CAG promoter methylation analysis. (E) 
CAG reprogramming vs. CAG puromycin methylation of the 8 CpG sites considered (left y-axis, CAG 
reprogramming, right y-axis CAG puromycin). Represented Mean±SD of the teratomas and the iPSC. 
 
Three teratomas and three iPSC lines were included in the analysis. The methylation 
of the reprogramming cassette promoter (CAG reprogramming, 60-95% methylation) 
is higher than the methylation of the puromycin promoter (CAG puromycin, 17-30% 
methylation) in all samples (Fig. 3, B, C) (Suppl. Fig. 5, A, B). As expected, the 
analysis of both promoters (CAG) showed intermediate values. No significant 
differences were found between teratomas and iPSC for any of the two promoters. 
These findings suggest that the epigenetic modifications are mainly triggered during 
reprogramming. GpC island specific evaluation shows homogenous methylation levels 
at all CpG sites in all amplicons (Fig. 3, D). The two different primers used for 
sequencing show consistent results (Fig. 3, compare with Suppl. Fig. 5). This data 
shows that already iPSCs have close to maximum methylation levels of the CAG 
reprogramming similar to the teratomas. This may explain the down-regulation of the 
expression of the exogenous pluripotency factors. However, the CAG puromycin 
promoter is significantly less methylated than the CAG reprogramming promoter 
demonstrating differential methylation of the two sequence-wise identical CAG 
promoters present in the piggyBac construct. 
 
2.4 Transposon removal by re-expression of pBase-dtTomato 
in iPSCs 
 
We have shown high methylation of the CAG reprogramming promoter (Fig. 3) (Suppl. 
Fig.5). However, RT-PCR analysis still detected the transposon-encoded transcript in 
the iPSC lines (Suppl. Figure 2). In order to generate a transgene-free iPSC line and to 
demonstrate the stability of the iPSC lines based on endogenous gene expression, we 
exemplarily removed the reprogramming transposon from DPZ_iRhpb#4. Cells were 
re-transfected with the transposase vector pBase-dtTomato (Fig. 4, A) 23. Two days 
after transfection, clusters of Tomato-positive cells were identified. Tomato-positive 
cells were sorted by FACS for selection of the potential transgene-free clones. Cell 
clones were expanded, and different clones were analyzed for the presence / absence 
of the transposon by PCR (Fig. 4, D and E).  Five different primer pairs were used to 
detect different fragments of the transposon (Fig. 4, E). One out of 28 clones showed 
no presence of the reprogramming cassette.  
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The resulting transgene-free subline DPZ_iRhpb#4Δpb remained undifferentiated 
under feeder-free conditions (Fig. 4, B, compare with Fig. 1, C) and full 
characterization was performed again after transposon removal. iRhpb#4∆pb showed 
high alkaline phosphatase activity, and expression of pluripotency markers OCT4A, 
LIN28, TRA-1-60, SOX2, TRA-1-81, and SALL4 on the protein level (Suppl. Fig. 6, 
A, B). iRhpb#4∆pb also produced teratomas (Suppl. Figure 6, C). To confirm the 
absence of the transposon on the mRNA level, iRhpb#4∆pb was analyzed via RT-PCR. 
iRhpb#4∆pb showed no exogenous expression of the LIN28-NANOG fusion transcript, 
confirming the absence of the transposon-derived mRNA. Additionally, iRhpb#4∆pb 
presents similar levels of endogenous OCT4A, SOX2, NANOG, and c-MYC expression 
in comparison with iRhpb#1-4 (Suppl. Fig. 2). Importantly, no chromosomal 
rearrangements were detectable by karyotyping in iRhpb#4∆pb after excision of the 
piggyBac construct (Fig. 4C). 
 
 
 
 
Figure 4: Transposon removal by re-expression of pBase-dtTomato in rhesus iPSC lines. 
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(A) iRhpb#4 two days after transfection with the transposase vector pBase-dtTomato. Left, red 
fluorescence channel; right, merged brightfield / fluorescence. Tomato positive clones were sorted and 
isolated in order to check for the removal of the transposon (Scale bar 100µm). (B) Brightfield image 
of iRhpb#4∆pb (Scale bar 50µm). (C) Representative G-banded karyotype of iRhpb#4∆pb. 
Karyotyping yielded a normal female rhesus macaque chromosome set without any numerical or 
structural abnormality.  (D) (E) Absence of the piggyBac construct from clone iRhpb#4∆pb. PCR 
amplicons for the detection of the reprogramming vector are schematically represented (#1-5). Beta-
actin was used as control for the presence of gDNA (ACTNB). Positive controls used for the analysis 
were iRhpb#1, iRhpb#2, iRhpb#3, and pTT-PB-SOKMLNpuro plasmid DNA. Rh_ESCs were used as 
negative control. 
 
In summary, marker expression and teratoma formation show that iRhpb#4∆pb 
remains pluripotent under feeder-free conditions and has a normal karyotype (Fig. 4) 
after removal of the transposon. 
 
2.5 Derivation of clonal rhesus macaque pluripotent stem cell 
lines 
 
To generate clonal iPSC lines with defined mutations, single-cell isolation and 
propagation protocols need to be established. Two cell lines, Rh_ESC and 
DPZ_iRhpb#4 were selected to develop a work-flow for clonal PSC line generation 
(Fig 1, C).  
 
The first step towards single-cell cloning is reliable and complete dissociation of cell 
clusters to a single cell suspension. In order to find the most suitable reagent, we tested 
three reagents commonly used in human PSC protocols: versene, accutase, and 
TrypLE Select (Fig, 5, A). After dissociation with the different reagents, we analyzed 
proliferation and differentiation of the cells. Five days after splitting, differentiation of 
Rh_ESC and DPZ_iRhpb#4 was assessed by alkaline phosphatase staining and 
proliferation by cell counting. The starting number was 200.000 cells. No 
differentiation was found for any of the three tested reagents (Fig, 5, B). Proliferation 
analysis of DPZ_iRhpb#4 reveals no significant differences between the dissociation 
reagents. In contrast, Rh_ESCs dissociated with accutase or versene show higher 
proliferation recovery in comparison with TrypLE Select (Fig, 5, C). The data 
collected suggest that accutase or versene are more suitable reagents for single-cell 
dissociation compared to TrypLE for Rh_ESCs. 
 
Subsequently, we transfected Rh_ESC and DPZ_iRhpb#4 with the vector pTT-PB-
pCAG-eCas9-GFP-U6-gRNA-Neo together with pBase-dtTomato encoding the 
transposase (Fig. 6, A). Three passages after transfection single cells were sorted into 
a 96-well plate by FACS (one and three cells / well, respectively). This approach 
allowed us to expand single clones and to obtain a representative number for analysis. 
We tested three different conditions to improve clonal expansion. Firstly, culture with 
and without pro-survival factor (PSF), secondly, with and without Activin A and, 
thirdly, under normoxia and hypoxia (5% O2). Only PSF significantly increased cell 
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survival and / or proliferation (Fig, 5 D), while neither Activin supplementation for 
two days after sorting (Fig, 5 E) nor hypoxia (Fig, 5 F) significantly improved clonal 
expansion.  In summary, the use of accutase in combination with medium 
supplemented with PSF for clonal expansion provides optimized conditions for the 
establishment of clonal rhesus PSC lines. 
 
Figure 5: (A)(B)(C) Clonal cell line derivation from rhesus macaque pluripotent stem cells. 
(A) Reagents and conditions tested for dissociation. (B) Alkaline phosphatase staining after 
single-cell dissociation and re-seeding of rhesus macaque PSCs, DPZ_iRhpb#4 and Rh_ESC 
(Scale bar 100µm). (C) Cell numbers three days after single-cell dissociation of  2*105 initial 
cells (n=4)(Mean ±SD). (D)(E)(F) Percentage of cells (iRhpb#4 and Rh_ESC) achieving 
clonal expansion after dissociation and sorting in 96 well plates. Left graph, clonal expansion 
after sorting one cell per well. Right graph, colony expansion after sorting three cells per well 
(Mean ±SD). (D) Cells sorted in standard UPPS medium (Control) and in UPPS medium 
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supplemented with 5 µM pro-survival factor (+PSF). (E) Clonal expansion of cells sorted in 
UPPS +5 µM PSF in normoxia and hypoxia (5% O2). (F) Percentage of wells with clonal 
expansion of cells sorted in UPPS + PSF (Control) vs. cells sorted in UPPS +PSF +Activin (50 
ng/µl). (*) p < 0.05, (**) p < 0.01.  
 
2.6 Genome editing of rhesus macaque stem cells using the 
piggyBac transposon Cas9/GFP vector 
 
In order to validate the cloning protocol, we designed and tested CRISPR/Cas9 guides 
to target clinically relevant mutations in the sarcomeric gene Titin (TTN). Two 
locations were targeted, one at the N-terminus and another one at the C-terminal part 
of the protein (rhesus exons homologous to human TTN exons 38 and 280, respectively; 
ENST00000589042.5). Guides were inserted in the pTT-PB-pCAG-eCas9-GFP-U6-
gRNA-Neo vector and transfected together with the transposase. The single-cell 
cloning protocol developed above was followed, and mono-clonal lines were expanded. 
Four clones with truncating mutations at the N- terminus of TTN, two for Rh_ESC 
and two for DPZ_iRhpb#4, were obtained. The efficiency of the process was 
systematically analyzed for the guide targeting the C-terminus, and independent 
biological replicas for each cell line were performed (transfection, sorting, and 
expansion). For the C-terminus mutation, 37 mutated clones were obtained from 42 
clones analyzed in total (DPZ_iRhpb#4: 27 mutated / 28 analyzed; Rh_ESC: 10 
mutated / 14 analyzed). The overall efficiency of the process for this gRNA was 85% 
(mutated clones / analyzed clones)  (Fig. 6, C and D).  In conclusion, we established 
tools and a protocol for the highly efficient generation of genetically modified clonal 
rhesus macaque ESC and iPSC lines carrying clinically relevant mutations. 
Preliminary characterization of the modified sequences was done exemplarily by 
sequencing of two clones, one mutated at the N-terminus and the other one mutated at 
the C-terminus (Fig. 6, D). 
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Figure 6: Genome editing of rhesus macaque pluripotent stem cells using the piggyBac system. (A) 
Schematic representation of the piggyBac vector used for CRISPR/Cas9 expression, pTT-PB-pCAG-
eCas9-GFP-U6-gRNA-Neo (13213bp). Three independent expression units are contained in the 
piggyBac construct. 1. U6 promoter regulating the expression of tRNA-gRNA, 2. CAG promoter-driven 
expression of eCas9-eGFP fusion transcript.  Both coding sequences are separated by a 2TA sequence, 
and 3. SV40 promoter driving the expression of the Kanamycin/Neomycin resistance gene. (B) Single-
cell cloning workflow. Detailed in the graph are the medium used, coating of the cell culture dish, and 
additives to the medium, together with a simplified overview of the cloning process. (C) Genome editing 
efficiency of the TTN C-terminus. Five independent experiments were performed: 2 with Rh_ESC and 
3 with iRhpb#4. All transfections led to mutated clones with an efficiency ranging from 50% to 100%. 
Overall, mutation efficiency was 85,3%. (D) Mutation analysis of two clones of iRhpb#4, one with a 
mutation in the N-terminus, and the other in the C-terminus. The top line shows the wildtype sequence, 
the middle and the bottom sequences the two mutated alleles in the two selected clones. 
 
2.7 Isogenic control generation 
 
The next step after the generation of the mutated clones will be to assess the phenotypic 
alteration in functional cells generated from the pluripotent stem cells lines, e.g., iPSC-
derived cardiomyocytes. Downstream analysis of the mutated cells requires the 
generation of proper isogenic controls, to exclude possible effects of the cloning 
process. Therefore, isogenic controls were generated for both lines. Transfection of the 
cells with the piggyBac Cas9 vector without guides (pTT-PB-pCAG-eCas9-GFP-U6-
gRNA-Neo), but also with transposase was performed. Isolation of appropriate 
isogenic clonal control populations expressing the Cas9-GFP construct was achieved 
for Rh-ESC and DPZ_iRhpb#4 (Suppl. Fig. 7). 
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3 Materials and Methods 
 
3.1 Animals and animal housing; ethics statement 
 
The German Primate Center (DPZ) is authorized by the local and regional veterinary 
governmental authorities (Reference number: 122910.3311900, PK Landkreis 
Göttingen). Rhesus macaque skin samples were made available during necropsy, from 
animals kept in the context of an unrelated project. DPZ_iRhpb#1-3 iPSC were derived 
from an adult male macaque (16 years), and DPZ_iRhpb#4 iPSC from a female (8 
years). 
 
3.2 Isolation of rhesus macaque primary fibroblasts  
 
Isolation of rhesus macaque fibroblasts from skin and gingiva biopsies was performed 
according to 30. In brief, a  tissue biopsy of approximately 1x1 cm was washed with 
PBS (1% (v/v) Penicillin/Streptomycin (Gibco), 0,25 μg/mL Amphotericin B (Sigma)) 
and subcutaneous adipose tissue was removed with a scalpel. Clean dermal tissue was 
chopped with scissors into small pieces and incubated in Collagenase type IV solution 
(10 mg/mL in DMEM) (Gibco) for three hours at 37ºC rotating (80 rpm). After 
digestion, cells were pelleted by centrifugation (5 min, 300g, RT). Fibroblasts were 
seeded in 10 cm diameter gelatine-coated culture dishes (0,1% gelatine; Sigma) and 
cultured in Rh15 medium [DMEM (Gibco), 15% (v/v) Fetal Bovine Serum (Gibco), 
1% (v/v) Penicillin/Streptomycin (Gibco), 0,1% (v/v) Amphotericin B (Sigma), 1% 
(v/v) MEM Non-Essential Amino Acids Solution (Gibco), 2 mM GlutaMAX (Gibco)] 
at 37°C and 5% CO2. Accutase dissociation reagent (Gibco) was used for passaging. 
 
 
3.3 Mouse embryonic fibroblasts (MEFs)  
 
Gamma-irradiated MEFs were used as feeder cells. The generation was described 
previously 23. 
 
3.4 Nucleofection and reprogramming procedure 
 
Primary fibroblasts were reprogrammed using the 6-factors in one vector piggyBac 
construct, coding for the marmoset monkey reprogramming factors SOX2, OCT4, 
KLF4, c-MYC, NANOG, and LIN28. 1*106 fibroblasts were transfected with a 4D-
nucleofector device (program CA-137; Lonza), using P2 nucleofection solution. The 
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reprogramming transposon vector was co-transfected with pBase-dtTomato 
transposase vector (9 µg, and 6 µg pDNA, respectively). The efficiency of the 
nucleofection was estimated two days after transfection by the expression of the 
Tomato reporter from the transposase vector.  
 
Two days after transfection antibiotic selection was started adding 1,5 µg puromycin 
(Sigma) to the fibroblast culture medium. Five days after selection the fibroblasts were 
plated (0,2*105 cells per plate) on gelatine coated 10 cm plates with MEFs and cultured 
in embryonic stem cell medium (ESM) [KO-DMEM (Gibco), 20% (v/v) KnockOut 
Serum Replacement (Gibco), 1% (v/v) Pen/Strep (Gibco), 0,25 μg/mL Amphotericin 
B (Sigma), 1% (v/v) MEM (Gibco), 2 mM GlutaMAX (Gibco), 50 μM 2-
mercaptoethanol (Gibco), 10 ng/ml FGF (ThermoFisher)]. ESM was supplemented 
with 2 mM valproic acid (Calbiochem) for the first 6 days of culture. 20 days after 
transfection first colonies were identified and new colonies appeared until day 60. 
Colonies were manually picked and transferred to new plates with MEFs. Around 
passage 5, mass passage was possible using Collagenase type IV (1 mg/mL). Rhesus 
macaque iPSC long-term storage was done using Rh_freezing medium [ESM, 
20%DMSO (Sigma), 10% FBS (Gibco)] at -150°C. 
 
3.5 Adaptation to feeder-free culture conditions 
 
Rhesus iPSC (iRhpb#4) in passage 10 were manually picked and transferred into 6 cm 
plates coated with Geltrex (0.16 mg/ml) (Thermo Fisher Scientific). Cells were 
cultured according to our previously published protocol (Chapter 2). NHP pluripotent 
stem cells medium UPPS [StemMACS™ iPS-Brew XF, human - Stem cell media 
(Miltenyi Biotec) supplemented with IWRI (1 µM) (Sigma), and Chir99021 (0.5 µM) 
(Merck/Millipore)]. The first day after picking, the medium was supplemented with 
ROCK inhibitor, PSF (Pro-survival Compound, 5 µM, Calbiochem). After 3 to 5 
passages, the culture stabilized showing no morphological differentiation. After 5 
passages cells were split using versene-EDTA solution (Thermo Fisher) (split ratios 
used were 1/10 to 1/15). To freeze rhesus iPS, the freezing medium was used (Essential 
8 medium, 20% DMSO (Sigma), and 10µM PSF). 
 
3.6 Alkaline phosphatase 
 
Alkaline phosphatase activity was demonstrated using Leukocyte Alkaline 
Phosphatase Kit (Sigma), following manufacturer’s recommendations. 
 
3.7 Immunofluorescence 
 
Rhesus iPSCs were cultured in wells equipped with coverslips. When the colonies 
reached 30 to 50% confluence, they were fixed with 4% PFA (v/v) for 20min (RT). 
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Fixation solution was removed and cells washed three more times with PBS. 1% BSA 
in PBS was used for blocking. For intracellular epitopes 1% BSA, TritonX-100 (0,1%, 
Sigma) was used. Primary antibodies were diluted in PBS/ 1% BSA and incubated for 
1 hour at 37°C. Subsequently, cells were washed with PBS and incubated with Alexa 
488-coupled secondary antibodies (Life Technologies) diluted in PBS/1% (w/v) BSA. 
Finally, coverslips were incubated with PBS/DAPI solution (0,5 µg/ml), for 10 min. 
After staining the coverslips were removed from the cell culture wells, and mounted 
using Citifluor mountant medium (CITIFLUOR ltd.). Immunofluorescence images 
were taken with a Zeiss Observer Z1 (Zeiss). Primary antibodies used were OCT4 
(Cell Signalling OCT-4A C52G3, 1:1600), SOX2 (Cell Signalling C70B1, 1:200), 
NANOG (Cell Signalling D73G4, 1:400), TRA-1-60 (eBioscience 14-8863, 1:100), 
TRA-1-81 (eBioscience 14-8883, 1:100), LIN28 (Cell Signalling A177, 1:100), and 
SALL4 (Abcam ab57577, 1:200). Secondary antibodies Alexa-488 conjugated Ab 
Donkey anti-Mouse IgG (H+L) (Life technologies A21202, 1:1000), Donkey anti-
Rabbit IgG (H+L) (Invitrogen A-21206, 1:1000) and Goat anti-mouse IgM (H+L) 
(Invitrogen A-21042, 1:1000). 
 
3.8 Reverse transcription PCR 
 
RNA was extracted from cell pellets using RNAeasy Mini Kit (Qiagen). 
Contaminating genomic DNA was eliminated by treating the samples with RNase-free 
DNase (Qiagen). cDNA was synthesized from 1 µg RNA using Oligo(dT) primers and 
the Omniscript RT Kit (Qiagen), according to manufacturer instructions. Primer pairs 
(Sigma) were designed and used for detection of the different pluripotency factors, and 
to discriminate between the endogenous (OCT4A, SOX2, NANOG, and c-MYC) and 
the exogenous (LIN28-NANOG fusion) transcripts (Table 2). As positive and negative 
controls rhesus embryonic stem cells (Rh_ESC) and MEFs, respectively, were used. 
Endogenous beta-actin (ACTNB) expression was used as a house-keeping gene. Taq 
DNA Polymerase with Standard Taq Buffer (New England BioLabs) was used for all 
RT-PCRs performed. Primers used are detailed in Table 2. 
 
3.9 Teratoma formation and histological analysis 
 
For teratoma formation assay, 8*105 cells from each iPSC line and 2*105 MEFs were 
co-injected subcutaneously into male immunodeficient RAG2-/-γc-/-mice. Before 
injection cells were resuspended in PBS supplemented with Geltrex (ThermoFisher, 
0.1 mg/mL), with a final injected volume of 120 µl. Teratomas were obtained and fixed 
as previously described 31. Histological tissue sections were stained for the detection 
of representative markers of each germ layer. Primary antibodies used were β-Tubulin 
III (Sigma, T8660, 1:600), smooth muscle actin (SMA; Sigma, A2547, 1:1000) and 
SOX9 (Millipore, AB5535, 1:1000) for detection of ectoderm, mesoderm, and 
endodermal epithelium respectively. Additionally, OCT4A (Cell Signalling OCT-4A 
C52G3, 1:1000), NANOG (Cell Signalling D73G4, 1:400), TRA-1-60 (eBioscience 
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14-8863, 1:50) and LIN28 (Cell Signalling A177, 1:100) primary antibodies were used 
for the detection of undifferentiated pluripotent cells in the teratomas. 
3.10 Promoter methylation assay 
 
Promoter methylation analysis was performed in three different iPSC (DPZ_iRhpb#1-
3) at different passages and in three teratomas (DPZ_iRhpb#1-3). As negative controls, 
Rh_ESC and rhesus macaque fibroblasts were included in the analysis. DNA 
methylation analysis of the CAG promoter was performed by bisulfite pyrosequencing. 
500 ng of the isolated genomic DNA was used for the DNA bisulfite conversion 
reaction with the EZ DNA Methylation-Direct™ Kit (Zymo), according to 
manufacturer’s instructions.  
 
For PCR, Fast Start Taq polymerase (Roche) was used to amplify the bisulfite-
converted DNA. PCR conditions and primers were designed with the Pyrosequencing 
Assay Design Software (Qiagen). The piggyBac 6-factor reprogramming construct 
contains two CAG promoters, one driving the expression of the reprogramming 
cassette, and the other one the puromycin resistance gene. In order to analyze both 
promoters separately, one assay for each CAG region was designed. Both assays 
contained the same forward primer but a different reverse primer located in the unique 
sequence of the reprogramming cassette (CAG Reprog) and the puromycin resistance 
gene (CAG Puro). In addition, a third assay was designed to evaluate both CAG 
promoters (CAG). For reducing the amplification bias, all three measurements were 
arranged in a nested/semi-nested approach consisting of two following PCRs for each 
assay. The first PCR round generates three different outer amplicons related to the 
three different assays (CAG Reprog, CAG Puro and CAG) (Table2) (Fig. 3). In the 
second PCR round, one primer combination of two primers located within the CAG 
promoter sequence was applied to all three different outer amplicons (CAG Reprog, 
CAG Puro and CAG) and generate the same inner amplicon for all three assays. This 
inner amplicon was sequenced with two sequencing primers, which together covered 
15 CpGs in total (S1: 7 CpGs; S2: 8 CpGs). As cycler conditions of the outer-PCR 
reactions, the standard PCR procedure according to manufacturer’s instruction was 
applied with a cycle number of 30 (annealing CAG Reprog: 60 °C; CAG Puro: 64 °C; 
CAG: 52 °C) (Table 2). The inner-PCR contained for all three assays the same 
combination of two primers. The cycler conditions of the inner-PCR corresponded to 
the standard PCR procedure according to manufacturer’s instruction (annealing 53 °C 
and 35 cycles). Finally, the products of the inner-PCR were sequenced in triplicates by 
Pyrosequencing following the manufacturer’s instruction. 10 µL of the generated 
inner-PCR products were used for the immobilization to Streptavidin Sepharose HP 
beads (GE Healthcare Life Sciences). The Pyrosequencing was performed on a 
Pyromark Q96MD system (Qiagen) and analyzed with the Pyromark Q-CpG software. 
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3.11 PiggyBac transposon removal/rhesus iPSC transfection 
 
iRhpb#4 in feeder-free conditions was nucleofected using 4D-nucleofector device 
(Lonza). 1*106 cells were transfected with pBase-dtTomato transposase vector (6 µg), 
using P3 nucleofection solution and program CA-137 (Lonza). UPPS medium was 
supplemented for 2 days with PSF (5 µM) after transfection. After 3 days Tomato 
positive clones were sorted using SH800S Cell Sorter (Sony Biotechnology), sorting 
10 cells per well in a 48 well plate. Potential transgene-free colonies were picked and 
expanded for 2-5 passages. Colonies were then pelleted and gDNA was extracted. 
Detection PCR was performed using primers specifically designed to detect different 
regions of the transposon (Table 2). PCR was performed using Taq DNA polymerase 
with Standard Taq Buffer (New England BioLabs) according to manufacturer 
instructions. Transgene-free clones were checked for the absence of the 
reprogramming construct every 10 passages. 
 
3.12 Karyotyping 
 
Metaphase arrest, fixation, G banding, and analysis protocols were described in detail 
in 30. 
 
 
3.13 PiggyBac CRISPR/Cas vector generation 
 
The pTT-PB-pCAG-eCas9-GFP-U6-gRNA-Neo vector was derived by modification of 
plasmid pCAG-eCAS9-GFP-U6-gRNA, which was a gift from Jizhong Zou (Addgene 
plasmid # 79145; http://n2t.net/addgene:79145; RRID: Addgene_79145). In order to 
convert this plasmid into a piggyBac transposon, the 5’- and 3’-PB inverted repeats 
were amplified from pTT-PB-SOKMLN-Puro by PCR and inserted respectively into 
the PacI and NotI/SbfI restriction sites using standard molecular cloning techniques. 
Additionally, a neomycin-resistance cassette was inserted into the BsrGI restriction 
site in order to enable antibiotic selection.   
3.14 Dissociation reagent testing 
 
Two stem cell lines, iRhpb#4 and Rh_ESC, were dissociated with three different 
reagents. Dissociation conditions are listed in detail in Fig. 5A. After dissociation, cells 
were collected and centrifuged (180g, 5min, RT). After centrifugation 200,000 cells 
were transferred into a well of a 6-well plate and cultured for 5 days. Alkaline 
phosphatase staining and cell counting were subsequently performed. Statistical 
analysis of the cell numbers was performed using GraphPad PRISM and one way 
ANOVA test [(*) p < 0.05, (**) p < 0.01.]. 
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3.15 Clonal expansion analysis 
 
iRhpb#4 and Rh_ESC were used for the testing of the clonal expansion potential after 
single-cell dissociation and FAC-sorting. Cells transfected with pTT-PB-pCAG-
eCas9-GFP-U6-gRNA-Neo were cultured for three passages and digested with 
accutase (37ºC, 5 min). The SH800S Cell Sorter (Sony Biotechnology) was used to 
sort Cas9-GFP positive cells. To evaluate the effect of PSF during clonal expansion, a 
control group was sorted with no PSF and compared to a test group with PSF. For the 
evaluation of the effect of Activin A (50 µg/µl; Miltenyi), or hypoxia (5%  O2), the 
different experimental groups were compared to each other. Since PSF turned out in 
the first experiment to support clonal cell line derivation, it was the standard based on 
which the remaining variables (Activin and hypoxia) were tested. All experiments 
were performed in triplicates. For the significance analysis, paired T-test was 
performed using GraphPad PRISM software. 
 
3.16 Induction of truncation mutations in rhesus macaque stem 
cells 
 
Two different guide RNAs for the CRISPR/Cas9 system were cloned (vectors 
digestion with BbsI, plus oligo alignment and ligation) and validated in the pTT-PB-
pCAG-eCas9-GFP-U6-gRNA-Neo vector (Table 2). Transfection of the iPSC was 
described above (piggyBac transposon removal/rhesus iPSC transfection). Cells were 
FACS-sorted in order to obtain clonal sublines, expanded, and pelleted for gDNA 
extraction and analysis (Macherey-Nagel™ NucleoSpin™ Gel and PCR Clean-up Kit). 
Primers for the mutation site amplification and PCR conditions are described in Table 
2. PCR products of the different clones were purified and sent for sequencing (LGC 
Genomics). Sequence analysis was performed using Serial Cloner software. Mutations 
in the two different alleles of the target gene of each clone were predicted using Poly 
Peak Parser 32. 
4 Discussion 
 
NHP as our closest relatives are excellent animal models to study human diseases. The 
phylogenetic relationship is reflected in similar physiology, genetics, life span, and 
relatively equal size 5 6 8 9 10 11. In order to model human pathologies with genetic origin 
in NHP, it is necessary to edit the embryonic genome. Therefore genome editing tools 
for these applications need to be validated in vitro before in vivo translation to 
guarantee the efficiency, accuracy and hence safety of the process. NHP-PSC share 
many molecular signatures of the cells present in the early embryo. Therefore, testing 
of novel editing tools in PSCs will help to assess their performance in vivo 7 33 34. 
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Four novel rhesus macaque iPSC lines were generated using our previously published 
6 reprogramming factor transposon 23. The generated iPSC were pluripotent as 
indicated by pluripotency marker expression and teratoma formation. RT-PCR was 
performed with primer pairs able to discriminate between endogenous and exogenous 
origin of pluripotency-related genes. Robust expression of endogenous OCT4A, SOX2, 
NANOG, and c-MYC transcripts was detected in the iPSCs as judged by comparison 
with Rh_ESCs. However, the analysis also revealed the presence of piggyBac-derived 
exogenous transcripts showing that the expression cassette was not fully silenced in 
iPSCs. The potency of the novel NHP-iPSC lines was also evaluated by teratoma 
formation. All lines analyzed formed teratomas. We were wondering whether the 
piggyBac cassette would be silenced upon iPSC differentiation over several weeks in 
the context of teratoma formation. Interestingly, most teratoma sections were negative 
for the pluripotency markers OCT4A, LIN28, and Nanog, for which we have 
established specific and sensitive immunohistochemical detection protocols 29 35. We 
found only scattered clusters of relatively few positive cells. This shows down-
regulation of endogenous pluripotency genes, and, even more importantly, also down-
regulation of the reprogramming construct in the differentiated cells of the teratoma.  
 
In order to analyze piggyBac silencing in the teratoma, we performed comparative 
methylation analysis of the two CAG promoters present in the piggyBac construct 
isolated from iPSCs and the teratomas. There was no clear difference between the 
methylation patterns found in iPSCs and in teratomas. However, between the two 
promoters, the CAG puromycin and the CAG reprogramming, we found differential 
methylation patterns. Surprisingly, the CAG reprogramming was highly methylated 
(in most samples close to 100%) in comparison with the CAG puromycin promoter, 
which shows around 30% methylation in teratomas and around 20% in iPSCs. These 
findings were generally reproduced in all three independent iPSC lines. This suggests 
that the cells can discriminate between the two sequence-wise identical CAG 
promoters in the construct. Either the gene products regulate the methylation of the 
promoters or the broader DNA sequence context in which the actual CAG promoters 
are embedded. Targeted methylation has been previously described for this and other 
reprogramming approaches 36. Moreover, the high methylation of the CAG 
reprogramming was not only found in the teratomas, but also in the iPSC. This 
indicates that methylation occurs mainly during fibroblast reprogramming and culture 
of the iPSCs, but not during differentiation, as we initially hypothesized. Constitutive 
reprogramming factor expression could lead to failed differentiation and 
tumorigenicity 37 38. However, in our experiments, we observed mainly differentiated 
cells within the teratomas. On the other hand, and more importantly, also the iPSC line 
after deletion of the piggyBac cassette (see below) shows some remaining OCT4A-
positive cells in the teratoma indicating that not (only) the exogenous OCT4A 
expression was still detectable, but (at least also) the endogenous variant. 
 
The piggyBac transposon can be removed from the genome of the cells without leaving 
a footprint 27 28 39. Even though the teratoma demonstrated silencing of the exogenous 
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reprogramming factors in most of the cells, this would not be a safe condition 
regarding cell transplantation, and exogenous genetic material present in the iPSC 
genome is not acceptable for transplantation purposes. In order to generate transgene-
free macaque iPSC, we exemplarily excised the reprogramming transposon from the 
genome of one iPSC line. The resulting transgene-free clone was then fully re-
characterized. Pluripotency factor expression and potency of the cell line remained 
unchanged after transposon removal. In addition, karyotyping showed that the 
excision-ligation process did not generate any detectable chromosomal abnormalities. 
We are of course aware of reprogramming approaches based on non-integrating 
vectors like Sendai viruses and episomes. However, our own data (Chapter 2) show 
that rhesus monkey iPSC generation is significantly less efficient than human iPSC 
generation. Considering this, the integrating, yet reversible piggyBac approach for 
NHP-iPSC generation is still useful because of its robustness. In fact, piggyBac-based 
reprogramming proved useful for the generation of marmoset monkey (Debowski et 
al. 2015 ) 23, baboon (Rodriguez-Polo et al. 2019) 30 and rhesus monkey (present study) 
iPSCs. From the latter two species, we obtained iPSCs also from adult and aged 
animals. 
 
We adapted two of the generated NHP-iPSC to feeder-free conditions. Feeder-free 
culture is essential to obtain pure cell populations without the presence of (feeder) cells 
from other species. Furthermore, this allows up-scaled production and facilitates more 
efficient use of biotechnological tools, like CRISPR/Cas9 40 41. The cell lines remained 
undifferentiated in the new conditions. Importantly, also the transgene-free iPSC line 
was cultured feeder-free. Hence, feeder-free and transgene-free culture of piggyBac-
derived rhesus iPSCs is possible. 
 
Genome editing and single-cell cloning of PSC is challenging due to the low efficiency 
of the process and stress-induced death of the stem cells forced to single-cell separation 
24 25. Fine-tuning of the protocols developed for human 25 42 and mouse PSC 43 was 
required in order to generate a robust protocol for rhesus macaque PSCs 44. We have 
demonstrated that accutase and versene are more suitable dissociation reagents for the 
generation of PSC single-cell suspensions than TrypLE. Furthermore, we tested 
different compounds and conditions to increase the number of surviving single cells / 
clones after sorting. ROCK inhibitor (PSF) shows a beneficial effect in single-cell 
survival in the two lines analyzed, while hypoxia and Activin A showed no effect on 
the cloning efficiency in our experimental setup. Taking these results together, we 
developed a robust single-cell cloning protocol for rhesus PSC.  Finally, we used a 
piggyBac vector containing eCas9-GFP plus guide RNAs to target two clinically 
relevant loci in the TTN gene. The piggyBac transposon combining all required 
components of the CRISPR/Cas9 editing machinery in one vector in combination with 
the fine-tuned protocol for single-cell cloning allowed us to reach very high efficiency 
in the generation of mutated clones, e.g., over 85% for the C-terminal TTN mutation. 
This genome editing approach is based on gDNA repair after targeting via non-
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homologous end joining (NHEJ). It is important to consider that this approach, even 
though being efficient, is imprecise.  
 
Altogether, we demonstrated the suitability of the piggyBac system to reprogram and 
gene edit rhesus macaque iPSCs. We developed an efficient platform to evaluate 
CRISPR/Cas based genome editing approaches in PSCs before in vivo application. In 
combination with the new protocol for clonal expansion of gene-edited rhesus PSCs, 
this represents a useful in vitro screening platform for gene editing and thereby 
contributes to the 3Rs (reduce, replace, and refine) in animal experimentation. 
Differential methylation of the two identical CAG promoters present in the vector was 
encountered, with high methylation of the CAG reprogramming and low methylation 
of the CAG puromycin promoter. This may suggest a specific methylation response to 
the gene product controlled by the respective promoters. Finally, we have 
demonstrated removal of the reprogramming transposon by re-expression of the 
transposase, resulting in transgene-free iPSCs cultured under feeder-free conditions. 
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  cDNA Protein (%) 
SOX2 93,96 % 99,68 % 
 OCT4 85,46 % 95,63 % 
KLF4 94,56 % 100,00 % 
LIN28 96,51 % 99,04 % 
c-MYC 94,65 % 97,95 % 
NANOG 86,06 % 94,44 % 
 
 
Table 1: Percentage of similarity for the reprogramming factors used between marmoset and rhesus 
macaque. Comparison on cDNA and protein level. Marmoset vs. rhesus macaque alignment for SOX2 
(ENSCJAG00000008401/ENSMMUG00000046147), OCT4A 
(ENSCJAG00000019789/ENSMMUG00000015688), KLF4 
(ENSCJAG00000016955/ENSMMUG00000006088), LIN28 
(ENSCJAG00000009796/ENSMMUG00000044953), c-MYC 
(ENSCJAG00000012620/ENSMMUG00000014601), and NANOG  
(ENSCJAG00000018999/ENSMMUG00000032158). 
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Table 2: Oligos used in this study. PCR conditions defined by annealing temperature (Tm), elongation 
(Elong), and amplicon (Amp). (*) 5‘-Biotin. 
 
 
Oligo name Sequence Tm (°C)Elong (sec)Amp (bp)
G302_LIN28-NANOG_fw AGCCATATGGTAGCCTCATGTCC 62 55 811
G70_LIN28-NANOG_rev GGTTGCTCCAGGTTGAATTGC
G2212_OCT4 endo_fw GAGAAGGAGAAGCTGGAGCAA 52.9 60 841
G2213_OCT4 endo_rev ACATCCTTCTCGAGCCCAA
G2008_SOX2 endo_fw GGTAGGAGCTTTGCAGGAAGT 61 30 428
G2009_SOX2 endo_rev CCAACGATGTCAACCTGCATG
G2237_NANOG endo_fw CAGAGATACCTCAGCCTCCAG 54.4 35 562
G2238_NANOG endo_rev CTTCAGGTTGCATGTTCGT
G2010_cMYCendo_fw CTGGTACTCCATGAGGAGACA 61 60 715
G2011_cMYCendo_rev CTCAGCCAAGGTTGTGAGGTT
G2204_beta actin GGTAGTTTCGTGGATGCCACA 61 30 379
G2205_beta actin GACCTGACTGACTACCTCATG
G1842_piggydetecF2Afw GTGAAACAGACTTTGAATTTTGACC 54 10 97
G1843_piggydetecF2Arev AATCCGAAGCCAGGTGTC
G1844_piggydetecE2Afw TACACATGAAGAGGCATTTTCAATG 55 10 114
G1845_piggydetecE2Arev TGCTGAAGCTGACGTTGA
G1846_piggydetecpAfw TGCCACTCCCACTGTCCTTTCCTA 57 10 116
G1847_piggydetecpArev CAATCCTCCCCCTTGCTG
G302_LIN28-NANOGfw AGCCATATGGTAGCCTCATGTCC 62 55 811
G70_LIN28-NANOG_rev GGTTGCTCCAGGTTGAATTGC
G244_Pcag-SOx2fw GGGGACGGCTGCCTTCGG 60 20 361
G395_Pcag-SOx2rev CGGTCGGGGCTGTTCTTCTG
G2204_beta actin GGTAGTTTCGTGGATGCCACA 61 30 379
G2205_beta actin GACCTGACTGACTACCTCATG
G1806_TTN_N-terminusfw CACCgGCTGACTACACCTTTGTGGC
G1807_TTN_N-terminusrev AAACGCCACAAAGGTGTAGTCAGCc
G1822_TTN_C-terminusfw CACCgGTTACTGCTTCCAATCGCCT
G1823_TTN_C-terminusrev AAACAGGCGATTGGAAGCAGTAACc
G2616_N-termfw GCATGGTGGCACAGAGTTGT 61 100 1861
G2617_N-termrev TAGACAGCTGCTAGGGACAC
G2654_C-termfw GCGACTCTGCCCAACTACAT 61 60 828
G2655_C-termrev GCAGTGTTGGTGACTTCCTC
G2656_CAG_Reprogfw GGGATTTTTTTTGTTTTAAATTTGTG 60 25 401
G2657_CAG_Reprogrev AATTCCACCACACTAAACTAAT
G2658_CAG_Purofw GGGATTTTTTTTGTTTTAAATTTGTG 64 35 575
G2659_CAG_Purorev TATCACCCTCTCAATATACCTATC
G2660_CAGfw GTAGTTATTGTTTTTTATGGTAA 52 25 373
G2661_CAGrev TAATAAAACAACACAATAACCAACAC
G2662_CAG_Inner_fw GGGATTTTTTTTGTTTTAAATTTGTG 53 29 333
G2663_CAG_Inner_rev TAATAAAACAACACAATAACCAACAC
G2664_CAG_Inner_Seq_fw CATAAACATAATTAACAAAAACTCT
G2665_CAG_Inner_Seq_rev CCCCCCCCATTTCCTT
RT-PCR
PiggyBac  detection 
gRNAs
Clonal line analysis
Methylation analysis 
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Suppl. Figure 1: Immunofluorescence staining of DPZ_iRhpb#4 and negative/isotype controls. (A) 
Immunofluorescence staining of DPZ_iRhpb#4. Detection of OCT4A, LIN28, TRA-1-60, SOX2, TRA-
1-81, and SALL4. OCT4A, LIN28, and SOX2 expression come from both endogenous and piggyBac 
expression. (Scale bar 20µm). (B) Immunofluorescence negative and isotype controls. Isotype controls. 
FITC (left column) plus DAPI (right column) (Scale bar 100µm). 
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Suppl. Figure 2: Rhesus iPSC characterization by RT-PCR: Expression analysis of the four generated 
Rhesus iPSC lines (DPZ_iRhpb#1-4), and transgene-free DPZ_iRhpb#4Δpb. Rhesus embryonic stem 
cells (Rh_ESC) and MEFS were added as positive and negative controls, respectively. Primers for the 
RT-PCR were designed for the specific amplification of the endogenous pluripotency factors OCT4A, 
SOX2, NANOG, and c-MYC. LIN28-NANOG amplicon shows transposon expression in the transgenic 
lines and absence of exogenous transcript in DPZ_iRhpb#4Δpb. Beta-actin expression (ACTNB) was 
used as a housekeeping gene (marker 1kb Plus DNA ladder, NEB). 
 
 
 
 
 
 
 
 
 
 
 
Suppl. Figure 3: Immunohistochemical analysis of DPZ_iRhpb#1 (A) and DPZ_iRhpb#3 (B) 
teratomas. Teratoma sections were stained for representative markers of the three germ layers: β- tubulin 
III, smooth muscle actin (SMA), and Alpha-1-Fetoprotein (AFP). Complementarily HE staining was 
performed to identify specific cytological features of representative tissues. β- Tubulin III indicate 
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mesodermal differentiation. Smooth muscle actin and AFP staining show ectodermal and endodermal 
differentiation, respectively. Presence of cartilage indicates mesoderm. Moreover, gut endodermal 
epithelium support AFP staining, showing also the presence of endodermal tissue (Scale bar 100µm). 
 
 
 
 
Suppl. Figure 4: Immunohistochemical analysis of DPZ_iRhpb#4 teratoma and isogenic controls 
(teratomas DPZ_iRhpb#1 and DPZ_iRhpb#3). (A) Teratoma sections from DPZ_iRhpb#4 stained for 
SOX9, β- tubulin III, smooth muscle actin (SMA), and OCT4A. β- Tubulin III staining indicate 
mesodermal differentiation. Smooth muscle actin show ectodermal differentiation and AFP staining 
demonstrate endodermal differentiation (Scale bar 100µm). (B) Isogenic controls for the teratoma 
staining. Upper row controls for  DPZ_iRhpb#1, lower row controls for  DPZ_iRhpb#3. Isogenic 
controls for the markers SOX9, β- tubulin III, SMA, and OCT4A (Scale bar 100µm). 
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Suppl. Figure 5: Methylation analysis of the reprogramming construct using sequencing primer, S1. 
Methylation analysis of three teratomas (teratomas 1-3), and three iPSC. Two samples were included 
as negative control: Fibroblast and Rh_ESC. Internal controls are represented (Mean 0% and Mean 
100%) (Mean±SD). (A) CAG reprogramming methylation analysis. (B) CAG puromycin methylation 
analysis. (C) CAG (including both promoters) methylation analysis.  
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Suppl. Figure 6: DPZ_iRhpb#4Δpb, characterization. (A) Immunofluorescence staining. Detection of 
OCT4A, LIN28, TRA-1-60, SOX2, TRA-1-81 and, SALL4. In DPZ_iRhpb#4Δpb the piggyBac 
reprogramming construct has been removed, and consequently, the expression of all pluripotency 
factors is endogenous (Scale bar 20µm). (B) Alkaline phosphatase staining of DPZ_iRhpb#4Δpb (Scale 
bar 100µm). (C) Immunohistochemical analysis of DPZ_iRhpb#4Δpb teratoma. Teratoma sections 
were stained for representative markers of the three germ layers SOX9, β- tubulin III, smooth muscle 
actin (SMA), and OCT4A to show cells that remain undifferentiated in the tumor (Scale bar 100µm). 
 
 
 
 
Suppl. Figure 7: Isogenic controls generated transfecting DPZ_iRhpb#4 (A) and Rh_ESC (B) with 
pCAG-eCas9-GFP-U6-gRNA-Neo. The lines constitutively express eCas9 and GFP but no gRNA 
(Scale bar 100µm). 
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Abstract. Cardiovascular diseases (CVDs) are a heterogeneous group of pathologies with 
high incidence in the population. Even though these diseases have a complex etiology, most 
of them have a genetic origin. CVD models will help to understand the cause and 
progression of the diseases. This becomes particularly relevant when looking at the 
economic and social burden caused by CVDs. To recapitulate CVD phenotypes, utilization 
of animal models sharing the complexity of the human cardiovascular system is necessary. 
Non-human primates (NHP), due to their close phylogenetic relationship with humans, 
meet all requirements of translational animal models. In recent years, genome editing has 
gained in sophistication, allowing human genotypes to be mimicked in NHP. However, this 
process is still laborious and time-consuming. Here, we combined previously published and 
novel approaches to generate genomically modified iPSC from NHP. Our workflow allows 
the generation of a species-specific iPSC based platform for in vitro evaluation of genome 
editing approaches. This becomes particularly relevant when thinking about genetically 
modified NHP in vivo models. Our study includes two Old World and one New World 
monkey species, and the iPSC lines from all of them, have been generated under equivalent 
conditions. Furthermore, differentiation of the transgenic iPSC into functional 
cardiomyocytes may allow at least partial in vitro prediction of the in vivo phenotype. 
Furthermore, we have tuned a CRISPR based approach to induce point INDEL and 
fragment deletion mutations in NHP-iPSC. Finally, we have empirically developed an 
approach to the treatment of monogenic CVDs. We hypothesized that the extraordinarily 
high percentage of clinically relevant symmetric exons in the giant Titin gene could be used 
to develop CRISPR based reframing strategies to treat dilated cardiomyopathy (DCM) in 
patients with truncating titin variants. In summary, we have developed an iPSC-based in 
vitro workflow for the refinement of genome editing approaches before they are applied in 
vivo in NHP.  
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1 Introduction  
 
Genetically modified animals are animals which genome has been modified by the human 
using biotechnological tools 1 2. Such animals have revolutionized many areas impacting 
on fields like agricultural industry, medicine, ecology, and biomedical research 3 4. The 
appearance of novel and highly efficient genome editing tools has facilitated the generation 
of additional animals species with highly sophisticated genetic modifications 5 6. 
 
Generation of disease-specific genetically modified animals is especially advantageous 
when considering the limitations of conventional disease induction methods (e.g., drug- or 
surgically-induced disease). Longitudinal studies can be achieved since the mutation is 
generally passed on to the offspring. This allows animal strain establishment and decreases 
experimental variation amongst different animals 5. 
 
Historically, genetic modification of rodents has been used in biomedical research, due to 
the easy handling of these animals, together with in-depth knowledge about their 
reproductive biology and the early availability of chimera-competent embryonic stem cells 
in mice 3 7. Other animal models, due to their species-specific characteristics, present more 
difficulties regarding the application of these technologies. In cardiovascular research, it is 
important to work with a model resembling human organ size and metabolism, general 
physiology, diet, and life span. While rodents fail to show these attributes, non-human 
primates (NHP) pose an interesting model candidates, due to their close phylogenetic 
proximity to human 8 6. Therefore, the generation of genetically modified NHP in order to 
model human diseases is one of the major research interests 5.  
 
For the induction of selected mutations of the NHP genome, it is essential to adapt genome 
editing protocols developed in other species to NHP 9. This needs to be done as precisely 
as possible in order to prevent any unintended mutations. Additionally, genetic 
modification of NHP entails some difficulties not found in other organisms 10. Despite the 
usage of refined genome editing methodologies like CRISPR/Cas, robust protocols that can 
be applied to these animal models are still required. Furthermore, the generation of a 
genetically modified NHP is a high-risk project, due to the long duration, high costs, and 
the experimental state of reproductive technologies in these species 4.  
 
The general work-flow for genetically modified animal generation is well defined and 
based on existing rodent models. Starting with the identification of a clinically relevant 
mutation in patients, the mutation is translated to the model's genotype in silico. Once the 
modification is fully defined, genome editing tools (e.g. CRISPR) are designed to target 
the location of interest.  The gene modification components are then introduced into an 
preimplantation embryo or a zygote and then retransferred into a foster mother. After 
gestation, the offspring is analysed genotypically and phenotypically 5 6.  
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To pave the way towards the generation of a precisely genetically modified NHP, we and 
others believe that it is imperative to include an additional pre-screening step. Before 
targeting the embryo an evaluation of the genome-editing tool is required in order to 
prevent the generation NHP with unintended genetic modifications. Additionally, an initial 
in vitro evaluation of the modification is necessary due to the ethical controversies 
associated with NHP experimentation. For the evaluation of a genome editing approach, it 
is necessary to use species-specific cells with a full genetic homology to the model species. 
NHP pluripotent stem cells (PSC) offer an excellent opportunity for this purpose. Besides 
the species-specific origin, they share molecular characteristics with the pluripotent stem 
cells of the early embryo 11 12 13. Additionally, these cells can be differentiated into cells of 
all three germ layers like cardiomyocytes and neurons, allowing a preliminary analysis of 
the in vivo phenotype. 
 
Generation of genetically modified NHP will help to understand pathologies like dilated 
cardiomyopathy (DCM), a disease that due to its complex etiology makes it challenging to 
understand its physiopathology. DCM is a disease that affects approximately 1 out of 2,500 
persons, and has been found in the last years showing accelerated frequency 14 15 16. DCM 
is diagnosed according to two factors: 1- left ventricular enlargement and 2- systolic 
dysfunction recognizable by reduction of myocardial contraction force 16. Approximately 
30% of the cases of DCM are inherited.  Mutations in more than 30 genes can lead to DCM, 
making it a highly complex and heterogeneous disease. 25% of familiar and 18% of 
sporadic cases can be accounted to mutations of the sarcomeric protein Titin (TTN) 
(nonsense, frameshift or canonical splice site) 16 17 18 19. Frameshift mutations in TTN alter 
the reading frame, generating truncated versions of the protein (tvTTN) that lead to 
premature termination of translation 20 21.  
 
To the present, therapies for DCM are limited, given the limited self-renewal capabilities 
of the cardiac muscle. In severe cases, heart transplantation is the only option. However, 
transplantations also represent a bottleneck due to limited donor organ availability. In 
contrast, promising approaches for treating a significant subset of DCM patients are 
genome editing technologies to reset the reading frame in patients with tvTTN 15 20.  
 
A skip or deletion of mutated exons leading to a shift of the open reading frame of a gene 
has already been considered as a potential strategy to treat DCM and other cardiovascular 
diseases (CVDs) 22 23. In the past years, a variety of endonuclease-based experimental 
treatments were tested and established to overcome frameshift mutations in sarcomeric 
proteins 24 25 26. These approaches can be summarized in four major groups (i) controlled 
splicing of mutated exons by inducing indel mutations in the splice acceptor-donor site (ii) 
full fragment/exon removal (iii) exon reframing via targeted frameshift and (iv) exon 
knock-in 26 27. It is crucial to explore novel treatments for DCM using the mentioned 
approaches. However, these genome editing approaches require, as the generation of 
genetically modified primates, validation. For this purpose, iPSC in combination with 
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predictive animal models will play a key role in the safe translation of such kind of novel 
gene-modifying therapies to the clinics. 
 
In the present study, we have refined our previously developed primate cell reprogramming 
and iPSC maintenance protocol (Chapter 2) and extended it to the marmoset monkey, a 
new world monkey species. Using the new work-flow, we are able to generate transgene- 
and feeder-free marmoset monkey iPSC meeting the high quasi clinical-grade standards 
for human. Additionally, we have developed a robust protocol to apply CRISPR/Cas 
technologies to the generated iPSC from all species with high efficiency. Altogether, we 
aim to establish a platform for the testing and evaluation of NHP genome editing 
approaches before their application in vivo, i.e. the generation of a genetically modified 
NHP. Finally aiming to contribute to the development of therapies to treat familiar DCM, 
we have carefully evaluated potential therapeutic target sites in TTN gene. Importantly, 
symmetric exons are statistically highly overrepresented in TTN, making this clinically 
relevant gene an extraordinary promising target for therapeutic reframing approaches. 
Selecting key exons highly accessible to recently developed genome editing tools would 
facilitate the establishment of novel CRISPR-based therapeutics to explore novel 
treatments for DCM. 
 
 
2 Results 
 
2.1 Universal protocol for the generation of transgene-free iPSC 
from a New World Monkey, Old World Monkeys, and human 
 
We aimed to establish a universal protocol for NHP-iPSC generation and culture for both 
Old World monkeys (OWM) and New World Monkeys (NWM). Generating iPSC from 
the different species under standardized conditions facilitates direct comparability amongst 
them as well as with human iPSC. Previously, we have shown the robust generation of 
human, baboon and rhesus macaque iPSC. The episomal vector system published by Okita 
et al. (2011) in combination with UPPS medium (Universal Primate Pluripotent Stem cell 
medium) enabled the generation of a relatively broad panel of OWM and human iPSC 
(Chapter 2, and 3). As these conditions were not tested for any NWM species, we selected 
the marmoset monkey as a biomedically relevant NWM species. 
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Figure 1: Marmoset induced pluripotent stem cells. (A) Six individual lines generated were generated 
(DPZCj_iPSC#1-6). Upper row iPSC colony morphology, bright field pictures (scale bar 100 µm). Lower 
row, alkaline phosphatase staining (scale bar 100 µm). (B) Work-flow for the generation of primate iPSC. 
The protocol is divided into three different phases: 1-reprogramming, 2-stabilization of the generated lines, 
and 3-maintenance. UPPS (Universal Primate Pluripotent Stem cell medium), and UPPS-Adv (Universal 
Primate Pluripotent Stem cell medium, plus Activin A and LIF). 
Fibroblasts extracted from skin biopsies from three different marmosets were cultured and 
expanded. We then applied our previously published protocol (Chapter 2) to the newly 
generated cells. Even though colonies with the typical morphology of pluripotent cells 
appeared in the primary plates, the expansion of these cells was not possible using UPPS 
medium. The cells differentiated, lost the typical cellular and colony morphology of PSC 
and stopped proliferation. Therefore we adjusted the protocol to find out suitable conditions 
to maintain also these marmoset cells. We tested different media (Essential 8 and MEF 
conditioned medium) and a broad range of small molecules, including dorsomorphin and 
recombinant Human Nodal Protein. None of the tested conditions was sufficient to keep 
marmoset iPSC in an undifferentiated state in feeder-free culture (data not shown). Only 
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the addition of Activin A to the UPPS medium resulted in undifferentiated iPSC 
populations. The generated lines presented the typical high nucleus/cytoplasm ratio and 
grew in compact colonies with distinct borders (Fig. 1). We named this medium UPPS 
Advance (UPPS-Adv). However, even though cells remained undifferentiated, the 
proliferation rates were low. While macaque and baboon iPSC were split every 2-3 days 
(using splitting ratios 1:10/15), marmoset iPSC in UPPS-Adv were split every 5-6 days 
(using the same dilution for passaging of the cells). However, proliferation could be boosted 
by the addition of leukemia inhibitory factor (LIF). Nonetheless, marmoset iPSC elicit 
lower proliferation rates in comparison with rhesus and baboon in UPPS. After 6-10 
passages in UPPS-Adv, the marmoset lines were again tested in UPPS and remained 
undifferentiated (Fig. 1, A). We then tested the capacity of rhesus, baboon, and human iPSC 
culture in UPPS-Adv . Human and OWM iPSC could also be maintained undifferentiated 
under the new conditions. All lines tested (2 human, 2 macaques, and one baboon line) 
were cultured for at least 3 passages and maintained in a morphologically undifferentiated 
state in UPPS-Adv (Suppl. Fig. 1, shown for one representative line of each species).   
With the data presented here, we provide a universal protocol that can be used for 
reprogramming of human, rhesus, baboon, and marmoset monkey fibroblasts. This protocol 
comprises the initial culture of the iPSC during the process of establishment (passage 1 to 
10) in UPPS-Adv medium. During this phase, the iPSC stabilize and can be easily 
expanded. When a homogeneous population of iPSCs is reached it is then possible to switch 
to standard UPPS medium for the characterization and downstream applications (Fig. 1, 
B).  
Using this protocol we generated 6 different marmoset iPSC lines (DPZCj_iPSC#1-6) from 
three different animals. DPZCj_iPSC#1 and 6 were generated from skin biopsies of two 
different newborn marmosets, and DPZCj_iPSC#2-5 from fetal fibroblasts. As a 
preliminary evaluation of the pluripotency of the generated iPSC lines, we performed 
alkaline phosphatase staining. All generated lines show alkaline phosphatase activity (Fig. 
1, A).   
 
2.2 Marmoset iPSC characterization 
 
Before characterization of the novel marmoset iPSC lines, we tested them for the presence 
of the reprogramming episomes via PCR. Only one line shows PCR signals 
(DPZCj_iPSC#1). The absence of signals in the other lines confirms that DPZCj_iPSC#2-
6 are transgene-free (Suppl. Fig. 2). 
In order to identify specific molecular signatures of pluripotency in the generated lines, we 
analyzed the expression of key pluripotency factors on the mRNA and protein level, 
respectively. RT-PCR analysis was performed for endogenous OCT4A, KLF4, and c-MYC 
markers. All lines show an upregulation in the expression of the selected pluripotency-
associated genes in comparison with the negative control (fibroblasts) (Suppl. Fig. 3). 
Furthermore, we confirm the expression of pluripotency markers on the protein level by 
immunostaining. All lines express OCT4A, LIN28, NANOG, SOX2, TRA-1-81 and TRA-
1-60 (Suppl. Fig. 4) (shown for DPZCj_iPSC#1, 2, 3, and 5).  
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Figure 2: Differentiation of marmoset iPSCs. (A) (B) Pluripotency assessment by embryoid body formation 
of marmoset iPSC lines DPZCj_iPSC#1, 2, 3 and 5. (A) Embryoid bodies exemplarily shown for 
DPZCj_iPSC#3 (scale bar 100 µm). (B) Staining of the differentiated cells with representative markers of 
each embryonic germ layer: beta three Tubulin (β-Tub III, ectoderm), Alpha-fetoprotein (AFP, endoderm), 
and smooth muscle actin (SMA, mesoderm) (scale bars 20 µm). (C) Directed differentiation of 
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DPZCj_iPSC#1 into cardiomyocytes. Staining for muscle-specific markers alfa actin (α-Actin), troponin I 
(TNI), atrial and ventricular myosin light chain 2 (MLC2a/v), titin (TTN), and connexin 43 (Cx43) (scale 
bars 20 µm). 
After characterization of the lines on the molecular level, we performed potency assessment 
by spontaneous differentiation. Embryoid body formation assay was used and 
differentiation evaluated by immunostaining. Smooth muscle cells positive to smooth 
muscle actin (SMA, mesoderm), hepatic-like cells stained by alpha-fetoprotein (AFP, 
endoderm), and neurons stained for beta III tubulin (β-III-Tub, ectoderm) were found for 
all lines (Fig. 2, shown for DPZCj_1, 2, 3 and 5).  
Additionally, directed differentiation into cardiomyocytes was tested for DPZCj_iPSC#1, 
2, 3, and 5. We used our previously published protocol (Chapter 3) that has proven to be 
highly efficient for baboon, macaque, and human. DPZCj_iPSC#1, 2, 3 and 5 developed 
into beating cells when exposed to the cardiomyocyte differentiation conditions. In order 
to confirm the identity of the generated iPSC-derived cardiomyocytes (iPSC-CM), we 
performed stainings for cardiomyocyte markers.  The marmoset iPSC-CM expressed alfa 
actin (α-Actin), troponin I (TNI), atrial and ventricular myosin light chain 2 (MLC2a/v), 
titin (TTN), and connexin 43 (Cx43) (Fig. 2, C). 
 
2.3 Single-cell cloning of primate iPSC 
 
In recent years, many efforts have been made to generate clonal human and mouse iPSC 
lines. However, even though new protocols show increased efficiencies, the process is yet 
challenging. Given that little is known on NHP-iPSC clonal line establishment, we tested 
different protocols for the derivation of clonal NHP-iPSC lines. 
We previously described a work-flow for the efficient generation of clonal lines from 
macaque iPSC. This protocol is based on the dissociation of cells using accutase solution, 
and cell sorting using UPPS medium supplemented with pro-survival factor (PSF) (Chapter 
3). In order to evaluate the translatability of the protocol, we have tested it with human, 
baboon, and marmoset iPSC lines.  
We evaluated the efficiency by counting the wells showing clonal expansion after FACS 
sorting. The complete work-flow was performed in parallel with the different lines from 
the four primate species consider in this study, human, macaque, baboon, and marmoset. 
The protocol was initiated three passages after transfection with the pTT-PB-pCAG-eCas9-
GFP-U6-gRNA-Neo vector in combination with the transposase containing vector pBase-
dtTomato. Primate iPSC were sorted according to the expression of the GFP reporter gene 
into 96 well plates, sorting one or three cells per well. Using the mentioned work-flow it 
was possible to isolate lines for all three primate species. The efficiency ranged from 5,55 
to 19,4% (1 cell per well) (Fig. 3, A). As expected, when three cells per well were sorted 
the efficiency increased, reaching 79% for the marmoset (Fig. 3, B). In parallel, cell 
differentiation was evaluated by analyzing the morphology of the resultant colonies. While 
human and rhesus macaque clonal lines were stable, baboon and marmoset clones were 
more unstable. Stabilization of these lines was achieved by an additional cultivation step in 
UPPS-Adv (Fig.3, C). All generated clonal lines constitutively express GFP, demonstrating 
the stability of the expression (Fig.3, C). 
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Figure 3: Clonal cell line derivation from primate iPSC. Human (DPZHs_iPSC#2.4), macaque 
(DPZRh_iPSC#25.3), baboon (DPZPv_iPSC#2.8), and marmoset (DPZCj_iPSC#6) (A)(B) Percentage of 
wells with cell expansion after single-cell dissociation and sorting into a 96 well plate. (A) Monoclonal line 
generation after sorting one cell per well. (B) Polyclonal line generation after sorting three cells per well. (C) 
Evidence of successful transgenesis. The iPSC express the GFP-Cas9 after sorting. Left panel, bright field 
pictures, right panel green fluorescence pictures of single clones growing in a well of a 96 well plate (scale 
bar 100µm). 
 
2.4 Induction of INDEL mutations in primate iPSC 
 
CRISPR/Cas was utilized for the generation of single-cell clones with defined mutations 
using all four primate iPSC. We used a piggyBac-CRISPR/Cas system as backbone for 
single guide RNA (sgRNA) insertion to target defined locations in the primate genome. We 
selected two exons in the disease-relevant gene Titin (TTN). One location induced a 
frameshift mutation next to the N-terminus part of the protein (human, exon 38) and another 
proximal to the C-terminus (human, exon 280) (ENST00000589042.5). Both exons are 
highly conserved (PSI>0,9) and clinically relevant since mutations in these positions have 
been found in DCM patients.  
In silico analysis of the homologous TTN locations in the NHP species considered in this 
study was performed  to guarantee the translatability of the editing approach. As final proof 
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that the editing system can be used in all primate species, we performed T7 endonuclease 
I assay in marmoset fibroblasts and human HEK293 cells (sgRNA validation for the rhesus 
macaque was demonstrated in Chapter 3). Both guides designed show editing activity in all 
species (Fig.4, A, shown for marmoset). 
Using the designed sgRNAs it was possible to generate monoclonal lines with INDEL 
mutations for human, rhesus, and marmoset. Targeting efficiency varies between lines and 
species. However, positive clones could be identified in all species. 
 
 
Figure 4: Genome editing in human and NHP iPSC. (A) sgRNA validation in marmoset fibroblast by T7 
endonuclease I assay, for TTN N-terminal (human TTN, exon 38) and C-terminal (human TTN, exon 280) 
locations. Wildtype (WT) fibroblasts are shown in comparison with targeted fibroblasts (mutated, Mut). 
Amplicon size detailed in Suppl. Table 1 (B) Schematic representation of TTN gene and the two targeting 
sites. The number of clonal iPSC lines with INDEL mutations in the proposed sites. DPZHs_iPSC2.4 (human 
iPSC), DPZRh_iPSC#25.3 (Rhesus macaque iPSC), and DPZCj_iPSC#1 (marmoset iPSC). 
We identified one human iPSC clone (DPZHs_iPSC#2.4) with a deletion in exon 38 of 
TTN (total number of clones analyzed: 2). Additionally, two clonal lines from the marmoset 
monkey (DPZCJ_iPSC#1) were generated with truncation mutations in exon 280 (total 
number of clones analyzed: 3) (Fig.4, B). Characterization of the mutations was performed 
by PCR amplification of the targeted genomic site and subsequent Sanger sequencing. 
Therefore, further analysis using refined methods will be required to identify the specific 
mutations in each of the alleles of the different clones.  
 
2.5  Fragment deletions in primate iPSCs using the combination 
of two CRISPR vectors 
 
The more precise way to induce patient mutations in cell or animal models is by homology-
directed repair (HDR) compared to the introduction of INDELs. Using this method it is 
possible to predefine the genetic modification that will be induced in the target genome. In 
contrast, using non-homologous end joining (NHEJ) the repair after cutting the genome is 
random. Therefore, induction of a defined modification is more challenging. We have 
demonstrated that editing of NHP-iPSCs is possible using NHEJ reparation mechanism 
(Chapter 3 for macaque iPSC) (Fig. 4, human, marmoset and macaque iPSC). As an 
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intermediate step between the already described approach and HDR, we test the potential 
of the described system to perform deletions. Combining two sgRNAs with Cas9, it is 
possible to target two genomic locations at the same time and delete DNA fragments.  
In order to test this approach, we designed two sgRNAs to target the intronic sequences 
flanking human TTN exon 280 (ENST00000589042.5). The sgRNAs were inserted in the 
pTT-PB-pCAG-eCas9-GFP-U6-gRNA-Neo backbone, and the system was tested  in 
marmoset fibroblasts (Fig. 5, A). We performed PCR to amplify the target location. For the 
wildtype, we expected an amplicon size of 1117 bp, whereas a size of 762 bp was expected 
for the mutated allel. PCR showed a faint band of 762bp. The identity of the fragment was 
confirmed by sequencing which revealed that the combination of two sgRNAs was able to 
delete a fragment of 389 bp corresponding to exon 280 (Fig. 5, A, B, and B´).  
The experiment was repeated using human (DPZHs_iPSC#2.4) and marmoset 
(DPZCJ_iPSC#1) iPSC. In this case, due to time limitations, it was not possible to generate 
monoclonal lines. Nevertheless, it was possible to show PCR bands corresponding to the 
deletion of exon 280 in all marmoset and human polyclonal iPSC populations (Fig. 5 C, 
and D). Analysis of the mutated populations was performed by PCR (Fig. 5 C, and D) and 
confirmed by subsequent sequencing of the respective amplicon (data not shown). 
 
Figure 5: Deletion of human TTN exon 280 by a two sgRNA-CRISPR systems. (A) Validation of the system 
by transfection of marmoset fibroblasts. PCR designed to amplify the deletion site. Expected size of the 
amplicon in the wildtype (WT) is 1117 bp. In contrast in the targeted fibroblasts (mutated, Mut), both 
fragments were present, the non-edited fragment (1117 bp) and the fragment with the deletion (728bp) after 
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removal of 389bp corresponding to the homologous human TTN exon 280. (B) (B´) Sequencing of the 
amplicon in the mutated cells (Deletion (B´)) shows specific removal selected sequence in comparison with 
the wildtype (WT (B)). (C) (D) Fragment deletion in (C) human (DPZHs_iPSC2.4), and (D) marmoset 
(DPZCj_iPSC#1) iPSC. PCR analysis (in duplicates) of three (1-3) different polyclonal populations of cells 
of two primate species. Two fragments are present in each PCR, the upper one corresponding to the 
unedited/INDEL mutated locus, and the lower one indicating the deletion (*). 
2.6 Ventricular fibroblast immortalization 
 
The combination of iPSC containing clinically relevant mutations with robust 
cardiomyocyte generation protocols will allow evaluation of phenotypic alterations in 
species-specific iPSC-CM. Nonetheless, we are aware that some cardiovascular disease 
phenotypes cannot be fully simulated in 2D cultures systems. Therefore, it will be necessary 
to adapt the cells to culture systems that allow the generation of organotypic responses. 
Many groups have generated platforms that allow these analyses. Most of them combine 
iPSC-CM with fibroblast to mimic the natural composition of the myocardium. 
In order to support and enhance this transition, we have extracted ventricular fibroblasts 
from the marmoset monkey. The extracted fibroblasts were immortalized and labeled using 
two different piggyBac systems.  Immortalization was performed by exogenous expression 
of the human telomerase (PTT-PB-hTERT-puro) 125. Labeling was performed by 
expression of a red fluorescence reporter (PTT-PB-dtTomato-puro) (Fig. 1 A). Red 
fluorescence was selected for labeling since the mutated iPSC lines we generated expressed 
the Cas9-GFP fusion transcript. Therefore, after the combination of green cells (primate 
iPSC-CM containing patient genotype) and red cells (species-tissue-specific fibroblasts), it 
will be possible to track both cell types and separate them from each other based on their 
fluorescence for downstream analyses. 
Immortalized and labeled fibroblasts were cultured in parallel with wild-type (WT) 
fibroblasts as control. Around passage 10 WT cells lost their proliferation capacity and 
became senescent. In contrast, immortalized fibroblasts maintained stable proliferation 
independent of the passage number (Fig. 6 A, compare with B). Constitutive expression of 
the telomerase was evaluated by RT-PCR with primers that cover the telomerase transcript. 
The immortalized fibroblasts in passage 16 show a higher telomerase expression in 
comparison to the WT (Fig. 6 C). 
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Figure 6: Marmoset ventricular fibroblasts immortalization and labeling. (A) Fibroblasts transfected with 
PTT-PB-hTERT-puro and PTT-PB-dtTomato-puro vectors at passage 16. Left picture bright field, right 
picture red fluorescence (scale bar 100µm). (B) Bright field picture of wildtype ventricular fibroblasts in the 
same passage show signs of senescence (scale bar 100µm). (C) RT-PCR for telomerase (amplicon size 653 
bp), comparing expression between wildtype (WT) and transfected cells (immortalized). Beta-actin used as 
housekeeping gene (amplicon size 285bp). 
 
2.7 Titin symmetric exon deletion 
 
Based on the intensive analysis of TTN across species we notice the very high percentage 
of symmetric exons in this gene (Fig. 7, A). This gene has higher number of exons with a 
nucleotide number multiple of three in comparison with other sarcomeric and cardiac 
relevant genes (Fig. 7, B) (Suppl. Table 3). Additionally, the number of symmetric exons 
does not strongly vary between the main isoforms. The TTN metatranscript contains 85% 
(311/363) of symmetric exons, and the different isoforms range between 67 and 83% 
(Novex-3 and the long cardiac isoform N2BA respectively) (Fig. 7, A).  
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Considering these results together with the feasibility to perform medium size deletions 
previously shown, we derived an empirical approach to threat DCM caused by mutations 
in TTN. We hypothesize that a complete deletion of symmetric exons containing mutations 
will not influence overall protein function, but restore the reading frame of TTN. 
In order to demonstrate the feasibility of this therapeutic strategy, the first step was the 
identification of appropriate symmetric exons in TTN (Fig. 7, A) (Suppl. Table 4). 
However, in order to select candidate exons suitable for deletion, some additional 
considerations must be taken into account. Targeted exons should be highly conserved 
amongst different isoforms, i.e. they should have a high PSI (percentage of splice in) value. 
A PSI value of 1 indicates that an exon is constitutively present in all isoforms. A PSI value 
close to zero indicates that the respective exon is present only in very few transcripts and 
absent from most. Mutations located in TTN exons with low PSI usually lead to mild 
phenotypes. Finally, exon size also needs to be considered. We assume that selection of 
small or medium-sized exons (300 bp or smaller) will allow to perform the deletions with 
higher efficiency and prevent chromosomal alterations. In addition, is necessary to be sure 
that restricting the exon size we still consider most TTN exons (Suppl. Fig. 5). This will be 
particularly important regarding preclinical and also clinical in vivo testing of these 
therapies (Fig. 7). 
In accordance with the criteria mentioned above, we have selected a set of candidate exons 
for the deletion from the TTN metatranscript (Suppl. Table 5). All selected exons are (1) 
symmetric, (2) highly conserved and have a PSI of >0.9, and (3) have 300 or less bp (Fig. 
7, C) (Suppl. Fig. 5). A library of 94 candidate exons that fulfill all requirements was 
identified (Suppl. Table 5).  We propose to apply an editing system composed of Cas9 and 
two gRNAs to target the intronic flanking sequences of selected exons of TTN. The whole 
system can be easily validated in the developed iPSC/CRISPR platform.  Finally the most 
promising candidates for the potential therapeutic deletion of mutated TTN exons can be 
then tested in vivo models.  
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Figure 7: (A) (B) Percentage of symmetric exons quantification. (A) Percentage of symmetric exons in the 
major Titin isoforms. Metatranscript (311 symmetric exons / 363 exons in total, 85,67%), N2BA (261/313, 
83,38%), N2B (142/191, 74,34%), N2A (261/312, 83,65%), Novex-1 (144/191, 75,39%), Novex-2 (143/192, 
74,47%), Novex-3 (31/46, 67,39%) and Cronos (97/124, 78,22%). (B) Percentage of symmetric exons in 
different cardiac genes. TNNT2 (8/16, 50%), TNNI3 (5/8, 62,5%), TNNC1 (1/6, 16,67%), TPM1 (2/9, 
22,21%), ACTC1(2/7, 28,57%), MYH7 (15/40, 37,5%), MYL3 (3/6, 50%), MYL2 (4/7, 57,14%), MYBPC3 
(14/35, 40%), TTN (311/363, 85,67%), TCAP (1/2, 50%), CSRP3 (0/7, 0%), MYOZ2 (2/6, 33,33%), ACTN2 
(13/23, 56,52%), OBSCN (84/116, 72,41%) and LDB3 (1/14, 7,14%) and DMD (40/79, 50,63%). (C) 
Schematic representation of the parameters considered for target exon identification. Selected exons are 
symmetric, highly conserved (PSI>0.9) and have maximally 300bp. (D) (E) Overview of the exon deletion 
therapy approach. Symmetric exons with mutations are deleted with a system combining Cas9 plus two 
gRNAs, targeting sites up- and downstream of the candidate exon.  TTN expression results in a shorter but 
functional protein. (D) Schematic representation of a frameshift mutation in exon 231 of TTN that leads to a 
truncated and partially non-sense version of the protein. The red color indicates a non-sense amino acid 
sequence different from TTN that originates from the frameshift mutation present in exon 231. The frameshift 
causes at the same time the occurrence of a stop codon on the transcript level, which in turn results in a 
truncated protein variant. (E) Schematic representation of the deletion of a symmetric exon to remove the 
frameshift mutation located in exon 231. 
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3 Material and methods 
 
3.1 Animals and animal housing; ethics statement 
 
The German Primate Center (DPZ) is an independent research institute authorized by the 
veterinary governmental authorities (Reference number: 122910.3311900, PK Landkreis 
Göttingen). Marmoset monkey skin samples were made available during the pathological 
examination, from animals from an unrelated project. DPZCj_iPSC#2-5 were generated 
from fetal fibroblasts extracted from a marmoset developing embryo. DPZCj_iPSC#1 and 
6 were generated from skin biopsies of two different new-born marmosets. Human, rhesus 
macaque and baboon iPSC derivation as described previously (Chapter 2). 
3.2 Isolation of marmoset primary fibroblasts  
 
Marmoset fibroblasts were extracted according to 29. In brief, skin biopsies were washed 
with PBS (1% (v/v) Penicillin/Streptomycin (Gibco), 0,25 μg/mL Amphotericin B 
(Sigma)) and minced with a scalpel. Following, the tissue was digested for 3 hours with 
Collagenase Type IV solution (10 mg/mL in DMEM) (Gibco)(37°C, rotating at 80 rpm). 
Next, undigested dermal tissue was removed, and the cell suspension centrifuged (5 min, 
300 x g, RT). The resultant pellet was resuspended in  Rh15 medium [DMEM (Gibco), 
15% (v/v) Fetal Bovine Serum (Gibco), 1% (v/v) Penicillin/Streptomycin (Gibco), 0,1% 
(v/v) Amphotericin B (Sigma), 1% (v/v) MEM Non-Essential Amino Acids Solution 
(Gibco), 2 mM GlutaMAX (Gibco), 10 ng/ml bFGF] and cultured in a cell culture plate 
coated with gelatine (0,1% gelatine; Sigma). Primary cultures were maintained at 37°C and 
5% CO2. Accutase (Gibco) was used for passaging. 
3.3 Reprogramming NHP fibroblasts 
 
 
Reprogramming was performed according to Chapter 2. In brief marmoset fibroblasts were 
nucleofected (4D-Nucleofector, P2 Primary Cell Solution (Lonza)) with the three plasmids 
pCXLE-hOCT3/4-shp53-F (#27077), pCXLE-hSK (#27078) and pCXLE-hUL (#27080) 
published by Okita et al. (2011) 30. 6 x 105 cells were transfected with 6 μg (2 μg each) of 
pDNA. Fibroblasts were kept in Rh15 medium supplemented with 0.5 mM sodium butyrate 
(Sigma-Aldrich) for 7 days, changing the medium every day. At day 7 the transfected cells 
were transferred to Geltrex (0.16 mg/ml; Thermo Fisher) coated plates and cultured in 
Essential 8 medium (Thermo Fisher) supplemented with sodium butyrate until day 11. 
From day 12 on only Essential 8 medium was applied. Approximately 30 days after 
transfection the first distinct colonies appeared.  
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Primary colonies were picked and maintained in UPPS-Adv medium [StemMACS™ iPS-
Brew XF, human, 1 μM IWR-1, (Sigma-Aldrich), 0.5 μM Chir99021 (Merck), 4 ng/ml 
activin A (Miltenyi Biotec), 10 ng/mL, Recombinant Human LIF (PeproTech)] for the first 
6-10 passages. Cells were maintained in these conditions until a homogeneous population 
of cells was reached. Cells were passaged using versene solution.  (Thermo Fisher 
Scientific). Around passage 15 cells stabilized and were subsequently cultured in standard 
UPPS (Chapter 2).  
To evaluate the possibility of maintaining human and OWM iPSC in the newly developed 
culture conditions, cell lines were differentially cultured in both UPPS and UPPS-adv. 
These conditions were maintained for minimum 3 passages, carefully evaluating 
morphology and proliferation rates. 
3.4 In vitro differentiation 
 
Embryoid body formation was performed for the marmoset iPSC lines. iPSC colonies were 
digested with collagenase type IV (200 U/ml; Worthington) for 10 min at 37 °C. After 
digestion, colonies were resuspended with the help of a cell scraper, trying to conserve the 
integrity of colonies. Cell clusters were placed in suspension in a non-adherent petri dish 
and cultured in differentiation medium [79 ml Iscove's Modified Dulbecco's Medium 
(IMDM, Thermo Fisher), 20 ml FBS, 1 ml 100x non-essential amino acids, 450 μM 1-
thioglycerol (Sigma-Aldrich)]. On day 8 cell clusters were transferred to Geltrex coated 
plates with coverslips. On transferring, Embryoid Bodies settled down and attached, 
allowing cells to expand and differentiate. Differentiated cells were maintained for 17 days 
(days 25 in total) before fixation and staining. Antibodies and dilutions used are described 
in Suppl. Table 2.  
 
3.5 Cardiac differentiation of marmoset iPSC 
 
The protocol for cardiac differentiation described in Chapter 2 was applied. The protocol 
consists of two different phases, mesodermal differentiation, and cardiac specification 
differentiations. First primate iPSCs were exposed to mesodermal induction medium 
[RPMI 1640, B27 without insulin, 1 mM sodium pyruvate (Thermo Fisher), 200 μM L-
ascorbic acid 2-phosphate, 1 μM Chir99021, 9 ng/ml Activin A (Miltenyi Biotec, premium-
grade) and 5 ng/ml BMP4 (Miltenyi Biotec, premium grade]. The medium was changed on 
day 1. On day three cardiac specification is induced by application of cardiomyocyte 
differentiation medium [RPMI 1640, B27 supplement without insulin, 1 mM sodium 
pyruvate, 200 μM L-ascorbic acid 2-phosphate, 5 μM IWR-1]. The medium was further 
changed on day 5. From day 7 on, cardiomyocytes are maintained in cardiomyocyte 
maintenance medium [RPMI 1640, B27 with insulin, 200 μM L-ascorbic acid 2-
phosphate]. 
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3.6 Immunostaining 
 
Immunostaining was performed according to the protocol described in 31. In brief, cells 
were washed with DPBS (Thermo Fisher) and fixed using 4% (w/v) paraformaldehyde 
(Merck) for 20 min (room temperature). Blocking was performed with 1% bovine serum 
albumin (Thermo Fisher), supplemented for staining of intracellular epitopes with 0.1% 
Triton X-100 (Sigma-Aldrich). Primary antibody incubation was performed overnight at 
4ºC (primary antibodies used detailed in, Suppl. Table 2). After incubation with the primary 
antibody, cells were washed three times with PBS and incubated for one hour with the 
secondary antibody (secondary antibodies used detailed in, Suppl. Table 2). Subsequently 
DAPI (1 μg/ml DAPI in H2O (Sigma-Aldrich)) staining was performed for 10 min at room 
temperature. Stained cells were mounted using Fluoromount–G (eBioscience) and analyzed 
by fluorescence microscopy (Zeiss). 
3.7 DNA and RNA isolation and polymerase chain reaction 
 
Genomic DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen) following the 
manufacturer's instructions. Presence of the episomes was analyzed by PCR using specific 
primers for the amplification of conserved sequences between the three used episomes 
(Table 1). Each PCR (final volume 50 μl) was performed with 50-100 ng DNA using Taq 
DNA Polymerase with Standard Taq Buffer (New England Biolabs) following 
manufacturers instructions.  
RNA was extracted from frozen pellets using NucleoSpin RNA Plus isolation kit 
(Macherey-Nagel), and treated with RNase-free DNase (Qiagen) to eliminate contaminant 
genomic DNA. Reverse transcription of 1 µg RNA was performed using Omniscript RT 
kit (Qiagen). cDNA was amplified using marmoset specific primers for the different 
pluripotency factors, all detailed in Suppl. Table 1. 
3.8  T7 endonuclease I assay 
 
Validation of the sgRNA was performed in marmoset fibroblasts, transfecting the cells with 
6 µg pDNA, using 4D nucleofector, and P2 nucleofection solution (Lonza). After at least 
3 days, fibroblasts were snap-frozen and the genomic DNA extracted as described in (3.7). 
Primers for specific amplification of the two locations in the TTN gene (Suppl. Table 1) 
were designed to generate an amplicon of approximately 1 kb with the potential mutation 
in the middle. PCR products were purified using NucleoSpin DNA RNA and protein 
purification kit (Macherey Nagel). T7 endonuclease assay was performed using T7 
Endonuclease I (NEB) according to manufacturer recommendations. 
 
3.9 Clonal expansion analysis 
 
One iPSC line for each primate species considered in the study was transfected with pBase-
dtTomato and pTT-PB-pCAG-eCas9-GFP-U6-gRNA-Neo according to the protocol 
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described in Chapter 3. Every transfection was performed in triplicates, and three passages 
after transfection the cells were sorted using SH800S Cell Sorter (Sony Biotechnology), 
according to Cas9-GFP expression. Each experimental group was sorted in a 96 well plate, 
sorting 1 (72 wells) or 3 (24 wells) cells per well. Clonal expansion was evaluated by 
counting of wells with undifferentiated, proliferating cells(Mean±SD, using GraphPad 
PRISM). 
3.10 Induction of truncation and deletion mutations in primate 
iPSC 
Construction of the vector pTT-PB-pCAG-eCas9-GFP-U6-gRNA-Neo from pCAG-eCas9-
GFP-U6-gRNA (Addgene #79145) was described in Chapter 3. Two guide RNAs were 
cloned into the CRISPR/Cas9 vector (Suppl. Table 1). Potential mutated clones were 
FACS-sorted in order to obtain clonal sublines, expanded, and pelleted for gDNA 
extraction and analysis (Macherey-Nagel™ NucleoSpin™ Gel and PCR Clean-up Kit). 
Primers for amplification of the potential mutated sites were described in (3.8) and are 
detailed in Suppl. Table 1. PCR products of the different clones were purified (NucleoSpin 
DNA RNA and protein purification kit, Macherey Nagel) and sequenced (Sanger) (LGC 
Genomics). Sequence analysis was performed using Serial Cloner, Poly Peak Parser 126, 
and MEGA software.  
3.11 NHP ventricular fibroblast immortalization 
 
Two adult marmoset hearts were dissected. Two biopsies from the ventricle were extracted 
and washed in PBS [1% (v/v) Penicillin/Streptomycin (Gibco), 0,25 μg/mL Amphotericin 
B (Sigma)]. Clean heart tissue was minced with a scalpel and digested for 2 hours using 
Collagenase Type IV solution (10 mg/mL in DMEM) (Gibco)(37°C, rotating at 80 rpm). 
Cells were centrifuged (5 min, 300 x g, RT) and resuspended in culture medium [DMEM 
(Gibco), 15% (v/v) Fetal Bovine Serum (Gibco), 1% (v/v) Penicillin/Streptomycin (Gibco), 
0,1% (v/v) Amphotericin B (Sigma), 1% (v/v) MEM Non-Essential Amino Acids Solution 
(Gibco), 2 mM GlutaMAX (Gibco), 10 ng/ml bFGF] and transferred to 10 cm gelatine 
coated plates (0,1% gelatine; Sigma). Primary cultures were split with Accutase (Gibco) 
(37°C and 5% CO2).  
Ventricular fibroblasts were immortalized and fluorescent-labeled by co-transfection of 
piggyBac vectors containing human telomerase gene (PTT-PB-hTERT-puro) 28,     and 
Tomato fluorescent reporter (PTT-PB-dtTomato-puro). All transposon transfections were 
done in combination with pBase-dtTomato. Transfected cells were selected with puromycin 
(1µg/ml) (Thermo Fisher Scientific) until a population of pure tomato positive cells was 
reached (approx. 3 passages). Non-transfected ventricular fibroblasts were cultured in 
parallel in order to compare proliferation and morphology of the cells. 
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4 Discussion 
 
Given the high incidence of CVD in the population, animal models for investigation of the 
initiation and progression of the disease are required. The generation of NHP models will 
facilitate corresponding research in a systematic and controlled experimental setup 8 33. The 
relevance of NHP for translational studies is reflected by the increased number of disease 
and biological studies using these models in the last years 34-39. Especially Old wold 
monkeys (OWM) have been used to study the influence of genetic variation on CVD risk 
34 35, caloric restriction and CVD 36, Chagas disease 37 38 or stem cell-based therapeutics for 
the cardiovascular system among others 8 39 40. While OWM are well established in 
biomedical research, NWM are gaining only now more interest this field 41 42.  
For the generation of genetically modified NHP containing disease-related mutations, it is 
necessary to be able to induce specific genetic modifications using genome editing systems 
2 6 7. Additionally, it is necessary to validate these tools prior to their application in vivo. 
For this purpose, NHP-iPSC represent an excellent alternative due to their shared 
similarities with PSC of the early monkey embryo and their differentiation capacity 9 43. 
We have established an in vitro preselection platform for the validation of genetic 
modification tools in NHP. In the present study, we have adapted our previously reported 
reprogramming and iPSC culture protocol (Chapter 2) to the particularities of the 
marmoset. Marmoset monkeys are animal models traditionally used in biomedical research 
during the last decades 10. They have a primate-specific genetic constitution and additional 
advantages like shorter generation times, easy handling and lower housing cost in 
comparison with other NHP models, e.g., the macaque or the baboon 9 41. We have 
generated 6 different marmoset iPSC lines under feeder-free conditions. Furthermore, for 
reprogramming we have used an episomal system resulting in five transgene-free iPSC out 
of six lines tested 30.  
The generated iPSC were characterized according to the standards established for human 
iPSC 44 45. We have demonstrated the reactivation of key endogenous pluripotency markers 
on the mRNA and protein levels, respectively.  Furthermore, we evaluated the potency of 
the different lines by embryoid body differentiation, demonstrating that these cells can 
differentiate into representative cell types from all three embryonic germ layers. We believe 
that additional in vivo differentiation assays are required considering that the generated 
lines could be used for transplantation projects. Therefore we injected the generated lines 
for teratoma assay. Due to time limitations, we do not know whether the cells form 
teratomas or not. 
Considering the versatility of the cells, they can be used to study different human 
pathologies. However, as we aim to use them in the context of CVD, we tested directed 
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differentiation towards cardiomyocytes. The four lines tested generated cardiomyocytes 
following the previously reported work-flow (Chapter 2) adapted from the publication of 
Tiburcy and colleagues 46. 
Once the marmoset iPSC were fully characterized, we tested if the modified protocol based 
on the combination of UPPS / UPPS-Adv medium and Geltrex surface coating of the 
culture dish could be used for other species of primates. Rhesus macaque, human and 
baboon iPSC could be cultured in the new conditions showing no signs of differentiation. 
Therefore, we have established a work-flow that allows maintenance of iPSC from human, 
two OWM and one NWM species under identical conditions. This allows evaluation of 
genome editing tools considering a broad range of NHP models and additionally conduct 
developmental 47 48 and evolutionary studies 49.  
 
Figure 7: Schematic representation of the proposed work-flow for validation of genome editing tools in NHP-
iPSC.  
Due to their cellular particularities, the generation of genetically modified PSC is 
challenging 50. For the generation of iPSC lines with defined mutations, it is crucial to be 
able to derive clonal cell lines. We have tested a single cell sorting protocol that allows the 
generation of monoclonal primate iPSC lines. Furthermore, using the versatility of the 
piggyBac system, we were able to induce clinically relevant mutations in human, rhesus, 
and marmoset iPSC genomes.  
Familiar dilated cardiomyopathy (DCM) is an inherited disease with a high incidence in 
the general population 51 52 53.  This pathology is caused in 25% of the cases by truncating 
mutations in the sarcomeric protein TTN 52. Generating animal models that share the 
genotype of the patients will allow the development of novel therapeutics. We targeted 
primate iPSC to induce frameshift mutations in locations affected in patients of DCM with 
severe phenotypes 51. Even though the mutations have not been fully characterized, we have 
demonstrated for the first time the possibility of inducing mutations with high-efficiency 
in different preclinically relevant primate species. 
Two different approaches for the genetic modification were used, both based on NHEJ 
repair of the DNA after cutting. First, we tested the system to induce point mutations in a 
specific location 7. Once the protocol was established, we used the system for DNA 
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fragment deletion. We used two different CRISPR/Cas vectors, to target adjacent locations 
in the primate genome. We are aware that for precise induction of clinically relevant 
mutations in animal models, the preferred path is HDR 9. However, we believe that our 
tools developed in this study will help to bring these kinds of gene therapy closer to in vivo 
testing in NHP models 9. 
Additionally, derived from the study of the TTN structure, we have empirically developed 
a potential therapeutic approach to DCM caused by a subset of TTN mutations. The high 
number of symmetric exons in TTN makes it an excellent candidate for a target gene for 
myoediting strategies. We have generated a library of potential target exons (94) to test 
exon deletion for reframing tvTTN variants in DCM patients. The 363 exons were 
categorized according to symmetry, size, and PSI. The list of potential therapeutic sites 
needs to be carefully validated using the described platform.  
Finally, for in vitro research on DCM, it will be necessary to use culture systems with 
increased complexity that allow the identification of organotropic responses 46 54. In order 
to facilitate this transition we have immortalized ventricular fibroblasts from the marmoset. 
Usually, patient-derived iPSC-CM are combined with fibroblasts in order to improve 
maturation and mimic the natural composition of the myocardium 46. Although we made 
the first steps to establish NHP iPSC-CM / fibroblast co-culture systems, tissue-specific 
fibroblast extraction for the remaining species is still required. Since fibroblasts acquire 
tissue-specific traits. e.g. they express tissue-specific collagens; we consider it instrumental 
for organo-typic in vitro testing to use also tissue-specific fibroblasts. This may be 
particularly true for the mechanically stressed heart tissue. 
In conclusion, we have generated a NHP iPSC-based in vitro pre-selection platform that 
allows the validation of genetic modifications prior to their in vivo application in NHP. The 
progress made not only represents an important contribution to the generation of preclinical 
disease models, but also to the 3Rs (reduce, refine, replace) in animal experimentation.  
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6 Supplementary data (Chapter 4) 
 
 
 
 
 
 Suppl. Table 1: Oligos used in this study. (*) Product size (bp) for the wildtype and the deleted 
fragments.  
 
 
Antibody Supplier Dilution 
OCT-4A    Cell Signaling, 2890    1:1600 
LIN 28A     Cell Signaling, 3978S    1:100 
NANOG  Cell Signaling, 4903   1:400 
SOX2  Cell Signaling, 3728     1:200 
TRA 1-60     eBioscience, 14-8863   1:100 
TRA 1-81 eBioscience, 14-8883    1:100 
Oligo applications Name Sequences 5´-3´ Amplicon (bp)
G0957_hTERT_fwd CTGGACGATATCCACAGGGC
G0958_hTERT_rev AAGTTCACCACGCAGCCATA
G0022_OCT4_fwd GATCGGATCCTTGGGGCGCCTTCCTTC
G0035_OCT4_rev CAGGGTGATCCTCTTCTGCTTC
G0091_KLF4_fwd GGAAGACGATCTTGGCCCCG
G0021_KLF4_rev  GTACTCTAGACAGTGTGGGTCATATCCACTG
G0079_c-MYC_fw ATAAGAATGCGGCCGCACTGGATTTTTTTCGGGCAGTGG
G00142_c-MYC_rev CCTGGATGATGATGTTTTTGATG
G2204_beta actin_fw GGTAGTTTCGTGGATGCCACA 
G2205_beta actin_rev GACCTGACTGACTACCTCATG
G1806_TTN_N-terminus_fw CACCgGCTGACTACACCTTTGTGGC
G1807_TTN_N-terminus_rev AAACGCCACAAAGGTGTAGTCAGCc
G1822_TTN_C-terminus_fw CACCgGTTACTGCTTCCAATCGCCT
G1823_TTN_C-terminus_rev AAACAGGCGATTGGAAGCAGTAACc
G2616_N-term_fw GCATGGTGGCACAGAGTTGT
G2617_N-term_rev TAGACAGCTGCTAGGGACAC
G2654_C-term_fw GCGACTCTGCCCAACTACAT
G2655_C-term_rev GCAGTGTTGGTGACTTCCTC
G2367_280delups_2_fw CACCGGTAGTCATACAAGATGATGA
G2368_280delups_2_rev AAACTCATCATCTTGTATGACTACC
G2369_280deldown_2_fw CACCGGTTACTGCTTCCAATCGCCT
G2370_280deldown_2_rev AAACAGGCGATTGGAAGCAGTAACC
G20_Human_fw CAACTTATTTTGGGAGGGATG
G21_Human_rev AACTTATTTTGGGAGGGATG
G22_marmoset_fw CACCGTGAGAGGCTCACATACA
G23_marmoset_rev AAACGTATCAAACACTATTTACTAAGGAG
G2000_Episomal_EBNA_fw GCTATTGCTTCCCGTATGGC
G2001_Episomal_EBNA_rev CAAAGGGAGATCCGACTCGT
G2002_Episomal_EBV_fw GGTTCACTACCCTCGTGGAAT
G2003_Episomal_EBV_rev CGGGGCAGTGCATGTAAT
 mutation
gRNAs exon 
280 deletion
1461/977*
1170/762*
555
592
Analysis 
deletion primers
Episomal 
detection
1861
828
Analysis point 
mutation primers
gRNAs point
RT-PCR primers
653
510
323
456
285
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β-Tubulin III Sigma, T8660    1:400 
AFP Dako, A0008    1:200 
Sox9 Millipore, AB5535   1:200 
SMA   Sigma, A2547     1:1000 
α-actinin     Sigma, A7811     1:1000 
Cx43 bcam, ab11370     1:1000 
cTNI Abcam, ab47003     1:200 
cTNT Thermo Fisher, MS295PABX   1:200 
Titin Merck, MAB1553   1:50 
Alexa 488 conjugated goat-α-mousse IgM   Thermo Fisher Scientific, A21042   1:1000 
Alexa 488 conjugated goat-α-mousse IgG   Thermo Fisher Scientific, A10667    1:1000 
Alexa 488 conjugated donkey-α-rabbit IgG   Thermo Fisher Scientific, A21206   1:1000 
Alexa 488 conjugated donkey-α-mouse IgG   Thermo Fisher Scientific, A21202   1:1000 
 
Suppl. Table 2: Antibodies used in this study.  
 
 
 
 
 
Suppl. Fig 1: Comparison of primate iPSC morphology after three passages in UPPS and UPPS-Adv. 
Comparison performed for the four primate species considered in this project. Human (DPZHs_iPSC#2.4), 
macaque (DPZRh_iPSC#25.3), baboon (DPZPv_iPSC#2.8), and marmoset (DPZCj_iPSC#6) (scale bar 
100µm). 
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Suppl. Fig 2: Detection of the reprogramming episomal vectors by PCR. Two different primer pairs specific 
for the vectors were used (WPRE and EBV).  Amplicon size in base pairs (bp) detailed on the right. Beta-
actin was used as control for the presence of DNA (ACTNB). Plasmid DNA from the three reprogramming 
constructs pCXLE-hOCT3/4, pCXLE-hUL, and pCXLE-hSK was used as positive control. Wildtype marmoset 
fibroblasts were used as negative control. Only DPZCj_iPSC#1 shows a signal for the detection of the 
episomes, suggesting that the episomes are still present. 
 
 
Suppl. Fig 3: RT-PCR for the marmoset lines DPZCj_iPSC#1-6. Semi-quantitative analysis of the expression 
of the endogenous pluripotency genes OCT4, KLF4, c-MYC. Beta-actin was used as internal control. 
Amplicon size detailed on the right (base pairs, bp). Marmoset fibroblasts were used as biological negative 
control. 
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Suppl. Fig 4: Marmoset iPSC characterization by immunofluorescence. Detection of the pluripotency 
markers OCT4, LIN28, NANOG, SOX2, TRA-1-81 and TRA-1-60 (scale bars 20µm). DPZCj_iPSC#2, 3 
and 5 are transgene-free so all the expression detected is endogenous. DPZCj_iPSC#1 still contains the 
plasmids; therefore, the expression comes from both, endogenous and exogenous expression.  
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Suppl. Fig 5: (A) (B) Distribution of TTN exons according to their size, in base pairs (bp). Defined size 
rages, smaller than 100bp (<100), between 100 and 200bp (100-200), between 201 and 300bp (201-300), 
between 301 and 400b`p (301-400), and bigger than 400 bp (>400). 
 
 
  
Gene 
No. 
Exons 
Accession number 
No. 
Symmetric 
exons  
Percentage 
of  
symmetric 
exons (%)   
Thin filament 
proteins  
 Cardiac troponin T 
(TNNT2)  16 ENST00000509001.5 8 50 
 Cardiac troponin I 
(TNNI3)  8 ENST00000509001.5 5 62.5 
 Cardiac troponin C 
(TNNC1)  6 ENST00000232975.7 1 16.66 
 α-Tropomyosin (TPM1)  9 ENST00000358278.7 2 22.22 
 α-Cardiac actin (ACTC1)  7 ENST00000358278.7 2 28.57 
Thick filament 
proteins  
 β-Myosin heavy chain 
(MYH7)  40 ENST00000290378.5 15 37.5 
 Ventricular regulatory 
light chain (MYL3)  6 ENST00000395869.5 3 50 
 Ventricular esential light 
chain (MYL2)  7 ENST00000228841.12 4 57.14 
 Cardiac myosin-bining 
protein C (MYBPC3)  35 ENST00000545968.5 14 40 
Titin and Z-disc 
proteins  
 Titin (TTN)  363 ENST00000589042 311 85.67 
 T-cap (TCAP)  2 ENST00000309889.2 1 50 
 MLP (CSRP3)  7 ENST00000533783.2 0 0 
 Myozenin-2 (MYOZ2)  6 ENST00000307128.5 2 33.33 
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 α-Actinin (ACTN2)  23 ENST00000546208.5 13 56.52 
 Obscurin (OBSCN)  116 ENST00000570156.6 84 72.41 
 Cypher (LDB3)  14 ENST00000429277.6 1 7.14 
Citoplasmic 
protein Dystrophin (DMD) 79 ENST00000357033.8 40 50.63 
 
Suppl. Table 3: Cardiac relevant genes quantification of symmetric exons. 
 
 
Transcript 
No. 
exons Accession number 
No. Symmetric 
exons Percentage of symmetric exons (%) 
Meta 363 ENST00000589042 311 85.67493113 
N2BA 313 ENST00000591111 261 83.38658147 
N2B 191 ENST00000460472 142 74.34554974 
N2A 312 ENST00000342992 261 83.65384615 
Novex-1 191 ENST00000359218 144 75.39267016 
Novex-2 192 ENST00000342175 143 74.47916667 
Novex-3 46 ENST00000360870 31 67.39130435 
CRONOS 124   97 78.22580645 
 
Suppl. Table 4: Symmetric exon quantification in the mayor TTN isoforms. 
 
Exon 
Nº Exon ID Length Location Domains 
Exon 
Phase 
Exon 
PSI 
3 ENSE00003807606 204 Z-disk Ig-like 1 1 1.00 
4 ENSE00003810976 288 Z-disk Ig-like 2 1 1.00 
8 ENSE00003803639 153 Z-disk Z-repeat 1 0 1.00 
9 ENSE00003810843 138 Z-disk Z-repeat 2 0 1.00 
10 ENSE00003803899 126 Z-disk Z-repeat 3 0 1.00 
13 ENSE00003805623 138 Z-disk Z-repeat 6 0 0.96 
14 ENSE00003801659 294 Z-disk Z-repeat 7 0 1.00 
15 ENSE00003804455 123 Z-disk   0 0.99 
16 ENSE00003810306 282 
near Z-
disk   0 0.99 
17 ENSE00003805296 66 
near Z-
disk   0 0.99 
20 ENSE00003804962 216 
near Z-
disk Ig-like 4 2 1.00 
23 ENSE00003807963 234 
near Z-
disk Ig-like 5 0 1.00 
26 ENSE00003811446 165 
near Z-
disk Ig-like 6 1 1.00 
29 ENSE00003809440 282 I-band Ig-like 11 1 1.00 
30 ENSE00003802960 267 I-band Ig-like 12 1 1.00 
31 ENSE00003804241 273 I-band Ig-like 13 1 1.00 
32 ENSE00003806988 264 I-band Ig-like 14 1 1.00 
Chapter 4: An iPSC-based preselection platform for disease-inducing genetic 
modifications in non-human primates 
 
142 
 
33 ENSE00003804968 261 I-band   1 1.00 
34 ENSE00003809850 261 I-band Ig-like 15 1 1.00 
35 ENSE00003806479 264 I-band   1 1.00 
36 ENSE00003804523 261 I-band   1 1.00 
37 ENSE00003807378 261 I-band Ig-like 16 1 1.00 
38 ENSE00003807271 261 I-band Ig-like 17 1 1.00 
42 ENSE00003802092 285 I-band Ig-like 19 1 1.00 
43 ENSE00003807103 126 I-band Ig-like 20 1 1.00 
44 ENSE00003801355 189 I-band Ig-like 20 1 1.00 
47 ENSE00003810791 57 I-band   1 1.00 
49 ENSE00003805227 279 I-band Ig-like 24 1 1.00 
219 ENSE00003804802 81 I-band PEVK27 1 1.00 
220 ENSE00003811452 75 I-band PEVK28 1 1.00 
221 ENSE00003807205 90 I-band   1 1.00 
222 ENSE00003806747 63 I-band PEVK29 1 1.00 
223 ENSE00003810755 90 I-band PEVK30 1 1.00 
226 ENSE00003803996 279 I-band Ig-like 81 1 1.00 
227 ENSE00003807976 276 I-band Ig-like 82 1 1.00 
230 ENSE00003811410 264 I-band   1 1.00 
231 ENSE00003805150 267 I-band Ig-like 83 1 1.00 
232 ENSE00003801907 264 I-band Ig-like 84 1 1.00 
235 ENSE00003811384 267 I-band Ig-like 85 1 1.00 
236 ENSE00003801954 267 I-band   1 1.00 
237 ENSE00003809996 267 I-band Ig-like 86 1 1.00 
245 ENSE00003811387 267 I-band Ig-like 90 1 1.00 
246 ENSE00003802653 267 I-band Ig-like 91 1 1.00 
247 ENSE00003802540 279 I-band Ig-like 92 1 1.00 
250 ENSE00003807647 267 I-band   1 1.00 
251 ENSE00003802353 270 I-band Ig-like 95 1 1.00 
256 ENSE00003809985 285 A-band   1 1.00 
261 ENSE00003809522 288 A-band Ig-like 96 1 1.00 
262 ENSE00003804879 297 A-band Fibronectin type-III 6 1 1.00 
265 ENSE00003806136 300 A-band Fibronectin type-III 8 1 1.00 
266 ENSE00003804290 300 A-band Fibronectin type-III 9 1 1.00 
270 ENSE00003808061 279 A-band Ig-like 97 1 1.00 
271 ENSE00003811164 300 A-band 
Fibronectin type-III 
12 1 1.00 
275 ENSE00003809346 300 A-band 
Fibronectin type-III 
15 1 1.00 
276 ENSE00003806782 297 A-band 
Fibronectin type-III 
16 1 1.00 
277 ENSE00003804121 285 A-band Ig-like 99 1 1.00 
278 ENSE00003804454 294 A-band 
Fibronectin type-III 
17 1 1.00 
279 ENSE00003803420 300 A-band 
Fibronectin type-III 
18 1 1.00 
285 ENSE00003801625 33 A-band Ig-like 101 0 1.00 
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287 ENSE00003804239 300 A-band 
Fibronectin type-III 
22 1 1.00 
289 ENSE00003801391 297 A-band Ig-like 102 1 1.00 
290 ENSE00003806021 300 A-band 
Fibronectin type-III 
24 1 1.00 
294 ENSE00003808790 282 A-band Ig-like 103 1 1.00 
297 ENSE00003807039 282 A-band Ig-like 104 1 1.00 
298 ENSE00003804106 300 A-band 
Fibronectin type-III 
29 1 1.00 
301 ENSE00003807476 282 A-band Ig-like 105 1 1.00 
302 ENSE00003807363 300 A-band 
Fibronectin type-III 
32 1 1.00 
303 ENSE00003808994 294 A-band 
Fibronectin type-III 
33 1 1.00 
306 ENSE00003805661 285 A-band Ig-like 109 1 1.00 
307 ENSE00003804742 300 A-band 
Fibronectin type-III 
42 1 1.00 
309 ENSE00003801707 276 A-band Ig-like 110 1 1.00 
310 ENSE00003810399 300 A-band 
Fibronectin type-III 
44 1 1.00 
312 ENSE00003802505 300 A-band 
Fibronectin type-III 
46 1 1.00 
313 ENSE00003806397 288 A-band Ig-like 111 1 1.00 
314 ENSE00003807889 297 A-band 
Fibronectin type-III 
47 1 1.00 
317 ENSE00003807542 288 A-band   1 1.00 
318 ENSE00003810775 291 A-band 
Fibronectin type-III 
50 1 1.00 
319 ENSE00003811210 288 A-band 
Fibronectin type-III 
51 1 1.00 
321 ENSE00003808777 105 A-band 
Fibronectin type-III 
52 1 1.00 
322 ENSE00003806939 198 A-band 
Fibronectin type-III 
53 1 1.00 
323 ENSE00003811024 297 A-band 
Fibronectin type-III 
54 1 1.00 
327 ENSE00003802597 297 A-band 
Fibronectin type-III 
99 1 1.00 
330 ENSE00003806587 297 A-band 
Fibronectin type-III 
102 1 1.00 
331 ENSE00003807681 288 A-band Ig-like 130 1 1.00 
332 ENSE00003811102 300 A-band 
Fibronectin type-III 
103 1 1.00 
336 ENSE00003811205 294 A-band 
Fibronectin type-III 
110 1 1.00 
337 ENSE00003808021 288 A-band Ig-like 133 1 1.00 
338 ENSE00003804355 300 A-band 
Fibronectin type-III 
111 1 1.00 
342 ENSE00003801213 291 A-band Ig-like 136 1 1.00 
343 ENSE00003809128 297 A-band 
Fibronectin type-III 
119 1 1.00 
346 ENSE00003809946 282 A-band Ig-like 137 1 1.00 
348 ENSE00003802641 288 A-band Ig-like 138 1 1.00 
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349 ENSE00003806194 300 A-band 
Fibronectin type-III 
124 1 1.00 
354 ENSE00003810204 300 A-band 
Fibronectin type-III 
129 1 1.00 
 
Suppl. Table 5: List of candidate exons for therapeutic removal. Exons were selected from the TTN 
metatranscript (ENST00000589042) and filtered according to symmetry, conservation between the different 
isoforms (PSI>0.9) and size (≤300bp).  
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IX. Discussion 
To accurately predict the effect of in vivo applications of stem cell therapeutics and to 
study human disease, utilization of animal models resembling patient phenotypes is 
necessary 7 8. Such model organisms will enhance CVD specific research aiming at the 
establishment of novel therapies. Especially regarding preclinical trials, NHP play an 
important role and have a higher predictive value compared to rodent animal models 8. 
Hence, even considering the practical and ethical difficulties accompanying these models, 
it is worth to further establish NHP models for biomedical research. Refining methods 
and shedding light into species-specific particularities of NHP will further improve the 
panel of available models for preclinical studies. 
 
The first aim of this Ph.D. thesis was to refine methodologies for NHP-iPSC generation. 
Establishment of robust reprogramming protocols will allow exploration of CV system-
related therapies in vitro and in vivo. With this aim, we have tested different 
reprogramming methods and generated a robust work-flow for iPSC generation from four 
different primate species. Additionally, we translate cardiomyocyte differentiation 
protocols to the particularities of these cells. 
 
The second aim was to mimic human CVD in vitro using genome editing technologies in 
NHP-iPSC. We generated a platform that allows evaluation of induced genetic 
modifications using species-specific iPSC. The platform will be crucial for future 
generation of genetically modified NHP. It may help to save resources, refine and reduce 
animal experiments and establish a relevant panel of NHP disease models. 
 
Last, based on the study of sarcomeric protein homology between different species, we 
propose a CRISPR based therapeutic approach for dilated titin mutation-induced 
cardiomyopathy (DCM). Our initial contribution to the emerging field of myoediting by 
symmetric exon deletion from the TTN gene needs significant experimental improvement 
and may complement the already existing approaches to treat monogenic cardiovascular 
diseases. 
 
1 Refinement of NHP-iPSC generation and culture 
 
Cell replacement therapies using versatile PSC made in the last years the way to the 
clinics 127. Nevertheless, there are still many open questions, which can be addressed 
using NHP models. Species-specific cell types generated by NHP-iPSC differentiation 
can contribute for testing stem cell-based therapeutics in highly predictive coherent 
models 92. Hence, generation of NHP-iPSC with similar quality as human iPSC is 
necessary. Furthermore, the limited number of available NHP-PSC lines as well as inter 
cell line variability, underline the importance of standardized and efficient NHP iPSC line 
generation protocols  42.  
 
Robust protocols for NHP-iPSC generation are currently unavailable. Reprogramming of 
cells from only a few primate species, e.g., macaques, have been achieved following the 
high standards for human iPSC generation 128 129. In contrast, other primate species like 
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marmoset or baboon seem to be more resistance to reprogramming and, therefore, the 
respective protocols still need to be adapted 130. The difficulties in generating NHP-iPSC 
is, amongst others, reflected in the high variability and discrepancies between studies 
using stem cells for regenerative purposes 42. Chong and colleagues evaluated the 
regeneration of macaque myocardium using human ESC as source of transplanted cells 
85 86. Shiba et al., on the other hand, used species-specific iPSCs to regenerate cynomolgus 
monkey myocardium, using, however, only one cell line 92. This could result in studies 
biased by selection of highly specific cell lines and questions reproducibility of the 
studies. Therefore, improvement and standardization of NHP-iPSC generation will 
significantly impact on many research areas. Furthermore, this may contribute to the 
establishment of additional NHP species as models for translational research. Species-
specific iPSC will further allow scientists to choose the adequate model according to their 
specific research interests and requirements. 
  
In the present study, we refined and improved methods for NHP fibroblast 
reprogramming (Fig. 4). The starting point was a publication by Debowski et al. (2015), 
which demonstrated the possibility of neonatal marmoset fibroblast reprogramming using 
the piggyBac system. The piggyBac transposon stably delivered six reprogramming 
factors facilitating efficient iPSC generation, while the transposon was still present in the 
cells 59. This study was used as a starting point for protocol optimization with the aims of 
increased efficiency of the generation process and improved quality of the resulting iPSC. 
The resulting protocols were further tested in three other primate species. We have 
explored two delivery mechanisms for the reprogramming factors, the piggyBac 59, and 
an episomal vector system 52. Both systems are DNA based and contain six (mSOX2, 
mOCT4, mKLF4, mC-MYC, mLIN28, and mNanog) or five (hOCT3/4, hL-MYC, hLIN28, 
hSOX2, hKLF4, plus shRNA against P53) reprogramming factors, respectively (h-
Human, and m-marmoset factors) (Fig. 4).  
 
 
 
Figure 4: Schematic representation of aims in iPSC generation and maintenance achieved during the three 
years of the Ph.D. project. Each arrow represents one of the aims: 1-reprogramming method resulting in 
transgene-free cells, 2-culture conditions without xenogenic feeder cells, and 3-applicability of the 
protocols to different primate species with preclinical relevance.  
 
First, the published piggyBac protocol was applied to rhesus macaque and baboon 
fibroblasts 59. Only minor modifications were necessary for successful reprogramming, 
namely adjustment of culture conditions and colony splitting protocols. Rhesus, baboon 
and marmoset piggyBac derived iPSCs were initially maintained on MEFs, however, as 
a first approximation to feeder-free culture systems, we adapted them a posteriori to 
feeder-free conditions using commercially available medium and culture dish coating for 
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human iPSCs (Chapter 1 and 3) 60 131. Feeder-free cultivation was successful for all three 
species, however not for all lines tested. Furthermore, the iPSCs showed limited 
differentiation and low proliferation in the new culture conditions. Hence, the protocols 
for maintenance needed adjustment. We suspected that the long term culture of the iPSCs 
on MEF impaired the plasticity of the cell lines. Furthermore, we hypothesize that 
differences between NHP- and human-iPSC require the development specific culture 
conditions for NHP-iPSC. Another disadvantage of this protocol was the insertion of the 
reprogramming construct (permanently Chapter 1 or transiently Chapter 3) in the genome. 
This could lead to mutagenesis, chromosomal abnormalities, failing differentiation and 
make the generated iPSCs useless for transplantation studies 39. To overcome the 
integration problem, we decided to test episomal vector reprogramming for all three NHP 
species. Episomal vector derived iPSC were cultured in feeder-free conditions from the 
beginning of reprogramming using commercial medium developed for human PSC. 
 
Using the episomal vector system containing the human factors published by Okita et al., 
we were able to reprogram human, baboon, rhesus and marmoset fibroblasts 52 (Chapter 
2 and 4). Even though primary colonies appeared with morphology indicating 
pluripotency of the cells in the primary plates after transfection, we faced the problem of 
maintaining these cells. Commercially available media led to NHP-iPSC instability and 
ultimately to differentiation. Hence, we tested different media compositions in order to 
generate a universal primate iPSC culture medium. Testing different compounds the 
Universal primate pluripotent stem cell (UPPS) medium was empirically developed 
(Chapter 2). Based on StemMACS™ iPS-Brew XF in combination with one Wnt pathway 
inhibitor (IWRI) and one activator (Chir99021), our culture conditions represent a 
suitable medium for rhesus, human and baboon iPSCs culture. Unfortunately, marmoset 
iPSCs differentiated under these conditions. During the last year, we focused on fine-
tuning of the UPPS medium to be able to culture all four primate species relevant in 
biomedical research. The addition of Activin A was the key to stabilize also marmoset 
PSCs (Chapter 4). Even though Activin A proved to be necessary for marmoset iPSC 
stability, the proliferation rate was affected negatively. To enhance proliferation, we 
added Leukemia inhibitory factor (LIF) in high concentration (10 ng/ml). We named the 
new formulation UPPS advanced (UPPS-Adv). This medium is able to stabilize beside 
marmoset iPSCs also rhesus, baboon and human iPSCs. Regardless of the addition of 
LIF, the proliferation rates were yet lower in comparison with UPPS. However, the use 
of UPPS-Adv is required only during the first passages of iPSC line establishment. In 
conclusion, we recommend using UPPS-Adv during NHP-iPSC establishment and 
switching to UPPS for further maintenance and experimental approaches (Chapter 4). 
 
NHP-iPSC generated using episomal vectors and maintained in the novel UPPS/UPPS-
Adv media were fully characterized, and the absence of the episomal vectors was 
confirmed for most of the newly generated iPSC lines. Taken together, we were able to 
generate stable transgene-free, feeder-free NHP-iPSC from all four primate species 
tested. 
 
1.1 Characterization of NHP-iPSCs 
In order to confirm the pluripotent stem cell identity of the generated lines, we performed 
an in-depth characterization. Human iPSCs used for cell-based therapeutics require 
clinical-grade quality. Furthermore, robust and reproducible directed differentiation 
protocols guarantee efficacy and safety of the therapeutic approach for the patients (GMP-
Discussion 
148 
 
compliance) 132 133. Hence, it was necessary to reach a consensus for the analysis required 
to consider iPSC “clinical grade”. This has been achieved in the last years following the 
guidance of institutions like the International Stem Cell Banking Initiative and by a series 
of workshops 64. For NHP, the standards are more diffuse, involving only few research 
groups trying to define the required minimum of analyses 42. In order to improve the 
current situation, we decided to establish and follow systematically a work-flow that 
allows us to ensure the quality of the cell lines generated 42. As mentioned, gold-standards 
for human are well-defined; hence we adopted these standards for our non-human primate 
iPSCs. We additionally added few tests required for proper evaluation of NHP cells (Fig. 
5). 
 
  
 
Figure 5: Work-flow for the generation and characterization of NHP-iPSCs generated in this project. The 
estimated duration of each step is indicated (Total duration 1-1,5 years per line). Figure modified from 42. 
 
Every step of the characterization was considered as a go/no go decision, only allowing 
us to proceed to the next steps in case positive results during the previous criterion. First, 
we performed a morphological characterization of the cells and colonies. Only lines 
showing a typical PSC morphology were considered for further characterization.  Then, 
as a preliminary characterization in early passages (10/15) alkaline phosphatase activity 
was evaluated. Subsequently, the expression of canonical pluripotency markers on the 
protein and mRNA level was analyzed. Only lines expressing a specific set of 
pluripotency markers endogenously were further studied. Next, sterility tests were 
performed to ensure the absence of selected viruses and mycoplasms (data not shown in 
this dissertation). This is particularly important regarding the potential preclinical 
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application of the cell lines for transplantation. Mycoplasma test was run every six 
months, and additionally, the cells were tested for SIV, SRV, STLV, and CeHV-1 viruses 
41. SIV testing is crucial in the case of rhesus macaque and baboon iPSCs since this virus 
could impact on the outcome of the experiments and, more importantly, it entails a risk 
for the researcher. Careful karyotyping is an analysis that scientists sometimes overlook. 
Chromosomal alterations may occur during the process of reprogramming and depending 
on the kind of mutation, affect the phenotype of the cell line drastically 134. We karyotyped 
the human, macaque, and baboon lines in collaboration with Prof. Bartels (Institute of 
Human Genetics, UMG Göttingen).  
 
Once the molecular identity of the different lines has been proven, pluripotency needs to 
be tested also on a functional level. We performed both in vitro and in vivo spontaneous 
differentiation assays in order to assess the pluripotent status of the cells. Teratoma 
formation assay, performed in collaboration with Prof. Dressel (Institute of Cellular and 
Molecular Immunology, UMG Göttingen), was exceptionally informative. While getting 
information on in vivo pluripotency, it also provides information about tumorigenicity of 
the lines. Finally, as we aim to use our cells in the context of CV research, we tested the 
capacity of the cells to differentiate into cardiomyocytes in vitro.  
 
Altogether approximately one and a half years of work are required to generate and 
characterize one line according to our self-set standards. Even though this process is 
laborious and time consuming, we consider it crucial to ensure the quality of the iPSC 
lines generated before they are used in (in vivo) downstream applications (Fig. 5). 
 
2 Efficient generation of functional NHP-iPSC cardiomyocytes 
 
After the generation of state of the art primate iPSCs, we tested different protocols to 
direct these cells towards cardiomyocyte-like cells. Future stem cell-based regenerative 
therapies of the myocardium will require large amounts of iPSC-CM. Therefore, efficient 
and fine-tuned protocols need to be established 135. Based on the protocol developed by 
Tiburcy and collaborators 84, Dr. Stauske was able to adapt this protocol to the generation 
of rhesus and baboon iPSCs-CM (Chapter 2) 84. Results obtained with these species could 
then be successfully translated to marmoset and human iPSCs (Chapter 4). The protocol 
is based on the modulation of key elements of the Wnt/β-catenin signaling pathways via 
small molecules and recombinant proteins. The differentiation can be divided into two 
phases, -1st an initial step to induce differentiation towards the mesodermal pathway (B-
27 Suppl minus Insulin, supplemented with Activin A, Chir99021, BMP4), and -2nd 
cardiomyocyte specification phase (IWRI, B-27 Suppl minus Insulin) (Chapter 2).  
 
Using this work-flow, it was possible to reproducibly generate iPSC-CM from all four 
primate species, while the human-specific protocol was not sufficient to induce CM 
differentiation reproducibly in all cell lines (Suppl. Video 1 macaque and 2 marmoset). 
Differentiation efficiency differed between species and cell lines and was accurately 
evaluated by FACS. The differences in the efficiency were overcome via metabolic 
selection of the CM resulting in almost pure iPS-CM cultures 136. Previous reports have 
shown CM-differentiation in macaque and marmoset 92 137 138. To our knowledge, 
however, we are the first who successfully applied a universal CM differentiation protocol 
to different primate species. Furthermore, to the present, there are no reports of baboon 
PSC derived cardiomyocytes. Additionally, marmoset ESC- derived cardiomyocytes 
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have been generated, however using protocols that do not allow the mass production of 
differentiated cells 138. 
 
Basic molecular characterization of the iPSC-CM was performed in the protein level by 
demonstrating the expression of specific cardiac markers (Chapter 2 and 4). In order to 
initially characterize the generated beating iPSC-CM functionally, we performed 
electrophysiological characterization of the generated cells using 2D (Microelectrode 
Array, MEA) and 3D (Engineered heart muscle, EHM) systems 84 139 140. The generated 
iPSCs-CM showed inotropic responses, reacting to isoprenaline, propranolol, and 
increased Ca2+ levels. EHM measurements are particularly relevant since this approach is 
able to analyze organotypic responses and to improve the maturation of the generated 
cells (proved for human iPSC in 84). Altogether, the generated NHP-iPSC-CM appear to 
be functional in different assays. These findings encourage their use in preclinical in vivo 
applications aiming at myocardial regeneration. 
3 Modeling cardiovascular disease in NHP-iPSCs 
 
To the present, NHP served as CVD models based on surgical and drug-induced 
approaches 8. Generation of transgenic NHP CVD models will allow the analysis of 
(human) disease with reduced heterogeneity between studies. Also, by the introduction 
of disease-relevant mutations in NHP the emergence and progression of the disease can 
be studied, which is in contrast to most conventional disease models. Furthermore, the 
genetically induced disease can be inherited to the offspring allowing cross-generation, 
longitudinal studies. These NHP model organisms will be crucial for the understanding 
of human diseases and for the establishment of novel therapeutic approaches. Essential 
for this approach is the genetic modification of NHP embryos 97. 
 
Even though advances in genome editing technologies have allowed the generation of 
few genetically modified NHP (including macaques, cynomolgus monkeys, and 
marmosets), research is yet struggling to develop robust workflows 8 142 143 144. Given 
ethical and practical limitations in NHP in vivo studies (reviewed in Chapter 3, 4 in detail), 
we believe that robust in vitro evaluation systems for the introduction of genetic 
modifications is imperative. These platforms will allow assessing the efficiency and 
efficacy of induced genomic mutations in vitro before engaging in the in vivo project. 
Usually, researchers back their NHP studies with in vivo data from small animals models 
like mice. As mentioned before, these studies are an approximation, but not necessarily 
predictive of the outcome of the study using NHP 99. Therefore we believe that is 
necessary to have a system to predict the molecular and cellular consequences of a 
genome modification in species-specific cells, before it is applied in vivo to modify an 
NHP. 
 
We used our transgene- and feeder-free NHP-iPSC to develop a platform for the 
assessment of genome editing (Fig. 5). Utilizing all four species will be possible to 
evaluate species-specific responses to induced mutations in vitro. Furthermore, our fine-
tuned CM-differentiation protocol may allow a preliminary assessment of the potential in 
vivo CVD phenotype. NHP-iPSC genome editing will provide information on efficiency 
and safety of the approach.  
 
Only very few publications show genome editing and subsequent single-cell cloning of 
NHP-iPSC 97 145. In order to develop a robust protocol, we searched the literature for 
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protocols generated for clonal expansion of human iPSC 146. We aimed to develop 
efficient universal protocols for all primate species used in this study. The first step 
towards induction of defined mutations is the adjustment of single-cell cloning protocols. 
In the course of this Ph.D. project, single-cell dissociation, sorting, and cloning have been 
adjusted for NHP-PSC (Chapter 3 and 4). We were able to generate a robust approach 
that could be applied to all species tested here. Furthermore using the versatility of the 
piggyBac transposon system in combination with CRISPR/Cas editing technology, we 
were able to induce clinically relevant mutations in all PSC. This process was especially 
laborious due to the high number of publications defining human protocols and the 
discrepancies between them. Additionally, the relatively poor genomic annotation of 
NHP makes the design of the editing tools challenging 8. 
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Figure 6: Proposed in vitro platform for the evaluation of genetic modifications for the generation of 
genetically modified NHP. (A) Schematic representation of the suggested work-flow with 5 distinctive 
phases: 1-generation of NHP-iPSC, 2-validation of the selected genome editing tools, 3-mutation induction 
and single cells cloning, 4- cardiomyocyte differentiation of the mutated iPSC, and 5-prediction of the in 
vivo phenotype. (B) Generated primate transgene- and feeder-free iPSC (Chapter 2, 3 and 4) (scale bars 
100µm). (C) CRISPR vector used for gRNA validation and mutation induction (Chapter 3). (D) Single-cell 
cloning protocol (upper pannel, Chapter 3 and 4), for the generation of genetically modified NHP 
monoclonal lines (lower panel). (E ) Representative marmoset iPSC-CM (scale bars 20µm). (F) Schematic 
representation of the combination of species-specific iPSC containing clinically relevant mutations 
(expressing Cas9-GFP fusion transcript) and immortalized ventricular fibroblasts (RFP positive cells) 
(Chapter 4) (scale bars 100µm). 
 
We strived to establish an in vitro evaluation work-flow that will support in vivo 
approaches to the establishment of genetically modified monkeys. We believe that the 
present study will reduce the ethical problematics connected with the genetic 
modification of NHP research and contributes to the 3Rs (reduce, refine, and replace) of 
animal research. This approach will complement future in vivo project in the early phases.  
Additionally, by refining protocols in vitro, it will help to reduce the number of animals 
needed for in vivo studies. 
 
4 Exploring new therapies for monogenic cardiovascular 
diseases 
 
Dilated cardiomyopathy (DCM) represents one of the leading causes of death in CVD 
patients. DCM has a high incidence in the general population and is characterized by left 
ventricle enlargement and/or dysfunction. DCM demonstrates a complex etiology and has 
been diagnosed with accelerated rates in the last years 147.  In recent years, Next 
Generation Sequencing (NGS), together with detailed epidemiological data, allowed 
researchers to identify the genetic background of this disease. Mutations in up to 40 genes 
have been related to inherited DCM 147 148. These mutations affect proteins related to a 
broad range of cellular structures like nuclear envelope, cytoskeleton, and sarcolemma 
amongst others 147. Within the mutated proteins, Titin (TTN) is particularly interesting as 
it is responsible for up to 25% of the familiar cases of DCM. 
 
TTN, being the largest protein in the human body, is crucial in striated muscle. Here, the 
protein is responsible for sarcomere assembly and passive tension 147 148. Studies in DCM 
have demonstrated truncation mutations in TTN as the most frequently occurring 
alteration in DCM patients. Myoediting approaches, relying on the reframing of the 
shifted, i.e. mutated open reading frame resulting in truncated proteins, have been recently 
introduced as a potential method of patient treatment. The approach describes the usage 
of CRISPR/Cas for correction of the disease-causing mutation in skeletal muscle and 
heart 149. The therapeutic application of CRISPR/Cas in this context can be divided into 
four main groups. 1- Exon deletion 150 151, 2- exon skipping 152 153, 3- exon reframing via 
targeted frameshift 154 and 4- exon knock-in 155. Exon deletion describes the deletion of 
mutation containing exons by targeting adjacent introns using two different gRNAs. Exon 
skipping strategies target the splice acceptor/donor sequence of the exon containing the 
mutation. Exon reframing induces a second mutation generating a second frameshift, 
restoring the protein reading frame. Finally, exon knock-in is the most elegant but at the 
same time challenging of all mentioned approaches. It involves the replacement of the 
mutated exon with a wildtype exon by HDR 149. All these approaches have been tested in 
vitro and in vivo to correct a variety of CVDs. To the present, most studies exploring the 
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different approaches focus on pathologies in which the disease-causing mutations are 
concentrated in hot-spots of a gene, e.g., DMD. For TTNtv-induced DCM the scenario is 
more complex, due to the broad range of locations of the mutations. Therefore, it is of 
utmost importance to test combinations of the mentioned approaches. This, in the end, 
might provide solutions for the treatment of most mutations and finally may result in 
causal disease treatment 149. 
 
In this study, we proposed a novel approach for DCM treatment (Chapter 4). The 
hypothesis is based on the extraordinarily high number of symmetric TTN exons. We 
hypothesized that the deletion of symmetric exons containing mutations can be used to 
overcome the DCM phenotype. By selecting the exons according to size, PSI, and 
symmetry, we have elaborated a library of candidate exons to test the approach. 
Furthermore, we have compiled a possible workflow for testing the hypothesis.  
 
First experimental data have been collected in order to evaluate the proposed approach. 
TTN exon 280 has been deleted in one human iPSC line (Chapter 4) and evidence of 
successful deletion of this exon in other cell lines has been provided. Further, 
characterization of the phenotypic alterations of this line is necessary; however, we 
provided proof of concept of this approach. 
 
For each one of the locations proposed, DCM exon deletion therapies need to be carefully 
evaluated.  However, the progress described here strongly encourages to deeper test this 
approach using also additional target exons. We believe that this approach is particularly 
useful to treat truncating variants of TTN and may provide in the future a clear benefit 
for the respective DCM patients. 
 
X. Conclusions/Outlook 
I have focused in these collaborative efforts in the context of my Ph.D. project on the 
development of tools and protocols contributing to the establishment and application of 
NHP-iPSC. We aim to apply the generated lines in stem-cell-based regenerative projects 
for the cardiovascular system and for CVD disease modeling. 
 
We were able to establish robust protocols for the generation and maintenance of iPSCs 
from four different primate species. All cell lines from the different species have been 
generated and characterized using one universal protocol. The developed protocol 
facilitates to go back and forth from NHP models to human, making possible direct 
translation of the results obtained using NHP. Furthermore, there are to date only few (or 
even none - depending on the species) publications describing the generation of NHP-
iPSC according to the standards set in this project.  
 
The best way to evaluate the impact and value of any biotechnological tool is to assess its 
acceptance by the scientific community. Even though most results generated in this 
project have not been published yet, the generated NHP-iPSC are already used in different 
basic and preclinical projects. For instance, we are currently screening in collaboration 
with partners for AAV serotype specificity for the heart using NHP iPSC-CM. 
Additionally, the generated cells are being used in different evolutionary and 
developmental studies. Furthermore, already testing the potential of the generated cells to 
regenerate for instance the myocardium or the macula is currently tested. .  
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Additionally, using the generated cells, we constructed to our knowledge the first NHP-
iPSC-based platform for the evaluation of genetic engineering approaches before their in 
vivo application. Generation of genetically modified NHP models is becoming a highly 
important field in biomedical sciences. Using the proposed work-flow it is possible to 
evaluate the accuracy and efficiency of a genome editing approach and may assist in the 
prediction the in vivo phenotype. Our main goals with this approach are (1) to contribute 
to the 3Rs inherent to NHP experimentation and (2) to support scientists in designing 
optimal approaches to the establishment of appropriate genetically modified NHP 
models.
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